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INTRODUCTION 
 
NANOTECHNOLOGY 
 
Nanoscience has been variously defined at different fora, books, journals and the 
web, yet one thing is common; it involves the study of the control of matter on an atomic 
and molecular scale. This molecular level investigation is at a range usually below 100 nm. 
In simple terms, a nanometer is one billionth of a meter and the properties of materials at 
this atomic or subatomic level differ significantly from properties of the same materials at 
larger sizes. Although, the initial properties of nanomaterials studied were for its physical, 
mechanical, electrical, magnetic, chemical and biological applications, recently, attention 
has been geared towards its pharmaceutical application, especially in the area of drug 
delivery.  
 This is because of the challenges with use of large size materials in drug delivery, 
some of which include poor bioavailability, in vivo stability, solubility, intestinal absorption, 
sustained and targeted delivery to site of action, therapeutic effectiveness, generalized 
side effects, and plasma fluctuations of drugs. Of recent, several researches in nanodrug 
delivery have been designed to overcome these challenges through the development and 
fabrication of nanostructures. It has been reported that, nanostructures have the ability to 
protect drugs from the degradation in the gastrointestinal tract; the technology can allow 
target delivery of drugs to various areas of the body. (Supriya A et al., 2018) 
The technology enables the delivery of drugs that are poorly water soluble and can 
provide means of bypassing the liver, thereby preventing the first pass metabolism 
Nanotechnology increases oral bioavailability of drugs due to their specialized uptake 
mechanisms such as absorptive endocytosis and are able to remain in the blood 
circulation for a long time, releasing the incorporated drug in a controlled fashion, leading 
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to less plasma fluctuations and minimized side-effects. Nanoscale size nanostructures are 
able to penetrate tissues and are easily taken up by cells, allowing for efficient delivery of 
drugs to target sites of action. Uptake of nanostructures has been reported to be 15–250 
times greater than that of microparticles in the 1–10 um range. Nanotechnology improves 
performance and acceptability of dosage forms by increasing their effectiveness, safety, 
patient adherence, as well as ultimately reducing health care costs. It may also enhance 
the performance of drugs that are unable to pass clinical trial phases. Nanotechnology 
definitely promises to serve as drug delivery carrier of choice for the more challenging 
conventional drugs used for the treatment and management of chronic diseases such as 
cancer, asthma, hypertension, HIV and diabetes. 
Nanotechnology is derived from the Latin word “Nano”, which means dwarf. One 
nanometer (nm) is equal to one-billionth of a meter, or else about the width of 6 carbon 
atoms or 10 water molecules. A human hair is approximately 80,000 nm wide, and a red 
blood cell is approximately 7000 nm wide. Atoms are smaller than 1 nm, however many 
molecules including some proteins range between 1 nm and larger.The theoretical 
foundations of nanotechnologies were first laid out in 1959 by the physicist Richard 
Feynman in his lecture, There’s plenty of room at the bottom. Feynman explored the 
possibility of manipulating material at the scale of individual atoms and molecules, 
imagining the whole of the Encyclopedia Britannica written on the head of a pin and 
foreseeing the increasing ability to examine and control matter at the nanoscale. The term 
nanotechnology was not used until 1974, when Norio Taniguchi, a researcher at the 
University of Tokyo, used it to refer to the ability to engineer materials precisely at the 
nanometer level. The primary driving force for miniaturization at that time came from the 
electronics industry, which aimed to develop tools to create smaller (and therefore faster 
and more complex) electronic devices on silicon chips. In medicine and pharmaceutics, 
nanotechnology is used to improve human health at a molecular level. The novel and 
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potential applications of nanotechnology in pharmaceutics are; development of diagnostic 
tools, formulation of drug carrier systems and gene therapy. The advantages of nanotech 
drugs compared to conventional counterparts lie on the basis of particle size. Drugs/drug 
products with nano dimension can be used at a lower concentration and can lead to early 
onset of bioactivity. Nano drug delivery systems (nanopharmaceutics) are, but not limited 
to, nanocapsules, nanospheres, nanosponges, nanoemulsions, solid lipid nanoparticles, 
nanovesicular systems (liposomes, niosomes), molecular systems (inclusion complexes) 
and nanocrystals. (Ahmed  et al., 2016) 
 
 
 
FIG: 1 Various systems of Nanotechnology 
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NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS 
1. SMART DRUG DELIVERY SYSTEMS 
One of the most outstanding achievements in the drug delivery field was the 
development of smart drug delivery systems (SDDSs), also called stimuli-sensitive 
delivery systems. The concept is based on rapid transitions of a physicochemical 
property of polymer systems upon a stimulus. This stimulus includes physical 
(temperature, mechanical stress, ultrasound, electricity, light), chemical (pH, ionic 
strength), or biological (enzymes, biomolecules) signals and such stimuli can either be 
internal, resulting from changes in the physiological condition of a living subject, or 
‘‘external’’ signals, artificially induced to provoke desired events. SDDS provides a 
programmable and predictable drug release profile in response to various stimulation 
sources (Masilamanb K et al., 2015). 
 
 
 
            FIGURE 2: Smart drug delivery system-Gold nanocage covered with polymer 
Depending on the desired applications, one may design different drug delivery 
systems for enhanced therapeutic efficiency with low systemic toxicity and side effects. 
SDDS has several advantages compared to conventional drug delivery systems. The 
conventional (Hamed Hamishehkar et al., 2015) controlled release systems are based 
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on the predetermined drug release rate irrespective of the environmental condition at the 
time of application. On the other hand, SDDS is based on the release-on-demand strategy, 
allowing a drug carrier to liberate a therapeutic drug only when it is required in response to 
a specific stimulation. The best example of SDDS has been self-regulated insulin delivery 
systems that can respond to changes in the environmental glucose level. One of the most 
widely used SDDSs has been polymeric micelles. Many polymeric micelles consisting of 
hydrophobic and hydrophilic polymer blocks have been developed. They have been found 
to dissolve water-insoluble drugs, such as doxorubicin or paclitaxel, at high concentrations. 
When administered to the body, drug release from polymeric micelles usually depends on 
simple diffusion, degradation of the micelle blocks, or disruption of the micelles by body 
components.  
The release kinetics of the loaded drug can be modulated by varying the 
degradation rate of hydrophobic polymer blocks, but because the degradation rate is 
usually very slow, the loaded drug is released by diffusion from polymeric micelles. This 
slow release by passive diffusion may not be desirable, as the polymeric micelles reaching 
the target site need to release their contents fast. To solve this problem, smart polymeric 
micelles have been designed to liberate the loaded therapeutic agent at the targeted site 
fast. For example, Poly (ethylene glycol)-b-polyhistidine (PEG-b-PHis) forms micelles only 
over the pKb of the polyhistidine block (pH 6.5–7.0). It is interesting to know that, the pKb 
can be adjusted by varying the molecular weight of polyhistidine. Since solid tumors have a 
slightly acidic environment, a small reduction in pH to less than 7 at the tumor site triggers 
dissociation of the polymeric micelle to release its contents. In a separate study, PEG-b- 
polyhistidine micelles containing doxorubicin effectively killed multi-drug resistant MCF-7 
cells at pH 6.8. Similarly, Hruby et al, (33) reported that, SDDS can achieve a highly 
localized drug accumulation at target sites even though it is administered parenterally. It is 
therefore postulated that, SDDS with enhanced targeting property is highly promising in 
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increasing the efficiency and efficacy of therapy while at the same time minimizing side 
effects 
2. POLYMER–DRUG CONJUGATES 
Polymer–drug conjugates are a class of polymer therapeutics that consists of a 
water-soluble polymer that is chemically conjugated to a drug through a biodegradable 
linker. The idea started in 1975 when Ringsdorf proposed the use of polymer–drug 
conjugates to deliver hydrophobic small molecules. The reasoning was that, small 
molecule drugs, especially hydrophobic compounds, have a low aqueous solubility and a 
broad tissue distribution profile such that, administration of the free drug may result in 
serious side effects. Therefore, conjugation of these compounds to hydrophilic, 
biocompatible polymers would significantly increase their aqueous solubility, modify their 
tissue distribution profile and enhance their plasma circulation half-life.  
An important attribute of colloidal systems is their hydrodynamic diameter, which are 
typically about 3–20 nm for polymer–drug conjugates and between 10 and 200 nm for 
colloidal particles such as micelles or liposomes. The colloidal nature or size of these 
vehicles can facilitate their retention within the circulation for prolonged periods, in 
comparison to low molecular weight small molecules. One major difference between 
polymer–drug conjugates and delivery systems that contain physically entrapped drug 
(e.g., micelles and liposomes) is that the drug is chemically conjugated to the polymer and 
therefore these systems qualify as new chemical entities (NCE). Classification as an NCE 
is often accompanied by additional development and regulatory hurdles that must be met 
in order to receive approval. Over the last decade, polymer conjugate technology has 
proven to be a viable formulation strategy. There have been reports (36 – 38) of 
bioconjugation of protein and peptide to PEG been able to significantly improve the efficacy 
of these macro- molecular drugs by increasing their stability in the presence of proteases 
and decreasing their immunogenicity. Studies have also shown that by using PEG in a 
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specific molecular weight range, the fast renal clearance and mononuclear phagocytic 
system uptake of the drugs can be prevented or delayed leading to a prolonged plasma 
half-life for the conjugated molecules. Successful applications have led to several FDA- 
approved products e.g. Neulasta®. The first practical use of polymer therapeutics that 
resulted in an FDA-approved anti-cancer treatment was the introduction of PEG-
Lasparaginase  (Oncaspar1) in 1994. This conjugate is composed of PEG polymer (MW ~ 
5 kD) attached to the enzyme, L asparaginase, and is used for the treatment of acute  
lymphoblastic leukemia (39). In fact, polymer–drug conjugate itself can be considered as a 
nanovehicle. Various conjugates have been developed and clinically tested.  
One of the major advantages of polymer–drug conjugates is prolonged circulation in 
the blood stream by retarding degradation/metabolism/excretion rates of the conjugated 
drugs. Many peptide and protein drugs cannot be delivered by oral administration because 
of their large molecular weights. Even when administered directly  into the blood stream, 
they do not remain in the blood for a long time due to fast degradation and metabolism, 
limiting the clinical applications. The circulation times of these drugs have increased 
substantially by conjugation with polymers, such as PEG. A good example is the glucagon-
like peptide-1, which regulates food uptake and insulin release. The peptide is a very 
useful therapeutic agent for diabetic patients, but it is liable to degradation by a plasma 
enzyme, dipeptidyl dipeptidase IV, but by introducing one PEG chain, Lee et al (40) 
showed that its half-life could be increased up to 40 folds over the natural form. Very often, 
low molecular weight drugs with high hydrophobicity are used for conjugation with 
attendant reduction in the degradation/ clearance rate as well as the toxicity of the 
conjugated drug. The therapeutic effect is achieved upon hydrolysis inside the target cells 
to release the original drug. The polymers used in conjugation usually have stimuli-
responsiveness, imparting unique properties into the conjugated drug such that, its 
activities can be turned on or off by external signals. For example,  the catalytic activity 
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endoglucanase 12A upon conjugation could be turned on by application of UV light or high 
temperature because, it was conjugated with either photosensitive or thermo-sensitive 
polymers. The active site of the enzyme was exposed by collapsing the conjugated long 
polymer chain by external stimuli. Once visible light was turned on or the temperature was 
lowered, the enzyme activity vanished due to the blocking of the active site by the 
extended polymer chain (Bhatt Neha et al., 2013). 
3. MULTIFUNCTIONAL DRUG CARRIERS 
A multifunctional drug delivery system (MDDS) refers to drug carrier that has 
multiple properties of prolonged blood circulation, passive or active localization at specific 
disease site, stimuli-sensitivity, ability to deliver drug into intracellular target organelles, 
and/or imaging ability (45). Technically therefore, it has two or more functions, infact, 
SDDS and polymer–drug conjugates discussed above can be considered MDDS. In 
addition to 74 Recent Advances in Novel Drug Carrier Systems delivering drugs, MDDS 
can carry out the second function, such as stimuli-responsiveness or hydrolysis inside 
cells. Some reported MDDS include the biotin-tagged pH-sensitive polymeric micelles 
based on a mixture of PLA-b-PEG-b-PHis-biotin (PLA=poly (L-lactic acid)) and PEG-b-PHis 
block copolymers by Lee et al (46) in which the targeting moiety, biotin, was masked until 
the carrier was exposed to an expected environment of pH 7.0. Once the nanocarrier was 
internalized to cancer cells by ligand– receptor interactions, lowered pH (< 6.5) destabilized 
the carrier resulting in a burst release of the loaded drug and that of Lukyanov et al (47), 
where a pH-degradable PEG-b-phosphatidylethanolamine (PE) liposome had anti-myosin 
monoclonal antibody as well as TAT or biotin attached on its surface. 
4. ORGANIC/INORGANIC COMPOSITES 
An inorganic-organic composite usually comprises an inorganic phase and a film 
forming organic phase. A typical green approach to developing an inorganic-organic 
composite involves the selection of film forming organic phase from starches having a 
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degree of polymerization; degree of substitution and viscosity such that the substituted 
starches are insoluble in water during mixing but dissolve at a higher processing 
temperature during forming, setting or drying of the composite. Thus, excessive migration 
of the starch is prevented and the composite is substantially strengthened. There has also 
been reports on the lab-on-a-chip approach, which embodies micron- or nano-sized 
machines composed of sophisticated circuits. Small devices have many advantages 
including portability/disposability, low cost, high reproducibility, high-throughput screening, 
and multiple functionalities in a single device.  
Recently, combined with other technologies such as optics, single molecular 
imaging, or cell/protein-based assay systems, biomedical lab-ona- chip devices have 
become an important part of drug discovery and diagnosis, but its application in drug 
delivery systems based on are just beginning to appear. As rightly noted by several 
authors, to release a drug from a nanodevice is more complicated than to perform assay or 
screening drug candidates, this is because, successful drug delivery requires at least four 
components namely; drug reservoir, pump, valve, and sensor (58). Drugs can be placed 
either in a fabricated reservoir or in conventional micro /nanoparticles. Other important 
organic/inorganic composites are metal nanoparticles, such as silver, iron oxide, or gold 
nanoparticles, coated with hydrophilic polymers. Their major application has been as 
theranostics. Only recently, Hirsch et al, (59) developed gold nanoshell, which provided 
tunable emission light for bioimaging. Importantly, is the fact that, gold nanoparticles can 
be detected by X-ray and emit thermal energy by excitation making it very useful for 
medical imaging and thermal therapy (theranostics). In a related report, Corot et al, (60) 
developed super paramagnetic iron oxide nanoparticles for magnetic resonance imaging 
(MRI) of the whole body. Mechanistically, these nanoparticles are primarily engulfed by 
monocyte or macrophage after intravenous administration. However, uptake of super 
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paramagnetic iron oxide by macrophage does not induce activation of nearby cells making 
it suitable for diagnosis of inflammatory or degenerative diseases.  
Approaches to improve the solubility or to increase the available Surface area for 
dissolution classified as 
 Physical modification are 
 Chemical modifications 
The Physical modifications are 
 Decreasing particle size (micronization, Nano suspensions) 
 Formation of polymorphs/pseudo polymorphs (including solvates) 
The chemical modifications are (Bhatt Neha et al., 2013) 
 Synthesis of soluble prodrugs and salts  
 Preparation of drug dispersions in carriers (eutectic mixtures, nonmolecular solid 
dispersions, solid solutions). 
 Approaches such as adding a surfactant/co-solvents 
 Complexation with cyclodextrine or/and preparing oil–in-water emulsions for 
intravenous applications have been developed for poorly water-soluble drugs 
 Thus, bioavailability of poorly water-soluble drugs will be affected positively when 
their dissolution rate is increased. These drugs show serious adverse clinical 
effects like non- steady absorption due to variability among patients and individual 
patient dosing. Drugs which have high permeability but low solubility (Class II 
according to Biopharmaceutics Classification System) are not easily dissolved so 
they may not be absorbed from the GI tract sufficiently. Moreover, such drugs 
incorporated into conventional dosage forms are usually affected by the fasted or 
fed state of the patient. This situation eventually causes inappropriate dosing and 
low bioavailability. 
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PHARMACEUTICAL APPROACHES  
For improving solubility of drugs, in order to enhance oral bioavailability. 
Solubilization poorly water-soluble drugs increases dissolution rate and absorption leading 
to a significant improvement of drug bioavailability. Approaches to improve the solubility or 
to increase the available surface area for dissolution are classified as physical and 
chemical modifications. Physical modifications are decreasing particle size (micronization, 
nanosuspensions), formation of polymorphs/pseudopolymorphs (including solvates), 
complexation/solubilization (use of surfactants or cyclodextrines, addition of cosolvents) 
and preparation of drug dispersions in carriers (eutectic mixtures, non-molecular solid 
dispersions, solid solutions).  
Approaches such as adding a surfactant/cosolvent, complexation with cyclodextrins 
or/and preparing oil–in-water emulsions for intravenous applications have been developed 
for poorly water-soluble drugs, but these approaches have limited application since the 
active drug substance must have specific physicochemical properties (for example, 
cyclodextrins must have suitable molecular weight for optimal conjugation of the conical 
structure with the drug for such applications to be successful). Solid dispersions are 
theoretically one of the appropriate methods for increasing dissolution rate, but molecules 
in the amorphous state are not thermodynamically stable; they can convert to the crystal 
form during storage. The use of surfactants or co-solvents sometimes leads to increased 
side effects and toxic reactions in the body (Abdul Hasan Sathali et al.,2015). 
Potential disadvantages of salt forms include, high reactivity with atmospheric 
carbon dioxide and water resulting in precipitation of the poorly water-soluble drug. 
Polymorphs are different crystalline forms of a drug that may have different physico 
chemical properties and biological activities with respect to morphology, density, melting 
point, hardness, compression, solubility and bioavailability. 
 Therefore, the preparation of actual drug polymorphs is crucial during 
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preformulation studies. An alternative drug delivery approach called micronization, has 
been developed to overcome poor solubility in water. Micronization of poorly soluble drugs, 
increases the dissolution rate of the drug due to the increase in surface area, but does not 
change the saturation solubility. In order to increase solubility and oral bioavailability, going 
down to the micron level may sometimes not be sufficient, so the next step, going down to 
the nano level, may be necessary.   
 INFLUENCE OF PARTICLE SIZE DISSOLUTION RATE Vs PARTICLE SIZE  
Intrinsic solubility can be explained as the number of moles of a substance per liter 
which dissolves in a particular solvent. Thus, dissolution is the process by which a solid 
substance dissolves. There are many factors that affect solubility; such as pH, co-solvent, 
surfactants, temperature and particle size. By changing these factors, solubility of active 
drug substances can be modified. Dissolution rate has been first described by Noyes and 
Whitney in 1897. In 1904, Nernst and Brunner explored the dissolution rate constant and 
diffusion coefficient of solutes. According to the Nernst Brunner equation, dissolution rate 
is proportional to the surface area of the active drug substance in contact with the 
dissolution medium. 
Dw/dt = D/h × S (Cs – Ct) 
Where, 
dw/dt-: Dissolution rate (mg/s) 
S- Effective surface area of the solid drug (cm2) 
Cs-Ct- Concentration gradient (mg/mL) 
Cs- Saturated concentration (mg/mL) 
Ct-Concentration of the solute at time t (mg/mL)  
h- Effective diffusion layer thickness (cm) 
D-Diffusion coefficient (cm/s) 
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It can be deduced from the formula that changing particle size of the active drug 
substance, it is possible to change the specific surface area and the dissolution rate of the 
active drug substance in body fluids . With this basic information in hand, it is clear that the 
dissolution rate and bioavailability of poorly water soluble drugs can be increased by 
decreasing the particle size of active drug substances. Additionally, particle size reduction 
results in a decrease in the diffusion layer thickness surrounding the drug particles and an 
increased concentration gradient between the surface of the drug particles (Tugba gulsun 
et al., 2009). 
 
 
 
(Total surface area 6cm2)   (Total surface area 12cm2)  (Total surface area 24cm2 ) 
 
FIGURE 3: Surface Area Enlargement by Particle Size Reduction Nanonization 
strategies for Poorly Water Soluble Drugs (Wang ZH et al.,2015).
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CHAPTER II                                                                             
 
NANOPARTICLES - A REVIEW 
 
Nanotechnology employs knowledge from the fields of physics, chemistry, 
biology, materials science, health sciences, and engineering. It has immense 
applications in almost all the fields of science and human life. Nanoparticles can be 
defined as particulate dispersions or solid particles with a size in the range of 10-
1000nm. The drug is dissolved, entrapped, encapsulated or attached to a nanoparticle 
matrix. Depending upon the method of preparation, nanoparticles, nanospheres or 
nanocapsules can be obtained. Nanocapsules are systems in which the drug is confined 
to a cavity surrounded by a unique polymer membrane, while nanospheres are matrix 
systems in which the drug is physically and uniformly dispersed. Depending upon to the 
method of preparation, nanoparticles, nanospheres or nanocapsules can be obtained. 
Nanocapsules are systems in which the drug is confined to a cavity surrounded by a 
unique polymer membrane, while nanospheres are matrix systems in which the drug is 
physically and uniformly dispersed. 
In recent years, biodegradable polymeric nanoparticles, particularly those coated 
with hydrophilic polymer such as poly (ethylene glycol) (PEG) known as long-circulating 
particles, have been used as potential drug delivery devices because of their ability to 
circulate for a prolonged period time target a particular organ, as carrier of DNA in gene 
therapy, and their ability to deliver proteins, peptides and genes. The input of today’s 
nanotechnology is that it allows real progress to achieve temporal and spatial site-
specific delivery. The market of nanotechnology and drug delivery systems based on 
this technology will be widely felt by the pharmaceutical industry. In recent years, the 
number of patents and products in this field is increasing significantly. . Several 
terminologies have been used to describe nanoparticulate drug delivery systems. 
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In most cases, either polymers or lipids are used as carriers for the drug, and the 
delivery systems have particle size distribution from few nanometers to few hundred 
nanometers. Nanomedicines is a large subject area and includes nanoparticles that act 
as biological mimetic (e.g. functionalized carbon nanotubes),”nanomachics”(e.g. those 
made from interchangeable DNA parts and DNA scaffolds such as octahedron and stick 
cube) ,nanofibers and polymeric nanoconstructs as biomaterials (e.g. molecular self- 
assembly and nano-fibers of peptides and peptideamphiphiles for tissue engineering) , 
shape memory polymers as molecular switches, nanoporous membranes) , and 
nanoscale microfabrication based devices (e.g. silicon microchips for drug release and 
micro machined hollow needles and two dimensional needles assay from single crystal 
silicon), sensors and laboratory diagnostics. Recent developments in nanotechnology 
have shown that nanoparticles (structures smaller than 100 nm in at least one 
dimension) have a great potential as drug carriers. Due to their small sizes, the 
nanostructures exhibit unique physicochemical and biological properties (e.g., an 
enhanced reactive area as well as an ability to cross cell and tissue barriers) that make 
them a favorable material for biomedical applications (Yuminoki K et al 2014). 
 The major goals in designing nanoparticles as a delivery system are to control 
particle size, surface properties and release of pharmacologically active agents in order 
to achieve the site-specific action of the drug at the therapeutically optimal rate and 
dose regimen. Though liposomes have been used as potential carriers with unique 
advantages including protecting drugs from degradation, targeting to site of action and 
reduction toxicity or side effects, their applications are limited due to inherent problems 
such as low encapsulation efficiency, rapid leakage of water-soluble drug in the 
presence of blood components and poor storage stability. On the other hand, polymeric 
nanoparticles offer some specific advantages over liposomes. For instance, they help to 
increase the stability of drugs/proteins and possess useful controlled release properties. 
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OBJECTIVES 
 
• Decrease drug resistance 
• Decrease toxicity  
• Enhance oral bioavailability 
• Enhance rate of dissolution 
• Enhance solubility  
• Increase the stability of drug and formulation 
• Increase drug targeting ability and patient compliance 
• Increase surface area 
• Reduce the dose needed 
ADVANTAGES  
 
1. This technology provides entrapment of active contents and side effects are less. 
 
2. It provides improved stability, elegance and formulation flexibility. 
 
3. It is non-mutagenic. 
 
4. Non-irritating, non-toxic. 
 
5. It provide extended release condition which is continuous action up to 12hr. 
 
6. Drug is protected from degradation. 
 
7. Therapeutic provide onset of action, formulations are cost effective. 
 
8. It can be used to mask unpleasant flavours and to convert liquid substances to 
 
solids. Less harmful side effects (since smaller quantities of the drug have 
 
contact with healthy tissue). 
 
9. Nanoparticle particles are soluble in water, so encapsulation can be done within the   
 
nanoparticle, by the addition of chemical called an adjuvant reagent. 
 
10. Particles can be made smaller or larger by varying the proportion of cross-linker to 
polymer. 
 
11. Easy scale-up for commercial production. 
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12. The drug profiles can be vary from fast, medium to slow release in case  
o f  dosing therapy. 
13. Predictable release. 
 
14. Biodegradable. 
 
Disadvantages 
 
1) nanoparticles include only small molecules. 
 
2) Depend only upon loading capacities 
 
The selection criteria of matrix materials depend on many factors such as:  
(a)  Size of nanoparticles required;  
(b)  Inherent properties of the drug, e.g., aqueous solubility and stability;  
(c)  Surface characteristics such as Charge and Permeability; 
 (d) Degree of biodegradability, biocompatibility and toxicity;  
e)  Drug release profile desired; and 
 (f)  Antigenicity of the final product. 
Limitations of Nanoparticles (An TT et al., 2014):  
a) Small size and large surface area can lead to particleparticle aggregation, 
making physical handling of nanoparticles difficult in liquid and dry forms. 
b) In addition, small particles size and large surface area readily result in limited 
drug loading and burst release. These practical problems have to be overcome before 
nanoparticles can be used clinically or made commercially available. 
Preparation of Nanoparticles  
Nanoparticles preparation is most frequently by three methods:  
(1) Dispersion of preformed polymers;  
(2)Polymerization of monomers; and  
(3) Ionic gelation or coacervation of hydrophilic polymers.  
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However, other methods such as supercritical fluid technology and particle 
replication in non-wetting templates have also been described in the literature for 
production of nanoparticles. The latter was claimed to have absolute control of particle 
size, shape and composition, which could set an example for the future mass 
production of nanoparticles in industry. 
DISPERSION OF PREFORMED POLYMERS  
Dispersion of preformed polymers is a common technique used to prepare 
biodegradable nanoparticle from poly (lactic acid) (PLA); poly (D,L-glycolide),PLG; poly 
(D,Llactide- coglycolide) (PLGA) and poly(cyanoacrylate) (PCA), This technique can be 
used in various ways as described further: 
SOLVENT EVAPORATION METHOD 
In this method, the polymer is dissolved in an organic solvent such as 
dichloromethane, chloroform or ethyl acetate, which is also used as the solvent for 
dissolving the hydrophobic drug. The mixture of polymer and drug solution is then 
emulsified in an aqueous solution containing a surfactant or emulsifying agent to form 
oil in water (o/w) emulsion. After the formation of stable emulsion, the organic solvent is 
evaporated either by reducing the pressure or by continuous stirring. Particle size was 
found to be influenced by the type and concentrations of stabilizer, homogenizer speed 
and polymer concentration. In order to produce small particle size, often a high-speed 
homogenization or ultrasonication may be employed (Bin Du et al.,2013). 
SPONTANEOUS EMULSIFICATION OR SOLVENT DIFFUSION METHOD 
This is a modified version of solvent evaporation method. I this method, the water 
miscible solvent along with a small amount of the water immiscible organic solvent is 
used as an oil phase. Due to the spontaneous diffusion of solvents a interfacial 
turbulence is created between the two phases leading to the formation 
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As the concentration of water miscible solvent increases, a decrease in the size 
of particle can be achieved. Both solvent evaporation and solvent diffusion methods can 
be used for hydrophobic or hydrophilic drugs. In the case of hydrophilic drug, a multiple 
w/o/w emulsion needs to be formed with the drug dissolved in the internal aqueous 
phase. 
POLYMERIZATION METHOD  
In this method, monomers are polymerized to form nanoparticle in an aqueous 
solution. Drug is incorporated either by being dissolved in the polymerization medium or 
by adsorption onto the nanoparticles after polymerization completed. The nanoparticle 
suspension is then purified to remove various stabilizers and surfactants employed for 
polymerization by ultracentrifugation and re-suspending the particles in an isotonic 
surfactant-free medium. This technique has been reported for making 
polybutylcyanoacrylate or poly (alkylcyanoacrylate) nanoparticles. 
COACERVATION OR IONIC GELATION METHOD  
The nanoparticles preparation is carried by using biodegradable hydrophilic polymers 
such as chitosan, gelatin and sodium alginate. Developing a method for preparing 
hydrophilic chitosan nanoparticles by ionic gelation. In this method, positively charged 
amino-group of chitosan interacts with negative charged tripolyphosphate to form 
coacervates with a size in the range of nanometer.  
Supercritical fluid technology 
Conventional methods such as solvent extraction-evaporation, solvent diffusion 
and organic phase separation methods require the use of organic solvents which are 
hazardous to the environment as well as to physiological systems. Therefore, the 
supercritical fluid technology has been investigated as an alternative to prepare 
biodegradable micro- and nanoparticles because supercritical fluids are environmentally 
safe. 
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A supercritical fluid can be generally defined as a solvent at a temperature above 
its critical temperature, at which the fluid remains a single phase regardless of pressure. 
Supercritical CO2 (SC CO2) is the most widely used supercritical fluid because of its 
mild critical conditions (Tc = 31.1 °C, Pc = 73.8 bars), nontoxicity, nonflammability 
nonflammability, and low price. The most common processing techniques involving 
supercritical fluids are supercritical antisolvent (SAS) and rapid expansion of critical 
solution (RESS). The process of SAS employs a liquid solvent, eg methanol, which is 
completely miscible with the supercritical fluid (SC CO2), to dissolve the solute to be 
micronized; at the process conditions, because the solute is insoluble in the supercritical 
fluid, the extract of the liquid solvent by supercritical fluid leads to the instantaneous 
precipitation of the solute, resulting the formation of nanoparticles. RESS differs from 
the SAS process in that its solute is dissolved in a supercritical fluid (such as 
supercritical methanol) and then the solution is rapidly expanded through a small nozzle 
into a region lower pressure, Thus the solvent power of supercritical fluids dramatically 
decreases and the solute eventually precipitates. This technique is clean because the 
precipitate is basically solvent free. RESS and its modified process have been used for 
the product of polymeric nanoparticles. Supercritical fluid technology technique, 
although environmentally friendly and suitable for mass production, requires specially 
designed equipment and is more expensive (Abdul Hasan Sathali. A., and 
Gopinath.M., et al., 2013). 
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TYPES OF NANOPARTICLES: 
 
 
 
SOLID LIPID NANOPARTICLES  
Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an 
alternative carrier system to emulsions, liposomes and polymeric nanoparticles as a 
colloidal carrier system for controlled drug delivery. Main reason for their development is 
the combination of advantages from different carriers systems like liposomes and 
polymeric nanoparticles. SLN have been developed and investigated for parenteral, 
pulmonal and dermal application routes. Solid Lipid Nanoparticles consist of a solid lipid 
matrix, where the drug is normally incorporated, with an average diameter below 1 μm. 
To avoid aggregation and to stabilize the dispersion, different surfactants are used that 
have an accepted GRAS (Generally Recognized as Safe) status. SLN have been 
considered as new transfection agents using cationic lipids for the matrix lipid 
composition. Cationic solid lipid nanoparticles (SLN) for gene transfer can be formulated 
using the same cationic lipids as for liposomal transfection agents.  
POLYMERIC NANOPARTICLES  
In comparison to SLN or nanosuspensions polymeric nanoparticles (PNPs) 
consists of a biodegradable polymer. The advantages of using PNPs in drug delivery 
are many, being the most important that they generally increase the stability of any 
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volatile pharmaceutical agents and that they are easily and cheaply fabricated in 
large quantities by a multitude of methods. Also, polymeric nanoparticles may have 
engineered specificity, allowing them to deliver a higher concentration of pharmaceutical 
agent to a desired location. Polymeric nanoparticles are a broad class comprised of 
both vesicular systems (nanocapsules) and matrix systems (nanospheres).  
DENDRIMERS  
Dendrimers, a unique class of polymers, are highly branched macromolecules 
whose size and shape can be precisely controlled. Dendrimers are fabricated from 
monomers using either convergent or divergent step growth polymerization. The well-
defined structure, mono dispersity of size, surface functionalization capability, and 
stability are properties of dendrimers that make them attractive drug carrier candidates. 
Drug molecules can be incorporated into dendrimers via either complexation or 
encapsulation. Dendrimers are being investigated for both drug and gene delivery, as 
carriers for penicillin, and for use in anticancer therapy. 
NANOTUBE  
Carbon nanotubes (CNTs; also known as buckytubes) are allotropes of carbon with 
a cylindrical nanostructure. Nanotubes have been constructed with length-to-diameter 
ratio of up to 132,000,000:1, which is significantly larger than any other material. These 
cylindrical carbon molecules have novel properties which make them potentially useful 
in many applications in nanotechnology, electronics, optics, and other fields of materials 
science, as well as potential uses in architectural fields. They may also have 
applications in the construction of body armor. They exhibit extraordinary strength and 
unique electrical properties, and are efficient thermal conductors. Nanotubes are 
members of the fullerene structural family, which also includes the spherical bucky balls. 
The ends of a nanotube may be capped with a hemisphere of the bucky ball structure. 
Their name is derived from their size, since the diameter of a nanotube is on the  
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order of a few nanometers (approximately 1/50,000th of the width of a human hair), 
while they can be up to 18 centimeters in length (as of 2010). Nanotubes are 
categorized as single-walled nanotubes (SWNTs) and multi-walled nanotubes 
(MWNTs).Chemical bonding in nanotubes is described by applied quantum chemistry, 
specifically, orbital hybridization. The chemical bonding of nanotubes is composed 
entirely of sp2 bonds, similar to those of graphite. These bonds, which are stronger than 
the sp3 bonds found in diamonds, provide nanotubules with their unique strength. 
Moreover, nanotubes naturally align themselves into "ropes" held together by Van der 
Waals forces (Afifa Bathool et al., 2012). 
NANOWIRE  
A nanowire is a nanostructure, with the diameter of the order of a nanometer (10−9 
meters). Alternatively, nanowires can be defined as structures that have a thickness or 
diameter constrained to tens of nanometers or less and an unconstrained length. At 
these scales, quantum mechanical effects are important — which coined the term 
"quantum wires". Many different types of nanowires exist, including metallic (e.g., Ni, Pt, 
Au), semiconducting (e.g., Si, InP, GaN, etc.), and insulating (e.g., SiO2, TiO2). 
pharmacokinetics monitoring of diabetes, and health care. In such plans, future medical 
nanotechnology is expected to employ Nano robots injected into the patient to perform 
work at a cellular level. Such Nano robots intended for use in medicine should be non-
replicating, as replication would needlessly increase device complexity, reduce 
reliability, and interfere with the medical mission. Instead, medical nanorobots are 
posited to be manufactured in hypothetical, carefully controlled nanofactories in which 
nanoscale machines would be solidly integrated into a supposed desktop-scale 
machine that would build macroscopic products. The most detailed theoretical 
discussion of nanorobotics, including specific design issues such as sensing, power 
communication, navigation, manipulation, locomotion, and onboard computation, 
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has been presented in the medical context of nanomedicine by Robert Freitas. Some of 
these discussions remain at the level of unbuildable generality and do not approach the 
level of detailed engineering.  
APPLICATIONS OF NANOPARTICLES: 
Tumor targeting using Nanoparticulate delivery system 
The rational of using nanoparticles for tumor targeting is based on (1) 
Nanoparticles will be able to deliver a concentrate dose of drug in the vicinity of the 
tumor targets via the enhanced permeability and retention effect or active nanoparticles. 
(2) Nanoparticles will reduce the drug exposure of health tissues by limiting drug 
distribution to target organ.An experiment demonstrated in mice treated with 
doxorubicin incorporated into poly (isohexylcynoacrylate) nanospheres that higher 
concentration of doxorubicin manifested in the liver, spleen and lungs than in mice 
treated with free doxorubicin (Ansari KA et al., 2011). 
Nanoparticles for oral delivery of peptide and proteins: 
Significant advances in biotechnology and biochemistry have led to the discovery 
of a large number of bioactive molecules and vaccines based on peptides and proteins. 
Development of suitable carriers remains a challenge due to the fact that bioavailability 
of these molecules is limited by the epithelial barriers of the gastrointestinal tract and 
their susceptibility to gastrointestinal degradation by digestive enzymes. Polymeric 
nanoparticles allow encapsulation of bioactive molecules and protect them against 
enzymatic and hydrolytic degradation. For instance, it has been found that insulin-
loaded nanoparticles have preserved insulin activity and produced blood glucose 
reduction in diabetic rats for up to 14 days following the oral administration. The surface 
area of human mucosa extends to 200 times that of skin 62. The gastrointestinal tract 
provides a variety of physiological and morphological barriers against protein or peptide 
delivery, e.g., (a) proteolytic enzymes in the gut lumen like pepsin, trypsin and  
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chymotrypsin; (b) proteolytic enzymes at the brush border membrane (endopeptidases); 
(c) bacterial gut flora; and (d) mucus layer and epithelial cell lining itself. The histological 
architecture of the mucosa is designed to efficiently prevent uptake of particulate matter 
from the environment. One important strategy to overcome the gastrointestinal barrier is 
to deliver the drug in a colloidal carrier system, such as nanoparticles, which is capable 
of enhancing the interaction mechanisms of the drug deliverysystem and the epithelia 
cells in the GI tract. 
Nanoparticles for Gene delivery  
Polynucleotide vaccines work by delivering genes encoding relevant antigens to 
host cells where they are expressed, producing the antigenic protein within the vicinity 
of professional antigen presenting cells to initiate immune response. Such vaccines 
produce both humoral and cellmediated immunity because intracellular production of 
protein, as opposed to extracellular deposition, stimulates both arms of the immune 
system. 
Targeting of nanoparticles to epithelial cells in the GI tract using ligands 
Targeting strategies to improve the interaction of nanoparticles with adsorptive 
enterocytes and M-cells of Peyer’s patches in the GI tract can be classified into those 
the surface of enterocytes and M cells display cell-specific carbohydrates, which may 
serve as binding sites to colloidal drug carriers containing appropriate ligands. The 
ability to increase oral bioavailability of various peptides (e.g., granulocyte colony 
stimulating factor, erythropoietin) and particles by covalent coupling to vitamin B-12 has 
been studied. For this intrinsic process, mucoprotein is required, which is prepared by 
the mucus membrane in the stomach and binds specifically to cobalamin. The 
mucoprotein completely reaches the ileum where resorption is mediated by specific 
receptors. 
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NANOTECHNOLOGY IN MEDICINE APPLICATION: 
Anti-Microbial Techniques (Maiti S et al., 2012): 
One of the earliest nanomedicine applications was the use of nanocrystalline silver, 
which is as an antimicrobial agent for the treatment of wounds, A nanoparticle cream 
has been shown to fight staph infections. The nanoparticles contain nitric oxide gas, 
which is known to kill bacteria. Studies on mice have shown that using the nanoparticle 
cream to releasenitric oxide gas at the site of staph abscesses significantly reduced the 
infection. Burn dressing that is coated with nanocapsules containing antibotics. If a 
infection starts the harmful bacteria in the wound causes the nanocapsules to break 
open, releasing the antibotics. This allows much quicker treatment of an infection and 
reduces the number of times a dressing has to be changed. A welcome idea in the early 
study stages is the elimination of bacterial infections in a patient within minutes,instead 
of delivering treatment with antibiotics over a period of weeks. 
Absorption enhancement using non-specific interactions 
In general, the gastrointestinal absorption of macromolecules and particulate 
materials involves either paracellular route or endocytotic pathway. The paracellular 
route of absorption of nanoparticlesutilises less than 1% of mucosal surface area Using 
polymers such as chitosan, starch or poly (acrylate) can increase the paracellular per- 
meability of macromolecules. Endocytotic pathway for absorption of nanoparticles is 
either by receptor-mediated endocytosis, that is, active targeting, or adsorptive 
endocytosis which does not need any ligands This process is initiated by an unspecific 
physical adsorption of material to the cell surface by electrostatic forces such as 
hydrogen bonding or hydrophobic interactions. Adsorptive endocytosis depends 
primarily on the size and surface properties of the material. If the surface charge of the 
nanoparticles is positive or uncharged, it will provide an affinity to adsorptive 
enterocytes though hydrophobic, whereas if it is negatively charged and hydrophilic,   
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it shows greater affinity to adsorptive enterocytes and M cells. This shows that a 
combination of size, surface charge and hydrophilicity play a major role in affinity. This 
is demonstrated with poly (styrene) nanoparticles and when it is carboxylated. 
 
Applications Of Nanocrystals By Various Routes Of Administration 
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Nanoparticles for drug delivery into the brain: 
The blood-brain barrier (BBB) is the most important factor limiting the development 
of new drugs for the central nervous system. Relatively impermeable endothelial cells 
characterize the BBB with tight junctions, enzymatic activity and active efflux transport 
systems. It effectively prevents the passage of water-soluble molecules from the blood 
circulation into the CNS, and can also reduce the brain concentration of lipid soluble 
molecules by the function of enzymes or efflux pumps. Consequently, the BBB only 
permits selective transport of molecules that are essential for brain function. Strategies 
for nanoparticle targeting to the brain rely on the presence of and nanoparticle 
interaction with specific receptor mediated transport systems in the BBB. 
For example polysorbate 80/LDL, transferrin receptor binding antibody (such as OX26), 
lactoferrin, cell penetrating peptides and melanotransferrin have been shown capable of 
delivery of a self non transportable drug into the brain via the chimeric construct that 
can undergo receptor-mediated transcytosis. 
 It has been reported poly(butylcyanoacrylate) nanoparticles was able to deliver 
hexapeptidedalargin, doxorubicin and other agents into the brain which is significant 
because of the great difficulty for drugs to cross the BBB. Despite some reported 
success with polysorbate 80 coated NPs, this system does have many shortcomings 
including desorption of polysorbate coating, rapid NP degradation and toxicity caused 
by presence of high concentration of polysorbate 80. OX26MAbs (anti-transferrin 
receptor MAbs), the most studied BBB targeting antibody, have been used to enhance 
the BBB penetration of lipsosomes. However, recently, Jiet al. demonstrated that brain 
uptake of lactoferrin, an ironbinding glycoprotein belonging to the transferrin (Tf) family, 
is twice that of OX26 and transferrrinin vivo. It is possible soon we will see these BBB 
specific molecules used for targeting nanoparticles to the brain (Singling Tang et al., 
2011). 
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 CHAPTER III 
LITERATURE REVIEW 
Supriya A et al., 2018 developed Formulation and Evaluation of Capsules of 
Asenapine Maleate Loaded Chitosan Nanoparticles. Asenapine Maleate is an 
antipsychotic drug which has poor bioavailability due to its insolubility in water and 
belongs to biopharmaceutics Classification-IV. The aim of this study is to enhance 
the bioavailability of Asenapine Maleate by the preparation of Nanoparticles using 
ionic gelation method. In present work different formulations were prepared by using 
different ratios of polymer, Tween 80 (stabilizer) and sodium tri polyphosphate (cross 
linking agent). Prepared Nanoparticle was evaluated for its Particle Size, zeta 
potential, scanning electron microscopy, Percentage practical yield, Drug 
Entrapment Efficiency, and in-vitro drug releas studies. NPs formulation was 
subsequently loaded into hard gelatin capsules that were evaluated for 
preformulation studies, in-vitro dissolution and pharmacokinetic behavior. The 
optimized CSNPs was found with particle size of 41.1 nm, zeta potential -9.9 Mv, 
percentage practical yield was 97.5%. Entrapment efficiency (%EE) of 65.7%, 
scanning electron microscopy irregular shape. The in-vitro release profile was found 
to be 92.5% sustained up to 510 minutes. Thus, incorporation of Asenapine maleate 
into CSNPs results in enhanced bioavailability when compared to pure drug.  
Ahmed  et al., 2016 developed the optimized freeze-dried finasteride nanoparticles 
(NPs) were prepared from drug nanosuspension formulation that was developed 
sing the bottom–up technique. The effects of four formulation and processing 
variables that affect the particle size and solubility enhancement of the NPs were 
explored using the response surface optimization design. The optimized formulation 
was morphologically characterized using transmission electron microscopy (TEM). 
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Physicochemical interaction among the studied components was investigated. 
Crystalline change was investigated using X-ray powder diffraction (XRPD). Crystal 
growth of the freeze-dried NPs was compared to the corresponding aqueous drug 
nanosuspension. Freeze-dried NPs formulation was subsequently loaded into hard 
gelatin capsules that were examined for in vitro dissolution and pharmacokinetic 
behavior. Results revealed that in most of the studied variables, some of the 
quadratic and interaction effects had a significant effect on the studied responses. 
TEM image illustrated homogeneity and shape of the prepared NPs. No interaction 
among components was noticed. XRPD confirmed crystalline state change in the 
optimized NPs. An enhancement in the dissolution rate of more than 2.5 times from 
capsules filled with optimum drug NPs, when compared to capsules filled with pure 
drug, was obtained. Crystal growth, due to Ostwald ripening phenomenon and 
positive Gibbs free energy, was reduced following lyophilization of the 
nanosuspension formulation. Pharmacokinetic parameters from drug NPs were 
superior to that of pure drug and drug microparticles. In conclusion, freeze-dried NPs 
based on drug nanosuspension formulation is a successful technique in enhancing 
stability, solubility, and in vitro dissolution of poorly water-soluble drugs with possible 
impact on the drug bioavailability responses. TEM image illustrated homogeneity 
and shape of the prepared NPs. No interaction among components was noticed. 
XRPD confirmed crystalline state change in the optimized NPs. An enhancement in 
the dissolution rate of more than 2.5 times from capsules filled with optimum drug 
NPs, when compared to capsules filled with pure drug, was obtained. Crystal 
growth, due to Ostwald ripening phenomenon and positive Gibbs free energy, was 
reduced following lyophilization of the nanosuspension formulation. Pharmacokinetic 
parameters from drug NPs were superior to that of pure drug and drug 
microparticles. In conclusion, freeze-dried NPs based on drug nanosuspension 
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formulation is a successful technique in enhancing stability, solubility, and in vitro 
dissolution of poorly water-soluble drugs with possible impact on the drug 
bioavailability. 
Masilamanb K et al., 2015 developed a new delivery systems for the controlled 
release of drugs is one of the most innovative fields of research in pharmaceutical 
sciences. Nanoparticles specially designed to release the drug in the vicinity of 
target sites. The aim of this study was to formulate and evaluate the Lansoprazole 
nanoparticles to improve the therapeutic efficacy of Lansoprazole by loading in 
nanoparticle drug delivery system. Lansoprazole loaded chitosan nanoparticles 
(CNP1 to CNP10) were prepared by ionotropic gelation method. The formulated 
nanoparticles were evaluated for external morphological characters, determination of 
particle size analysis, zeta potential, drug content, entrapment efficiency and in-vitro 
release studies. The drug content for the Lansoprazole loaded chitosan 
nanoparticles varied from 69.5±7.2% to 87.9±1.2%. The entrapment efficiencies 
were found to be minimum and maximum of 39.3±2.6% and 85.6±1.2%, the 
optimum entrapment efficiency was found to be 85.3±0.8%, particle size varied from 
360±12nm to 814±62nm, zeta potential values were in positive and increased from 
11.2±1.2mV to 18.7±0.4mV. In-vitro release of drug follows zero order and showed 
sustained release behavior for a period of 24 hr. The study demonstrated the 
successful preparation of sustained release polymeric nanoparticles of 
Lansoprazole.  
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 Hamed Hamishehkar et al., 2015 developed the Evaluation of Different Methods 
for Preparing Nanoparticle Containing Gammaoryzanol for Potential Use in Food 
FortificationGammaoryzanol is a natural antioxidant and could provide beneficial as 
used in the food products due to the antioxidant activity and potential health benefits. 
Nanotechnology has been introduced into several aspects of the food science, 
including encapsulation of materials and used as delivery systems. The field of 
nanoparticle delivery systems for nutrients and nutraceuticals has been expanding 
over the last decades. The aim of this work was evaluation of different methods for 
preparation of polymeric nanoparticle containing gammaoryzanol. Nanoprecipitation 
technique, where polymer and gammaoryzanol were dissolved in acetone, nano-
emulsion template method, by stepwise addition of water in to the oil phase 
consisting of ethyl acetate, gammaoryzanol and surfactant mixtures, as well as 
emulsification solvent evaporation technique, where gammaoryzanol and polymer 
were dissolved in ethyl acetate and chloroform, were used for preparation of 
nanoparticles. Two ratio of gammaoryzanol-polymer (Ethyl cellulose) (1:2 and 1:4) 
as well as different solvents and surfactants were used in these methods to produce 
gammaoryzanol nanoparticles. Among these methods, solvent evaporation 
technique has been successfully employed to produce gammaoryzanol loaded 
nanoparticles with desired characteristics.  
Natarajan Tamilselvan et al.,2015 developed the Formulation and characterization 
of anti-alzheimer’s drug loaded chitosan nanoparticles and its In vitro biological 
evaluation. The main objective of the study is to formulate hydrophilic drug loaded 
sustained release nanoparticles with the size of 200 nm and to increase the 
encapsulation efficiency of the drug. The nanoparticles were prepared by simple 
ionic gelation method using various concentrations of chitosan and TPP. The 
prepared nanoparticles were evaluated for particle size, shape, charge,  
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encapsulation efficiency, in vitro drug release and in vitro cytotoxicity.  The optimized 
drug loaded nanoparticles showed the size of 125 ± 4mn with PDI 0.25 ± 0.05, 
potential of +40 ± 2mV, encapsulation efficiency of 65.5 ± 1.2% and the drug release 
of 68.4 ± 1.6% with an initial burst effect up to one hour followed by sustained release 
up to 24 hrs. Further the optimized formulation was subjected to investigate the 
cytotoxicity of CS-NP in SH-SY-5Y cell lines it revealed that the cell viability was 
above 90% without any toxicity. These preliminary results demonstrate that the 
possibility of delivering hydrophilic drugs to brain with enhanced encapsulation 
efficiency.  
Bhatt Neha et al., 2013 worked in drug delivery to the brain using polymeric 
nanoparticles. Nanoparticle drug carriers consist of solid biodegradable particles in 
size ranging from 10 to 1000 nm (50–300 nm generally). The use of minute particles 
as drug carriers for targeted treatment has been studied over a long period of time. 
A selective accumulation of active substances in target tissues has been 
demonstrated for certain so-called nanocarrier systems that are administered bound 
to pharmaceutical drugs. Great expectations are placed on nanocarrier systems that 
can overcome natural barriers such as the blood-brain barrier (BBB) and transport 
the medication directly to the desired tissue and thus heal neurological diseases that 
were formerly incurable. Polymeric Nanoparticle have been shown to be promising 
carriers for CNS drug delivery due to their potential both in encapsulating drugs, 
hence protecting them from excretion and metabolism, and in delivering active agent 
across the blood – brain barrier without inflicting any damage to the barrier  Different 
polymers have been used and different strategies like surface modification have 
been done to increase the retention time of nanoparticles.  
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Graves et.al., 2015 developed and evaluation of biodegradable nanoparticles for the 
oral delivery of fenretinide. Fenretinide is an anticancer drug with low water solubility 
and poor bioavailability. The goal of this study was to develop biodegradable 
polymeric nanoparticles of fenretinide with the intent of increasing its apparent 
aqueous solubility and intestinal permeability. Three biodegradable polymers were 
investigated for this purpose: two different poly lactide-co- studies. The release 
kinetics was analyzed using zero-order model, first-order model and higuchi’s 
square root equation. FT-IR was performed to know the compatibility of the drug with 
various excipients and SEM analysis was performed to know the morphology of the 
pellet. All the 10 formulations are kept for Stability studies and carried out for 3 
months at 40°C/75 %RH and 25°C/60 % RH according to ICH guidelines. The 
optimized formulation F10 was shown desirable in vitro acid and buffer drug release 
during the stability period and comparable to the innovator. 
 Amighi K et al., 2005, prepared nifedipine nanoparticles using high pressure 
homogenization. Nanoparticals were characterized in terms of size, morphology 
and redispersion characteristics following water removal. Saturation solubility and 
dissolution characteristics were investigated and compared to the un- milled 
commercial NIF to verify the theoretical hypothesis on the benefit of increased 
surface area. Crystalline state evaluation before and following particle size 
reduction was also conducted through differential scanning calorimeter (DSC) and 
Powder X-Ray diffraction (PXRD). Through this study it has been shown that initial 
crystalline state is maintained following particle size reduction and that the 
dissolution characteristics of Nifedipine nanoparticles were significantly increased 
in regard to the commercial product. This approach should have a general 
applicability to many poorly      water soluble drug entities.  
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Abdul Hasan Sathali et al.,2015 developed and evaluation of Amisulpride 
Nanocrystal tablets. Amisulpride is an antipsychotic drug which belongs to BCS type 
II clacification.The present study aims to develop nanocrystal of Amisulpride in order 
to enhance solubility and dissolution rate by decreasing particle size of drug. The 
amisulpride nanocrystal with small and uniform particle size were successfully 
prepared by emulsion solvent diffusion method is based on the high pressure 
homogenization technique using β-cyclodextrin, sodium lauryl sulphate, hydroxy 
propyl methyl cellulose E15 and polyvinyl alcohol as stabilizers at different 
concentrations. The compatibility studies was done by infrared spectroscopy and 
differential scanning calorimetry showed that no interaction between the drug and 
stabilizers. The amisulpride nanocrystals were evaluated for drug content, invitro 
dissolution study, SEM, X-ray powder diffraction, particle size distribution, zeta 
potential and solubility studies. The X-ray powder diffraction (XRPD) confirmed that 
there was no change in the crystalline state by this size reduction process. The 
presence of stabilizers made the nanocrystal formulations more stable. The solubility 
and in vitro dissolution studies suggested that the dissolution rate when compared to 
pure drug. It was showed that BCD 1.8% concentration gives better drug release and 
enhances the solubility. The amisulpride nanocrystal tablets were successfully 
prepared from the best formulation by direct compression method. Recompression 
and post compression evaluation studies are also performed. Amisulpride 
nanocrystal tablet showed better drug release profile when compared to market and 
amisulpride tablet.   
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Wang ZH et al.,2015, developed and evaluation of transferrin-stabilized paclitaxel 
nanocrystal formulation. The aim of the present study was to prepare and evaluate a 
paclitaxel nanocrystal-based formulation stabilized by serum protein transferrin in a 
non-covalent manner. The pure paclitaxel nanocrystals were first prepared using an 
antisolvent precipitation method augmented by sonication. The serum protein 
transferrin was selected for use after evaluating the stabilizing effect of several 
serum proteins including albumin and immunoglobulin G. The formulation contained 
approximately 55-60% drug and was stable for at least 3months at 4°C. In vivo 
antitumor efficacy studies using mice inoculated with KB cells demonstrate 
significantly higher tumor inhibition rate of 45.1% for paclitaxel-transferrin formulation 
compared to 28.8% for paclitaxel nanosuspension treatment alone. Interestingly, the 
Taxol(®) formulation showed higher antitumor activity than the paclitaxel-transferrin 
formulation, achieving a 93.3% tumor inhibition rate 12days post initial dosing 
However, the paclitaxel-transferrin formulation showed a lower level of toxicity, 
which is indicated by a steady increase in body weight of mice over the treatment 
period. In comparison, treatment with Taxol(®) resulted in toxicity issues as body 
weight decreased. These results suggest the potential benefit of using a serum 
protein in a non-covalent manner in conjunction with paclitaxel nanocrystals as a 
promising drug delivery model for anticancer therapy.  
Lockhart et al.,2015 developed Polyester nanoparticles (NPs) co- loaded with 
tamoxifen (TAM) and quercetin (QT) to investigate the loading,  release and in vitro 
metabolism of a dual drug formulation. The NPs are made in 2 variations, 4% and 
8% crosslinking densities, to evaluate the effects on metabolism and release 
kinetics. The NP-4% formulation with a particle size of 89.3 ± 14.8 nm was found to 
have loading percentages of 6.91 ± 0.13% TAM  and 7.72 ± 0.15% QT after 
targeting 10% (w/w) each. The NP-8% formulation with a particle   size of 91.5 ± 9.8 
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nm was found to have loading percentages of 7.26 ± 0.10% TAM & 7.80 ± 0.12% 
QT. The stability of the formulation was established in simulated gastrointestinal 
fluids, and the metabolism of TAM was shown to be reduced 2-fold and 3-fold for 
NP-4%s and NP-8%s, respectively, while QT metabolism was reduced 3 and 4-fold. 
The implications for improved bioavailability of the NP formulations were supported 
by cytotoxicity results that showed a similar efficacy to free dual drug formulations 
and even enhanced anti-cancer effects in the recovery condition. This work 
demonstrates the suitability of the nanosponges not only as a dual release drug 
delivery system but also enabling a regulated metabolism through the capacity of a 
nanonetwork. The variation in crosslinking enables a dual release with tailored 
release kinetics and suggests improved bioavailability aided by a reduced 
metabolism.   
Umar PS et al., 2015 developed clotrimazole loaded – cyclodextrin nanoparticles 
containing vaginal gels using polymers like hydroxyl propyl methyl cellulose 
(HPMC), Sodium Carboxy Methyl Cellulose (NaCMC), Methyl cellulose and 
Carbopol. The gel formulations were prepared with a view to improve permeability of 
drug. The prepared gels were evaluated for pH, viscosity, spreadability, 
extrudability, and mucoadhesive time and invitro diffusion study. The correlation 
coefficient values revealed that the diffusion profiles follows zero order kinetics and 
the mechanism of drug release was governed by peppas model. The diffusion 
exponent of release profiles (slope) has a value of (n> 0.5) which indicates non 
fickian diffusion. It was found that the clotrimazole loaded nanoparticles containing 
gels prepared with HPMC showed good extrudability, homogeneity, spreadability 
and required diffusion rate in comparison with other. Formulations and was selected 
as suitable candidate to  be delivered through vaginal route at controlled rate. 
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Gouri sankar et al., 2015 developed simvastatin loaded - cyclodextrin nanoparticles 
with carbonyldiimidazole as a crosslinker and chitosan as ucoadhesive agent for 
oral drug delivery for enhancing the solubility of simvastatin. Solid dispersion 
technique has been used for drug incorporation.  The particle size loaded 
nanosponge was found to be between 350-600nm with minimum PI (0.374-
0.417).The loaded nan osponges have shown more solublisation efficiency in 
comparison with plain simvastatin and – cyclodextrin complex. It was found that 
solubility of simvastatin was enhanced more than 20- folds with a nanosponge 
system. The zeta potential was sufficiently high (- 26.8 to -29.5Mv) which indicates 
formation of a stable colloidal nanosuspension. The simvastatin loaded 
nanosponges were characterized by FT-IR, DSC and powder x-ray diffraction 
(XRD) studies and it confirmed the interactions of simvastatin with nanosponges. 
The invitro drug release of simvastatin was controlled over a prolonged period of 
time and was influenced by the crosslinker ratio. The formulations were stable 
under the conditions of storage.  
Singling Tang et al., 2011, improved the oral bioavailabilty of genistein, by 
nanoparticles. Nanoparticles were prepared by the nanoprecipitation technique 
using Eudragit E100 as carrier. The drug loaded nanoparticles were spherical on 
observation by transmission electric microscopy(TEM). Release of drug from the 
genistein nanoparticles was two times greater than that from the conventional 
capsules. These esults suggested that a nanoparticle system was a potentially 
promising formulation for the efficient delivery of poorly water soluble drugs by oral 
administration.  
     Sureshkumar P et al., 2015 developed Miconazole loaded cyclodextrin nanoparticle 
    were prepared by cross linking - cyclodextrin with carbonate bonds of diphenyl 
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carbonate in different proportions, which are porous as well as nanosized.Drug 
was incorporated by  solvent evaporation method by dissolving the drug in various 
solvents like ethanol, methanol, acetone and chloroform. The formulated 
nanosponges are influenced by the solvent used for drug loading by solvent 
evaporation technique. Based on the drug encapsulation efficiency, drug content 
and extent of sustained nature, the gel prepared with polymer and crosslinking 
agent in 1:1 ratio, chloroform as a  solvent and carbopol as a felling agent(F12) 
formulation was concluded to be  the best formulation zero order release kinetics 
and mechanism of drug release  was governed by peppas model. The diffusion 
exponential coefficient values were found to be in between 0.9402 to 1.1864 
indicating non fickian diffusion mechanism. The optimized formulation has good 
spreadability extrudability and mucoadhesive nature. The pH and viscosity of the 
formulation were appropriate for the vaginal drug delivery and nanosponge 
technique was a better choice for the burst effect.  
Shende PK et al.,2015 developed Meloxicam loaded β-cyclodextrin-based  
nanoparticles to enhance their solubility and stability and to prolong release  using 
different methods that included physical mixing, kneading and sonication.  Particle 
size, zeta potential, encapsulation efficiency, stability study results, in  vitro and in 
vivo drug release study results, FTIR, DSC and XRPD were used  as 
characterization parameters. SEM studies revealed that the particle sizes of the 
nclusion complexes of meloxicam were within the range of 350 ± 5.69-765 ± 13.29 
nm. The zeta potentials were sufficiently high to obtain stable formulations. In vitro 
and in vivo release studies revealed the controlled release of meloxicam from the 
nanosponges for 24h. The interaction of the meloxicam with the nanoparticles was 
confirmed by FTIR and DSC. A XRPD study revealed that the crystalline nature of  
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meloxicam was changed to an amorphous form due to the complexation with the 
nanoparticles. A stability study revealed that the meloxicam nanosponges were 
stable. Therefore, β-cyclodextrin-based nanosponges represent a novel approach 
for the controlled release of meloxicam for anti-inflammatory and analgesic 
effects.parameters. SEM studies revealed that the particle sizes of the inclusion 
complexes of meloxicam were within the range of 350 ± 5.69-765 ± 13.29 nm. The 
zeta potentials were sufficiently high to obtain stable formulations. In vitro and in 
vivo release studies revealed the controlled release of meloxicam from the 
nanosponges for 24h. The interaction of the meloxicam with the nanosponges was 
confirmed by FTIR and DSC. A  XRPD study revealed that the crystalline nature of 
meloxicam was changed to an amorphous form due to the complexation with the 
nanosponges. A stability study revealed that the meloxicam nanosponges were 
stable. Therefore, β-cd- based NS represent a novel approach for the controlled 
release of meloxicam  for anti-inflammatory and analgesic effects.  
Wang ZH et al., 2015 developed and evaluation of transferrin-stabilized paclitaxel 
nanocrystal formulation. The aim of the present study was to prepare and evaluate a 
paclitaxel nanocrystal-based formulation stabilized by serum protein Tansferrin in a 
non-covalent manner. The pure paclitaxel nanocrystals were first prepared using an 
antisolvent precipitation method augmented by sonication. The serum protein 
transferrin was selected for use after evaluating the stabilizing effect of several 
serum proteins including albumin and immunoglobulin G. The formulation contained 
approximately 55-60% drug and was stable for at least 3months at 4°C. In vivo 
antitumor efficacy studies using mice inoculated with KB cells demonstrate 
significantly higher tumor inhibition rate of 45.1% for paclitaxel-transferrin 
formulation compared to 28.8% for paclitaxel nanosuspension treatment alone. 
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Interestingly, the Taxol(®) formulation showed higher antitumor activity than the 
paclitaxel-transferrin formulation, achieving a 93.3% tumor inhibition rate 12days 
post initial dosing. However, the paclitaxel-transferrin formulation showed a lower  
level of toxicity, which is indicated by a steady increase in body weight of mice over 
the treatment period. In comparison, treatment with Taxol resulted in toxicity issues 
as body weight increased. These results suggest the potential benefit of using a 
serum protein in a non-covalent manner in conjunction with paclitaxel nanocrystals 
as a promising drug delivery model for anticancer therapy.  
Yuminoki K et al 2014, developed preparation and evaluation of high dispersion 
stable nanocrystal formulation of poorly water-soluble compounds by using povacoat. 
In this study, we reported the application of Povacoat®, a hydrophilic polyvinyl 
alcohol copolymer, as a dispersion stabilizer of nanoparticles of poorly water-soluble 
compounds. In addition, the influence of aggregation of the nanoparticles on their 
solubility and oral absorption was studied. Griseofulvin (GF) was used as a model 
compound with poor water solubility and was milled to nanoparticles by wet bead 
milling. The dispersion stability of GF milled with Povacoat® or the generally used 
polymers (polyvinyl alcohol, hydroxypropylcellulose SSL, and polyvinylpyrrolidone 
K30) was compared. Milled GF suspended in ovacoat® aqueous solution with 
mannitol, added to improve the disintegration rate of freeze-dried GF, exhibited high 
dispersion stability without aggregation (D90 = ca. 0.220 μm), whereas milled GF 
suspended in aqueous solutions of the other polymers aggregated (D90 > 5 μm). 
Milled GF with Povacoat® showed improved aqueous solubility and bioavailability 
compared with the other polymers. The aggregation of nanoparticles had significant 
impact on the solubility and bioavailability of GF. Povacoat® also prevented the 
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aggregation of the various milled poorly water-soluble compounds 
(hydrochlorothiazide and tolbutamide, etc.) more effectively than the other 
polymers. These results showed that Povacoat® could have wide applicability to 
the development of nano formulations of poorly water- soluble compounds. 
Sezione di Scienze de et al 2014 Developed formulation strategy and evaluation 
of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-
drying. Piroxicam (PRX) is a non-steroidal anti-inflammatory drug characterized by 
a poor water solubility and consequently by a low oral bioavailability. In this work, 
different nanocrystal orally disintegrating tablets (ODT) were prepared to enhance 
piroxicam dissolution rate and saturation solubility. PRX nanocrystals were 
prepared by means of high pressure homogenization technique using poloxamer -
188 as stabilizer. Three different ODTs were prepared with the same 
nanosuspension using different excipients in order to study their effect on the PRX 
dissolution properties. PRX nanocrystal size and zeta potential were determined by 
photon correlation spectroscopy. Additional characterization of PRX nanocrystal 
ODT was carried out by infrared spectroscopy, X-ray powder diffractometry, 
differential scanning calorimetry. Dissolution study was performed in stilled water 
(pH 5.5) and compared with PRX coarse suspension ODT, PRX/poloxamer 188 
physical mixture, Bulk PRX samples and a PRX commercial ODT. All PRX 
nanocrystal ODT formulations showed a higher drug dissolution rate than coarse 
PRX ODT. PRX nanocrystal ODT prepared using gelatin or croscarmellose as 
excipient showed a higher PRX dissolution rate compared with the commercial 
formulation and ODT prepared using xanthan gum. Overall results confirmed that 
improved PRX dissolution rate is due to the increased surface-to-volume ratio due 
to the nanosized drug particle but also revealed the important role of different 
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excipients used. 
 
Vidya viswanad et al., 2014 developed cephalexin loaded Nanoparticles 
were  prepared by solvent evaporation method by using hydroxy ethyl  cellulose 
and poly vinyl alcohol polymers.The particle size and entrapment  efficiency was 
around the range of 200- 400 nm and 88.5%- 95.6%  respectively.Five different 
formulations of hydrogel prepared by using carbopol  934 with varying 
concentration of penetration enhancer (Propylene glycol).  The invitro release 
studies revealed that the formulation with higher concentration of penetration 
enhancer (15% Propylene glycol) showed greater release from the kinetic study, 
the best linearity was found with first order and Higuchi’s equation .The permeation 
studies showed that the formulation having high concentration of permeation 
enhancer showed good skin permeation.  
An TT et al., 2014 developed isradipine nanosuspension by using the son 
precipitation method for stable nanosuspensions. Nanosuspension systems were 
prepared upon various factors including amplitude  and the time length of 
ultrasonication. The dissolution test was performed according to the USP paddle 
method in intestinal fluid (pH 6.8). The crystalline structure of drug, the molecular 
interaction, morphology and size of nanosuspension were also investigated to 
determine the mechanism of dissolution enhancement. The sonoprecipitation 
method with use of HPMC showed its potential in enhancement of the drug release 
rate. Stable nanosuspension was significantly depended on amplitude and time of 
ultrasonication since these factors affected on the size of nanoparticles. The 
synergistic effects of reduction of drug crystallinity and particle size could increase 
the dissolution rate of isradipine by providing a stable nanosuspension. This work 
may contribute to a new strategy  for improvement dissolution rate of isradipine.  
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Bhatt Neha et al., 2013 worked in drug delivery to the brain using polymeric 
nanoparticles. Nanoparticle drug carriers consist of solid biodegradable particles in 
size ranging from 10 to 1000 nm (50-300 nm generally. The use of minute particles 
as drug carriers for targeted treatment has been studied over a long period of time. A 
selective accumulation of active substances in target tissues has been demonstrated 
for certain so-called nanocarrier systems that are administered bound to 
pharmaceutical drugs. Great expectations are placed on nanocarrier systems that 
can overcome natural barriers such as the blood-brain barrier (BBB) and transport the 
medication directly to the desired tissue and thus heal neurological diseases that 
were formerly incurable. Polymeric Nanoparticle have been shown to be promising 
carriers for CNS drug delivery due to their potential both in encapsulating drugs, 
hence protecting them from excretion and metabolism, and in delivering active agents 
across the blood – brain barrier without inflicting any damage to the barrier. Different 
polymers have been used and different strategies like surface modification have been 
done to increase the retention time of nanoparticles.  
Zuki Abu Bakar Zakaria et al., 2013, synthesized biobased calcium carbonate 
nanocrytals had demonstrated to be an effective carrier for delivery of anticancer drug 
Doxorubicin (DOX). These nanocrystls displayed high levels of selectivity and 
specificity in achieving effective cancer cell death without non-  pecific toxicity. The 
CaCo3/DOX nanocrystals were relatively stable at neutral pH (7.4), resulting in slow 
release of drug, but, progressively dissociated in acidic pH (4.8) and faster release of 
DOX. They indicated that, CaCo3/DOX nanocrystals were more sensitive and gave a greater 
reduction in breast cancer cell growth by controlled and targeted cancer therapy than free 
DOX. 
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Bin Du et al.,2013 developed oral nanocrystal capsules were produced using  
nanocrystal formulations in order to optimize dissolution properties of poorly  soluble 
drug glimepiride and improve its bioavailability. The mean particle size and 
polydispersity index were investigated systematically, and the optimal values were 
0.2% glimepiride (w/v), 1.2% Lipoid S100, 0.6% PEG 6000 (w/v), 0.6% PVPK 30  
w/v), 500W and 2 min, respectively. Characterization of  glimepiride nanocrystal was 
carried out by X-PRD, DSC and SEM Invitro dissolution test, the nanocrystal-loaded 
capsules of glimepiride showed an  evident increase in dissolution rate compared to 
micronized and market  capsules. The in vivo studies demonstrated that a marked 
enhancement of  bioavailability of nanocrystal-loaded capsules was superior 
compared to the  marketed formulation and microcrystal-loaded capsules, which 
may reduce the  risk of side effects by allowing a reduction in either the dose or its 
frequency of  administration.   
Mbo D et al.,2013 developed Cyclodextrin-based nanosponges (NS) are  solid 
nanoparticles, obtained from the cross-linking of yclodextrins .In this  work, new 
carboxylated cyclodextrin-based nanosponges (Carb-NS) carrying  carboxylic  roups 
within their structure were purposely designed as novel  Acyclovir carriers. TEM 
measurements revealed their spherical shape and size  of about 400 nm.The 
behaviour  of Carb-NS, with respect to the incorporation  and delivery of Acyclovir, 
was compared to that of NS, previously investigated  as a drug carrier. DSC, XRPD 
and FTIR analyses were used to investigate the two NS formulations. The results 
confirm the incorporation of the drug into the NS structure and NS-Acyclovir 
interactions. The Acyclovir loading into Carb- NS was higher than that obtained 
using NS, reaching about 70% (w/w). In vitro release studies showed the release 
kinetics of Acyclovir from Carb-NS to be prolonged in comparison with those 
observed with NS, with no initial burst effect. The NS uptake into cells was evaluated 
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using fluorescent Carb-NS and revealed the nanoparticle internalization. Enhanced 
antiviral activity against a clinical isolate of HSV-1 was obtained using Acyclovir 
loaded in Carb-NS.  
Abdul Hasan Sathali. A., and Gopinath.M., et al., 2013, developed Paliperidone 
nanocrystal in order to enhance the solubility and dissolution rate by decreasing the 
particle size of the drug and also sustained the drug release profile by using 
EudragitL100 as polymer at different ratio. The Paliperidone nanocrystals were 
successfully prepared by nanoprecipitation method using different stabilizers (PVP 
K30, Poloxamer 1888, Poloxamer 407, combination of PVP K30 and Poloxamer 
407, combination of PVP K30 and Poloxamer 188).  The formulations were 
evaluated for entrapment efficiency, morphology, size distribution, zeta potential, 
solubility studies and stability studies. The presence of stabilizers made the 
nanocrystal formulation more stable. The solubility studies and Invitro dissolution 
studies suggested that the nanocrystal formulations can improve the bioavailability 
of Paliperidone when compared to pure drug. The X-ray powder diffraction (XRPD) 
confirmed that, there was no change in the crystalline state by this size reduction 
process. Stability studies were favorable for the development of this nanocrystal 
formulation.  
Bhay S. Sapre et al., 2012 developed the Design of a buccal mucoadhesive, 
nanoparticles based delivery system of fluoxetine.  The study was attempted to 
develop an alternative oral mucosal delivery of nanoparticles based system for 
antidepressant drug. The aim was to formulate a novel, transmucosal (buccal), 
polymeric nanoparticles based mucoadhesive system (diskettes) that could deliver 
fluoxetine hydrochloride with bypass first pass effect, with relative rapid onset, higher 
absorption and sustain release effect to increase bioavailability compared to oral  
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absorption. In this study, the drug was encapsulated into poly (methyl vinyl ether / 
maleic anhydride) (Gantrez MS-955) mucoadhesive polymer nanoparticles. The 
drug bearing nanoparticles were prepared by emulsion solvent evaporation method. 
The effect of critical formulation variables like, polymer concentration, emulsifier 
concentration and process variable like rate of homogenization were studied for the 
particle size distribution; drug entrapment efficiency and mucoadhesion. The 
dependent variables of the formulations were optimized using 32 full factorial 
designs and defined in mathematical equations. The desired values of response 
variables were found by contour plots generated using the design-expert® 8 version 
8.0.6.1 software. The drug encapsulated polymeric nanoparticles were gently 
compacted along ethyl cellulose layer into small round shaped diskettes for 
facilitating buccal application in such a way that polymer layer adhere with buccal 
mucosa.   The gently compacted diskettes gave dose precision through uniform drug 
distribution, high surface areas for better drug releases with sustain effect and 
without disrupter of nanoparticles. The in vitro studies of the diskettes included 
mucoadhesion and drug release profile were characterized. The in vivo studies were 
performed on rats. A significant improvement in the pharmacokinetic parameters of 
bioavailability like Cmax, Tmax and AUC was observed when compared with oral 
solution. The stability study was conducted on the optimized formulation at 
accelerated conditions.  
Afifa Bathool et al., 2012 dveloping the formulate and characterize atorvastatin 
loaded chitosan loaded nanoparticles prepared by solvent evaporation method for 
sustained release. Low oral bioavailability of Atorvastatin calcium (14%) due to an 
extensive high first-pass effect makes it as prime target for oral sustained drug 
delivery. Weighed amount of drug and polymer were dissolved in suitable organic 
solvent DMSO and 2% acetic acid as an organic phase. This solution is added drop  
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wise to aqueous solution of Lutrol F68 and homogenized at 25000rpm followed by 
magnetic stirring for 4hrs. Nanoparticles were evaluated for its particle size, 
scanning electron microscopy (SEM), Fourier-Transform infrared spectroscopy 
(FTIR), percentage yield, drug entrapment and for in vitro release kinetics. Among 
the four different ratios, 1:4 ratio showed high drug loading and encapsulation 
efficiency. SEM studies shows that prepared nanoparticles were spherical in shape 
with a smooth surface. Particle size of prepared nanoparticles was found to be in 
range between 142 nm to 221 nm. FTIR and DSC shows drug to polymer 
compatibility ruling out any interactions. In vitro release study showed that the drug 
release was sustained up to 7 days. Hence, prepared nanoparticles proved to be 
promising dosage form for sustained drug delivery of atorvastatin reducing dosing 
frequency, thus increasing the patiesnt compliance.  
Maiti S et al., 2012, studied liquid-crystal and nanocrystal technology for   
solubilization of poorly water soluble drugs. Any material with a dimension of less 
than 1 micrometer i.e. 1000 nm, should be referred to as nanoparticles, not a 
nanocrystal. Crystalline nanoparticles are often provide single domain crystalline 
system that can be studied to provide information, that can be help to explain the 
behavior of macroscopic samples of similar material. Nanocrystal is also a registered 
trademark of Elan Pharma International Ltd (Ireland). That improves the 
bioavailability of drugs by nanoscale particles that can be suspended in liquid, made 
into powder, pressed into tablets or encapsulated. As decreased size of the drug 
particles, may increase oral bioavailability of sparingly water soluble drugs. Drugs 
nanocrystals can be used for chemical stabilization of chemically labile drugs. The 
increased stability can be explained by a shield effect of the surfactant. 
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Ansari KA et al., 2011 developed resveratrol loaded with cyclodextrin-based  
nanoparticles (NP).They have been used to increase the solubility and stability  of 
poorly soluble actives. This study aimed at formulating complexes of resveratrol 
with β-cyclodextrin nanopartices in different weight ratios. DSC, FTIR and X-ray 
powder diffraction (XRPD) studies confirmed the interaction of resveratrol with NP. 
XRPD showed that the crystallinity of resveratrol decrease after encapsulation. The 
particle sizes of resveratrol-loaded NP are in between 400 to 500 nm with low 
polydispersity indices. Zeta potential is sufficiently high to obtain a stable colloidal 
nanosuspension. TEM measurement also revealed a particle size around 400 nm 
for NP complexes. The in vitro release and stability of resveratrol complex were 
increased compared with plain drug. Cytotoxic studies on HCPC-I cell showed that 
resveratrol formulations were more cytotoxic than plain resveratrol. The permeation 
study indicates that the resveratrol NP formulation howed good permeation in 
pigskin. The accumulation study in rabbit mucosa showed better accumulation of 
resveratrol NP formulation than plain drug. These results signify that resveratrol NP 
formulation can be used for buccal delivery and topical application.  
Singling Tang et al., 2011, improved the oral bioavailabilty of genistein, by 
nanoparticles. Nanoparticles were prepared by the nanoprecipitation technique 
using Eudragit E100 as carrier. The drug loaded nanoparticles were spherical on 
observation by transmission electric microscopy(TEM). Release of drug from the 
genistein nanoparticles was two times greater than that from the conventional 
capsules. These esults suggested that a nanoparticle system was a potentially 
promising formulation for the efficient delivery of poorly water soluble drugs by oral 
administration. 
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Peng Quan et al., 2011, developed solid formulation containing Nitrendipine 
nanoparticle for oral delivery. Nitrendipine nanoparticles were prepared by using a 
tandem precipitation homogenization process. The optimal process was follows firstly 
nitrendipine/acetone solution(100mg/ml)was added to a polyvinyl alcohol solution 
(1mg/ml) at 10oc, then the presuspension was homogenized for 20 cycles at 1000bar. 
The invitro dissolution rate of the nanocrystal was significantly increased and 
compared with the physical mixture and commercial tablets. The Cmax of the 
nanoparticle was approximately 15 folds and 10 folds greater than that of physical 
mixture and commercial tablet, respectively. And the AUC0→24 of the nanocrystals 
was approximately 41 folds and 10 folds greater than that of physical mixture and 
commercial tablet, respectively. The spray drying method was found to be suitable for 
conversion of the nanoparticle into solid form.  
Peng Quan et al., 2011, developed solid formulation containing Nitrendipine 
nanoparticle for oral delivery. Nitrendipine nanoparticles were prepared by using a 
tandem precipitation homogenization process. The optimal process was follows 
firstly nitrendipine/acetone solution(100mg/ml)was added to a polyvinyl alcohol 
solution (1mg/ml) at 10oc, then the presuspension was homogenized for 20 cycles 
at 1000bar. The invitro dissolution rate of the nanocrystal was significantly 
increased and compared with the physical mixture and commercial tablets. The 
Cmax of the nanoparticle was approximately 15 folds and 10 folds greater than that 
of physical mixture and commercial tablet, respectively. And the AUC0→24 of the 
nanocrystals was approximately 41 folds and 10 folds greater than that of physical 
mixture and commercial tablet, respectively. The spray drying method was found to 
be suitable for conversion of the nanoparticle into solid form. 
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Ansari KA et.al., 2011 developed resveratrol loaded with cyclodextrin-based 
nanoparticles (NS).They have been used to increase the solubility and stability of 
poorly soluble actives. This study aimed at formulating complexes of resveratrol with 
β-cyclodextrin nanoparticles in different weight ratios. DSC, FTIR and X-ray powder 
diffraction (XRPD) studies confirmed the interaction of resveratrol with NS. XRPD 
showed that the crystallinity of resveratrol decrease after encapsulation. The particle 
sizes of resveratrol-loaded NP are in between 400 to 500 nm with low polydispersity 
indices. Zeta potential is sufficiently high to obtain a stable colloidal nanosuspension. 
TEM measurement also revealed a particle size around 400 nm for NP complexes. 
The in vitro release and stability of resveratrol complex were increased compared 
with plain drug. Cytotoxic studies on HCPC-I cell showed that resveratrol formulations 
were more cytotoxic than plain resveratrol. The permeation study indicates that the 
resveratrol NP formulation showed good permeation in pigskin. The accumulation 
study in rabbit mucosa showed better accumulation of resveratrol NP formulation 
than plain drug. These results signify that resveratrol NP formulation can be used for 
buccal delivery and topical application. 
Muhammed Rafeeq P E et al., 2010 developed isoniazid in chitosan Nanoparticles 
inorder to enhance bioavailability and to reduce dose frequency.Chitosan was 
dissolved in acetic acid aqueous solution at various concentrations; Drug was 
dispersed in above Chitosan solution kept over magnetic stirrer at room temperature. 
It shows good encapsulation efficiency. And good release profile follows first order 
release kinetics. From all these results it concludes that formulation No 2 I the best 
formulation and which is recommended for future studies like Nano dry powder 
preparation. 
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Adlin Jino Nesalin. J et al., 2009, formulated Flutamide nanoparticles using 
chitosan polymer by ionic gelation technique. Nanoparticles of different core : coat 
ratio were formulated and analysed for total drug content, loading efficiency, particle 
size and in vitro drug release studies. The drug loading capacity of nanoparticles 
containing drug : polymer in various ratios of 1:1, 1:2, 1:3, 1:4 and 1:5 were found to 
be 63.3 ± 0.43, 66.3 ± 0.58, 68.1 ± 0.38, 75.2 ± 0.52, 71.0 ± 0.46. Thus there was a 
steady increase in the entrapment efficiency on increasing the polymer 
concentration in the formulation. The formulation F4 registered highest entrapment of 
75.2%. The particle size distribution was found to be 400nm by scanning electron 
microscopy (SEM) analysis. From the drug release studies it was observed that 
nanoparticles prepared with chitosan in the core : coat ratio 1:4 was showed better 
sustained release for about 12hours as compared to other formulations. 
Levent Oner et al., 2009, studied the major application areas of nanotechnology in 
pharmacy is nanoparticular drug delivery systems. Preparation of drug nanocrystals 
to improve the solubility of poorly water soluble drugs for oral delivery is also one of 
the important applications. Nanocrystal dispersion comprises water, active drug 
substance and a stabilizer. Different techniques can be used to prepare nanocrystal 
formulation of a drug powder such as homogenization, co-precipitation, spray drying 
and milling. Nanocrystals are physically stable due to the presence of stabilizers. 
The advantage of Nanocrystals formulations are enhanced oral bioavailability, 
improved dose proportionality, reduced food effects, suitability for administration by 
all routes and possibility of sterile filtration due to decreased particle size range. This 
technology will be substantially useful for the manufacture of poorly water soluble 
drug products for oral delivery. 
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Dlin Jino Nesalin. J et al., 2009, formulated Flutamide nanoparticles using 
chitosan polymer by ionic gelation technique. Nanoparticles of different core: coat 
ratio were formulated and analysed for total drug content, loading efficiency, particle 
size and in vitro drug release studies. The drug loading capacity of nanoparticles 
containing drug : polymer in various ratios of 1:1, 1:2, 1:3, 1:4 and 1:5 were found to 
be 63.3 ± 0.43, 66.3 ± 0.58, 68.1 ± 0.38, 75.2 ± 0.52, 71.0 ± 0.46. Thus there was a 
steady increase in the entrapment efficiency on increasing the polymer 
concentration in the formulation. The formulation F4 registered highest ntrapment of 
75.2%. The particle size distribution was found to be 400nm by scanning electron 
microscopy (SEM) analysis. From the drug release studies it was observed that 
nanoparticles prepared with chitosan in the core : coat ratio 1:4 was showed better 
sustained release for about 12hours as compared to other formulations. 
ADLIN JINO NESALIN J et al., 2009 dveloped th formulation and evaluation of 
nanoparticles containing flutamide. Flutamide, a substituted anilide, is a potent 
antiandrogenic that has been used in the treatment of prostate carcinoma having 
short biological half-life of 5-6 hrs; thus it is a good candidate for the formulation of 
sustained release dosage form. In the present work nanoparticles of Flutamide were 
formulated using chitosan polymer by ionic gelation technique. Nanoparticles of 
different core: coat ratio were formulated and analyzed for total drug content, loading 
efficiency, particle size and in vitro drug release studies. From the drug release 
studies it was observed that nanoparticles prepared with chitosan in the core: coat 
ratio 1:4 gives better sustained release for about 12 hrs as compared to other 
formulations. 
Muller H et al., 2007, investigated the feasibility of nanosuspension technology by 
high pressure homogenization to enhance the chemical stability of ascorbyl 
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palmitate (AP), followed by lyophilization. Sodium dodecyl sulfate (SDS) and Tween 80 were 
chosen as emulsifying agents to stabilize the develop AP nanosuspension. After 3 months of 
storage at 3 different temperature (4oC, 25oC and 40oC), the photon correlation spectroscopy 
(PCS) analysis of AP nanosuspension revealed that the mean particle size of these stabilized 
with SDS significantly increased compared to those stabilize with Tween 80. The percentage 
of AP remaining in nanosuspension stabilized with Tween 80 was higher than 90% after 
3months storage at 4oC, 25oC and 40oC. To increase the chemical stability of AP 
nanosuspension. A drug powder was prepared by lyophilization. The effect of the presence of 
cryoprotectant terhalose on the physical stability was evaluated at different concentrations. 
After redispersing the lyophilized product the mean size of AP nanosuspensions without 
terhalose was significantly higher compared with system with terhalose. It was found that the 
mean size of AP nanosuspensions stabilized with Tween 80 remained in the nanometer 
range and the amount of the active determined by HPLC, was more than 90% when stored at 
3 different temperatures during 3 months. From the X-Ray diffracto grams, it was shown that 
AP remained in a crystalline state which is physiochemically and thermodynamically more 
stable than AP in an amorphous state.  
Akas M et al., 2006  developed  Long-alkyl  chain  functionalized poly 
(propyleneimine) dendrimer, poly(ethyleneimine) hyperbranched polymer, and beta-
cyclodextrin derivatives, which are completely insoluble in  water, have the property 
of encapsulating organic pollutants from water.  Ceramic porous filters can be 
impregnated with these compounds resulting in  hybrid organic/ inorganic filter 
modules. These hybrid filter modules were tested   for   the   effective   purification   of   
water,   by   continuous filtration experiments, employing a variety of water pollutants. 
It has been established that polycyclic aromatic hydrocarbons (PAHs) can be 
removed very efficiently (more than 95%), and final concentrations of several ppb 
(microg/ L) are easily obtained. Representatives of the pollutant group of trihalogen 
methanes (THMs), monoaromatic hydrocarbons (BTX), and pesticides (simazine) can also  
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be removed (>80%), although the filters are saturated considerably faster in these 
cases.  
Amighi K et al., 2005, prepared nifedipine nanoparticles using high pressure 
homogenization. Nanoparticals were characterized in terms of size, morphology and 
redispersion characteristics following water removal. Saturation solubility and 
dissolution characteristics were investigated and compared to the un-milled 
commercial NIF to verify the theoretical hypothesis on the benefit of increased 
surface area. Crystalline state evaluation before and following particle size reduction 
was also conducted through differential scanning calorimeter (DSC) and Powder X-
Ray diffraction (PXRD). Through this study it has been shown that initial crystalline 
state is maintained following particle size reduction and that the dissolution 
characteristics of Nifedipine nanoparticles were significantly increased in regard to 
the commercial product. This approach should have a general applicability to many 
poorly water soluble drug entities.  
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CHAPTER-IV 
AIM OF THE WORK 
    A major hurdle in pharmaceutical formulation is water insolubility of most of the 
drugs affecting stability and bioavailability of the drug, if the drug is also insoluble in 
organic medium, it is difficult to deliver the drug in a sufficiently bioavailable form and 
hence it is a great challenge to formulation researchers to overcome such difficulty. 
Although some approaches are available for enhancing the dissolution of poorly 
soluble drugs but has certain draw backs like low drug loading and large doses. 
However, a new solution to poorly water soluble drug candidates is now available i.e. 
nanonisation and it leads to much more soluble, more biologically available and safer 
dosage form of poorly soluble and poorly bioavailable drugs. During the last two 
decades, many modern technologies such as high throughput screening, combinatorial 
chemistry, and computer-aided drug design in the pharmaceutical research and 
development area is leading to a vast number of drug candidates possessing a very 
good efficacy.  
Many of these drug candidates are exhibiting poor aqueous solubility. Although 
some approaches are available for enhancing the dissolution of poorly soluble drugs, 
but has certain drawbacks like low drug loading and large dose. Dapoxetine Hcl as a 
highly potent serotonin-transporter inhibitor and increase the synaptic serotonin level. 
In vitro studies suggest that dapoxetine is cleared by multiple enzyme systems in the 
liver and kidneys, primarily CYP2D6, CYP3A4, and flavin monooxygenase (FMO1). 
Following oral dosing in a clinical study designed to explore the metabolism of 14C-
dapoxetine, dapoxetine was extensively metabolised to multiple metabolites primarily 
through the following biotransformational pathways: N-oxidation, N-demethylation, 
naphthyl hydroxylation, glucuronidation and sulfation. There was  
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evidence of presystemic first-pass metabolism after oral administration.   The absolute 
oral bioavailability of Dapoxetine Hcl following oral administration is mean 42% and 
half-life 1-1.6hour. Dapoxetine hydrochloride is a white to slightly yellow powder. It is 
freely soluble in methanol, propylene glycol, some organic solvents (eg. N,N-
dimethylformamide) and slightly soluble in ethanol. The solubility of dapoxetine 
hydrochloride in aqueous media is a function of the pH (soluble at pH 3.9, sparingly 
soluble at pH 2.1 and insoluble at pH >7.0). 
Drug nanoparticles are pure solid drug particles with crystalline character and a 
particle size in the nanometer range. In recent years, drug nanoparticles have been the 
subject of much interest due to their novel physical properties, which mainly depend on 
particle size. It has been reported that the dissolution rate and saturation solubility of 
some water insoluble drugs can be increased by reduction of the particle size; hence, 
the bioavailability is improved. However, it is difficult to modify the in vitro release 
profiles of drug nanoparticles in the carrier free drug delivery system. 
The present study is carried out to develop nanoparticles of Dapoxetine Hcl in 
order to enhance the solubility and bioavailability by decreasing the particle size of the 
drug. Drugs nanoparticles are prepared by solvent evaporation method. Solubility and 
dissolution profile of obtained nanoparticles are compared with pure drug. The best 
formulation is selected based on the drug content, invitro dissolution studies, particle 
size and solubility studies. Dapoxetine Hcl nanoparticle capsules are formulated from 
the best formulation and invitro dissolution profile is compared with the Dapoxetine Hcl 
capsules and Dapoxetine Hcl capsules. 
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CHAPTER V 
PLAN OF WORK 
Step-I  
Preformulation Studies Standard Curves for Dapoxetine  
a) Determination of λmax of Dapoxetine Hcl in 0.01N Hydrochloric acid. 
b) Calibration curve for the Dapoxetine Hcl at λmax in 0.01N Hydrochloric 
acid. 
c) Determination of λmax of Dapoxetine Hcl in Phosphate buffer pH 6.8. 
d) Calibration curve for the Dapoxetine Hcl at λmax in Phosphate buffer 
pH 6.8 
Step-II  
Drug –Polymer Interaction Studies  
 Fourier Transform Infrared spectroscopic (FT-IR) studies. 
Step-III  
Preparation of Dapoxetine Hcl Loaded Controlled Release Nanoparticle by 
Inclusion Complex Methods  
a) Solvent Evaporation Method  
  Nanoparticles prepared by using different polymers like Ethyl cellulose, 
Chitosan, HPMC K100, β-cyclodextrin are using dissolved in 20 ml of  
dichloromethane. Add this mixture into 100 ml aqueous solution of Polyvinyl 
Alcohol (PVA) in dist. water . Stir the mixture at 1000 rpm for 2 hours in a magnetic 
stirrer. Then filter the product and dry it an oven at 400C for 24 hours. 
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       b)  Hyper Cross-linked (Betacyclodextrin Nanoparticles) 
Nanoparticles obtained by reacting Cyclodextrin with a Cross-linker (Diphenyl 
Carbonate). It Synthesize by in neutral and Acid forms. The average diameter of a 
Nanoparticle is below 1 µm but fractions below 500 nm can be selected 
Step-IV  
Characterization of Dapoxetine Hcl Loaded Controlled Release 
Nanoparticles Using Inclusion and Non-Inclusion Complex  
 Determination of Production Yield  
 Determination of drug content. 
 Determination of drug entrapment efficiency 
 Solubilization efficiency 
 Determination of particle size, polydispersity index & zeta 
potential.  
 Invitro release studies of Dapoxetine Hcl loaded 
nanoparticles by using inclusion and  Non-inclusion complex  
 Kinetics of drug release  
 Stability studies  
 Invivo studies of nanosponge formulation  
Step-V  
Selection and Evaluation of Best Formulation  
The best formulation is selected depending on the results obtained from  
 Production yield  
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 Particle size, Polydispersity Index & Zeta potential  
 Entrapment Efficiency 
 Solublization efficiency  
 In-vitro drug release studies  
 Release Kinetics  
 Stability studies  
Step-VI  
Evaluation of Best Formulation  
 Particle Size, Poly dispersity Index & Zeta potential  
 Scanning Electron Microscopy (SEM)  
 X-ray Powder Diffraction (XRPD) analysis. 
 Release Kinetics  
 Invivo studies of the nanoparticles formulation.  
Step - VII  
Formulation of Dapoxetine Hcl Nanoparticles Loaded Capsules  
Dapoxetine Hcl Nanoparticles capsules are formulated by Hand filling method.  
microcrystalline cellulose is used as a diluents, magnesium stearate is used as a  
Lubricant. All the ingredients are passed through #60mesh separately. Then the 
ingredients are weighed and mixed in geometrical order after sufficient mixing of 
drug as well as other components and formulated into capsules. Dapoxetine Hcl 
Nanoparticles capsules are prepared by hand filling method without using any 
solubility enhancement method for comparison of invitro drug release studies 
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with Dapoxetine Hcl Nanoparticles capsules and Dapoxetine Hcl conventional 
capsules.  
Step - VIII 
Evaluation of Dapoxetine Hcl Nanoparticles Capsules 
 
a) Compatibility Studies 
 Fourier transform Infrared spectroscopic (FTIR) studies. . 
b) Pre compressional evaluation of powder blend: 
Angle of repose 
Bulk density 
Tapped density 
Compressibility index 
Hausner’s ratio 
Drug content 
c) Post compressional evaluation of Nanoparticles loaded Dapoxetine 
Hcl Capsules 
General appearance 
Length of capsules 
Weight variation 
Drug content 
Invitro release studies 
 
d) Comparison of Invitro release of Dapoxetine Hcl Nanoparticles 
capsules with Dapoxetine Hcl capsules.  
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CHAPTER-VI 
 
MATERIALS AND EQUIPMENTS 
 
S.No. Materials Manufacturer  
1 Dapoxetine Hcl Gift sample from Drug Testing Laboratory, 
Chennai, India.  
2 Ethyl cellulose  Gift sample from Shasun Pharmaceuticals,  
Chennai, India.  
3 Chitosan Gift sample from Madras Pharma, 
Chennai, India. 
4 HPMC  K100 M Gift sample from Shasun Pharmaceuticals, 
 
Chennai, India. 
5 Poly vinyl alcohol  Pharmafabrikon, Madurai, India.  
6 Dichloromethane    Central Drug House (P) Ltd, New Delhi, 
India. 
7 Ethanol  Central Drug House (P) Ltd, New Delhi, 
India. 
8 Betacyclodextrin  Central Drug House (P) Ltd, New Delhi, 
India. 
9 Diphenyl Carbonate  Central Drug House (P) Ltd, New Delhi, 
India. 
10 Empty Hard gelatin  
capsules  
Gift sample from Strides Shasun , 
Pudhucherry,  
India.  
11 Microcrystalline  
Cellulose  
Paris Dakner , Madurai, India.  
12 Magnesium Stearate  Universal scientific appliances, Madurai, 
India.  
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MATERIALS AND EQUIPMENTS 
 
 
S.No. Equipments Company 
1 Electronic Weighing Balance A&D Company HR 200,Japan. 
2 Mechanical Strirrer Remi Motors,India. 
3 Magnetic Stirrer MC Dalal & Co India 
4 UV Visible Spetrophotometer Shimadzu,Japan. 
5 Digital Tablet Dissolution Test Disso 2000,Lab India. 
6 X-ray Machime Stallion 20,Elpro Internationak Ltd. 
7 Digital Scanning Calorimeter DSC 60 Shimadzu 
8 SEM Analyzer Hitachi,Japan 
9 Malvern Zetasizer and 
Particle size analyser 
Malvern instruments,UK 
10 Ultracentrifuge Eppendorf centrifuge 5417 R,Germany 
11 Ultrasonic Processor MODROBS - AICTE 
12 Stability Chamber Inlab Equipments Madras PVT (LTD) 
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CHAPTER VII 
DRUG PROFILE 
DAPOXETINE HCL 
Synonym 
 Dapoxetina
 Dapoxetinum
Structural Formula 
Empirical Formula 
C21H23NO 
Chemical Name 
(S)-N,N-Dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine 
hydrochloride 
Molecular Weight  
305.4134 
Chemical Data 
  Melting Point   :   181.75 
  Boiling Point   :      160-170 
  Solubility Profile    :   Soluble in Soluble in DMSO (68MG/ML AT 
250C
Soluble in chloroform, methanol, ethanol
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Description : 
Bioavailability : 
Protein Binding : 
Half-Life : 
pH range : 
Log P : 
Dose Range : 
White powder 
Mean 42% 
>99% 
1-1.6 hours 
5.87 
 (Octanol/Water Partition Coefficient) 6.8 
30mg, 60 mg 
Identification 
λmax at 292 nm in UV spectrophotometer 
Pharmacodynamic Properties 
Pharmacological studies show Dapoxetine Hcl to be a highly potent 
serotonin-transporter inhibitor. Although this pharmacological activity is similar to 
that of clomipramine and conventional selective serotonin reuptake inhibitors 
(SSRIs), chemical features of the structure of dapoxetine and its pharmacokinetic 
profile differentiate it from other SSRIs. For instance, and unique among SSRIs, it 
is not a halogenated compound), while all other SSRIs contain one or more 
halogen atoms. The molecular structure of dapoxetine also includes a naphthyl 
moiety and it is possible that these features underpin the physicochemical and 
pharmacokinetic properties of the molecule. In recent Phase III trials, the efficacy 
of dapoxetine was tested in patients with moderate to severe PE who, at baseline, 
had a measured mean IELT of <1 min (an IELT inclusion criteria of <2 min was 
used throughout trials with Dapoxetine Hcl). 
In the light of the rapid peak drug concentration, patients were asked to 
take Dapoxetine (30 or 60 mg) or placebo, on-demand, at 1–3 h before 
anticipated sexual intercourse. This contrasts with other PE studies in which 
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patients were obliged to take their medication daily for several weeks, to detect 
any benefit. Even those studies that purport to examine ‘on-demand’ drug dosing, 
use long pre-intercourse dosing intervals such as 3–8 h or pre-load patients with 
the trial drug for several weeks. 
Pharmacokinetic Properties 
Absorption 
Dapoxetine is a white powder substance and water- insoluble. Taken 1–3 
hours before sexual activity, it is rapidly absorbed in the body. Its maximum 
plasma concentration (Cmax) is reached 1–2 hours after oral administration. The 
Cmax and AUC (Area Under the plasma vs. time Curve) are dose dependent. The 
Cmax and Tm (time needed to obtain the maximum plasma concentration) after 
single doses of dapoxetine 30 mg and 60 mg are 297 and 498 µg/mL at 1.01 and 
1.27 hours respectively. A high fat meal does reduce the Cmax slightly, but it is 
insignificant. In fact, food doesn't alter dapoxetine pharmacokinetics. Dapoxetine 
can be taken with or without food. 
Distribution 
Dapoxetine is absorbed and distributed rapidly in the body. Greater than 99% of 
dapoxetine is bound to the plasma protein. The mean steady state volume is 162 
L. Its initial half-life is 1.31 hours (30 mg dose) and 1.42 hours (60 mg dose,) and 
its terminal half life is 18.7 hours (30 mg dose) ansd 21.9 hours (60 mg dose). 
Biotransformation 
In vitro studies suggest that dapoxetine is cleared by multiple enzyme 
systems in the liver and kidneys, primarily CYP2D6, CYP3A4, and flavin 
monooxygenase (FMO1). Following oral dosing in a clinical study designed to 
explore the metabolism of 14C-dapoxetine, dapoxetine was extensively 
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metabolised to multiple metabolites primarily through the following 
biotransformational pathways: N-oxidation, N-demethylation, naphthyl 
hydroxylation, glucuronidation and sulfation. There was evidence of presystemic 
first-pass metabolism after oral administration. Intact dapoxetine and dapoxetine-
N-oxide were the major circulating species 
in the plasma. In vitro studies show that dapoxetine-N-oxide was inactive in 
a battery of in vitro binding and transporter studies. Additional metabolites include 
desmethyldapoxetine (DED) and didesmethydapoxetine, which account for less 
than 3% of the circulating medicinal product related material.  In vitro binding 
studies indicate that DED is equipotent to dapoxetine and didesmethydapoxetine 
has approximately 50% of the potency of dapoxetine. The unbound exposure of 
DED is approximately 1/2 of the free exposure of dapoxetine. The unbound Cmax 
of DED is estimated to be 20-25% of dapoxetine Cmax in the absence of intrinsic or 
extrinsic factors that may change exposure levels. 
Excretion 
The metabolites of dapoxetine were primarily eliminated in the urine 
conjugates. Unchanged active substance was not detected in the urine. 
Dapoxetine has a rapid elimination, as evidenced by a low concentration (less 
than 5% of peak) 24 hours after dosing.  There was minimal accumulation of 
dapoxetine following daily dosing. The terminal half-life is approximately 19 hours 
following oral administration. The half-life of DED is similar to that of Dapoxetine 
Hcl
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Mechanism of Action 
Onset and Duration of Efficacy 
The on-demand efficacy of dapoxetine in PE is the key feature that sets the 
drug apart from other PE treatments. Although various authors have claimed ‘on-
demand’ efficacy for other treatments (e.g. the conventional SSRIs), close 
inspection of the studies often reveals methodological failings. Often hybrid 
treatment regimens have been used, comprising periods of chronic drug 
administration followed by on-demand treatment. Moreover, double-blind, placebo-
controlled trials are the exception rather than the rule. These idiosyncratic protocols 
make the results difficult to assess, and true on-demand efficacy has not been 
convincingly shown for existing agents. 
   The efficacy of on-demand dapoxetine suggests that the drug, despite its 
biochemical similarities to other SSRIs, may have a different mechanism of action in 
PE, possibly due to its pharmacokinetic profile or physicochemical properties. 
Tolerability/Safety 
The most common and a dose-dependent adverse effect with both the 
conventional SSRIs and dapoxetine is nausea. Even so, nausea after dapoxetine is 
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mainly mild, transient and related to the presence of dapoxetine in the body. Other 
adverse effects occurred less frequently and were not consistently dose-related. 
One of the largest issues when treating PE with conventional daily dosing of 
SSRIs is the high incidence of sexual side-effects: chronic treatment with these 
SSRIs reduces libido and compromises erectile function, possibly due to the 
adaptive receptor and messenger changes inherent in their actions. Of patients on 
chronic SSRIs, 30–50% experience sexual side-effects. By contrast, sexual side-
effects are infrequent with dapoxetine. On-demand dapoxetine has no significant 
adverse effects on libido (<1%) or erection (<4%), presumably because it does not 
persist in the body and thus there are no adaptive changes. 
Side effects of Dapoxetine hydrochloride. 
 Nausea
 Dizziness
 Diarrhea
 Anorgasmia,
 Erectile dysfunction,
 Diminished libido
Contraindications 
 contraindicated when used in combination with monoamine oxidase inhibitors
(MAOIs) 
 Dapoxetine should also not be used in combination with thioridazine or other
drugs that inhibit the CYP450 2D6 hepatic enzyme may raise plasma 
thioridazine levels. Administration of thioridazine alone may lead to prolongation 
of the QTc interval associated with severe ventricular arrhythmias such as 
torsades de pointes and sudden cardiac death. 
 Dapoxetine should also not be used in combination with the drug pimozide
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 Dapoxetine should not be used in men with moderate to severe hepatic
impairment and in those receiving CYP3A4 inhibitors such as ketoconazole, 
ritonavir, and telithromycine. 
 Dapoxetine can also not be used in patients with heart failure, permanent
pacemaker, or other significant ischemic heart disease. 
 Caution is advised in men receiving thioridazine, monoamine oxidase
inhibitors, SSRIs, serotonin-norepinephrine reuptake inhibitors, or tricyclic 
antidepressant. If a patient stops taking one of these drugs, he should wait 
for 14 days before taking dapoxetine.. 
Interactions 
 With phosphodiesterase inhibitors (PDE5 inhibitors)
 With ethanol
Brand Names 
 Dasutra
 Kutub
 SD-Pill
 Sustinex
 TD-Pill
(Drug bank, Clark’s analysis, Martindale Wikipedia, drugs.com)
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               CHITOSAN 
 
 
Synonym 
 
 Poliglusam  
 Deacetylchitin  
 Chicol 
 Chitosan hydro chloridum  
  Structure 
 
  
Emprical Formula 
 
  C56H103N9O39 
 
Molecular Weight 
 
1526.464 g/mol 
 
Description 
 
Appearance : Powder 
 
Color  : White or creamy white powder  
 
Odor                : Odourless  
 
Taste   : Tasteless 
 
Solubility 
 97%  in 1% Acetic Acid 
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 Sparingly soluble in water 
 Practically insoluble in ethanol (95%) 
 Neutral or alkali solutions at pH above approximately 6.5 
pH 
4.0 - .6.0 (1% w/v aqueous solution) 
Functional Category 
 Coating agent 
 Controlled release agent 
 Viscosity increasing agent 
 Mucoadhesive material 
 Film former 
Storage Conditions 
 Chitosan should be stored in a tightly closed container in a cool and 
dry place. 
 It should b stored at a room temperature of  2 - 80C. 
Incompatibility 
  Chitosan is incompatible with strong oxidizing agent 
Handling Precaution 
 It is compatible 
 Open flames should be avoided 
 It is temperature sensitive and should not be heated above 2000C. 
 It should be handled in a well-ventilated environment. 
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Regulatory Status  
Chitosan is registered as a food supplement in some countries. 
Application 
 Controlled drug delivery 
 Peptide delivery 
 Colonic drug delivery 
 Gene delivery 
 Pharmaceutical formulation including gel, films, beads microsphere, 
tablet and liposomes (Singling Tang et al., 2011). 
 
 
 
ETHYL CELLULOSE 
 
 
 
Synonym 
 
 Aquacoat ECD 
 
Aqualon 
 
Ethocel 
 
Sucrelease 
 
Structure 
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Emprical Formula 
 
C12H23O6 (C12H22O5) nC12H23O5 
 
Molecular Weight 
 
40, 000 
 
Description 
 
   Color  : White to light tan-coloured powder 
 
Odor  : Odourless 
 
Taste   : Tasteless 
 
Melting Point 
 
1650 0 – 18500 C 
 
Solubility 
 
         Practically  insoluble in propylene glycol, glycerine and water freely 
soluble in chloroform, ethanol, ethyl acetate, methanol and toluene. 
 
Functional Category 
 
 Coating agent 
 Flavouring fixative 
 Tablet binder 
 Tablet filler 
 Viscosity - increasing agent. 
Storage Conditions 
 
It should be stored at a temperature not exceeding 32800 C (900F) in a 
dry area away from all sources of heat. 
Handling Precautions (Muhammed Rafeeq P E et al., 2010): 
 
 To prevent fine dust clouds of ethyl cellulose from reaching 
 
potentially explosive levels in the air. 
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 It may be an irritant to the eyes and eye protection should be 
worn. 
 
Regulatory Status 
 
Included in the FDA inactive ingredients  
 
 
 
 
 
BETA CYCLODEXTRIN 
Synonyms 
 b-Cyclodextrin beta-cycloamylose 
 Beta-dextrin 
 Betadexum 
Empirical Formula 
C42H70O35 
Molecular Weight 
1135g/Mol 
Structural Formula 
      
 
Functional Category 
 Solubilizing agent  
 stabilizing agent 
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Description 
 
Cyclodextrin occur as white, practically odorless, fine crystalline powders, 
having a slightly sweet taste. Some cyclodextrin derivatives occur as amorphous 
powders. 
Pharmacopeial Specifications 
 
Solubility 
 
Soluble 1 in 200 parts of propylene glycol, 1in50 of water at 208C, 1 in 20 at 
     508C; practically insoluble in acetone, ethanol (95%), and methylene chloride. 
Specific Rotation 
 
                D25= þ162.08; 
 
Surface Tension (at 258c)  
            
               1 mN/m (71 dynes/cm) 
 
Stability and Storage Conditions 
 
 β-Cyclodextrin is stable in the solid state if protected from high humidity. 
 
 β-Cyclodextrins should be stored in a tightly sealed container, in a cool, dry  
place. 
 
Method of Manufacture 
 
Betacyclodextrin is produced by the action of the enzyme cyclodextrin glucosyl 
transferase upon starch or a starch hydrolysate. An organic solvent is used to direct the 
reaction that produces betacyclodextrin, and to prevent the growth of microorganisms 
during the enzymatic reaction. The insoluble complex of betacyclodextrin and organic 
solvent is separated from the non cyclic starch, and the organic solvent is removed in 
vacuum so that less than 1 ppm of solvent remains in the betacyclodextrin. The 
betacyclodextrin is then carbon treated and crystallized from water, dried, 
andcollected (Peng Quan et al., 2011). 
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Safety 
nontoxic and nonirritant and cyclodextrin are approved for use in food 
products and orally administered pharmaceuticals in a number of countries. 
Cyclodextrins are not irritant to the skin and eyes, or upon inhalation. 
 
There is also no evidence to suggest that cyclodextrins are mutagenic or 
 
teratogenic. 
 
Handling Precautions 
 
It should be handled in a well-ventilated environment 
 
Applications 
 
 
 Cyclodextrin may be used to form inclusion complexes with a variety 
of drug molecules, resulting primarily in improvements to dissolution 
and bioavailability 
 Primarily used in tablet and capsule formulation 
 
 Bioavailability enhancement 
 
 Cholestrol free products 
 
 Multifunctional dietary fiber 
 
 Other food applications 
 
 Aerosols 
 
 Clinical applications 
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HYDROXY PROPYL METHYL CELLULOSE 
 
 
SYNONYM: 
 Hypromellose. 
 Methocel 
 
STRUCTURE: 
 
 
 
where R is H, CH3, or CH3CH(OH)CH2 
 
EMPIRICAL FORMULA: 
 
It is a partly O-methylated and O-(2-hydroxypropylated) cellulose. It is 
available in several grades that vary in viscosity and extent of substitution. 
MOLECULAR WEIGHT: 
 
10,000–15, 00,000 Dalton 
 
DESCRIPTION: 
 
 Colour: white or creamy-white fibrous or granular powder 
 Odour: odourless 
TASTE: 
   Tasteless 
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Solubility: 
  Soluble in cold water, forming a viscous colloidal solution; practically insoluble 
in hot water, chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol 
and dichloromethane, mixtures of methanol and dichloromethane, and mixtures of 
water and alcohol. Certain grades of hypromellose are soluble in aqueous acetone 
solutions, mixtures of dichloromethane and propan-2-ol, and other organic solvents. 
Some grades are swellable in ethanol. 
Melting point:  
 
 Browns at 190–2008C; chars at 225–2308C 
 
METHOD OF MANUFACTURE: 
A purified form of cellulose, obtained from cotton linters or wood pulp, is reacted 
with sodium hydroxide solution to produce a swollen alkali cellulose that is chemically 
more reactive thanuntreated cellulose. The alkali cellulose is then treated with 
chloromethane and propylene oxide to produce methyl hydroxypropyl ethers of 
cellulose. The fibrous reaction product is then purified and ground to a fine, uniform 
powder or granules. Hypromellose can then be exposed to anhydrous hydrogen 
chloride to induce depolymerization, thus producing low viscosity grades. 
Typical viscosity values for 2 % (w/v) aqueous solutions of different viscosity 
grades of hpmc at 20°c: 
Methocel K100 Premium LVEP100 
 
Methocel K4M Premium : 4000 
 
Methocel K15M Premium : 15000 
 
Methocel K100M Premium : 100 000 
 
Methocel E4M Premium : 4000 
Methocel F50 Premium 50 
Methocel E6 Premium LV 6 
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Methocel E15 Premium LV 15 
Methocel E50 Premium LV 50 
 
Metolose 60SH : 50, 4000, 10 000 
 
Metolose 65SH : 50, 400, 1500, 4000 
 
Metolose 90SH : 100, 400, 4000, 15 000 
 
STORAGE CONDITION: 
 
It should be stored in a well-closed container, in a cool, dry place. 
 
HANDLING PRECAUTION: 
 
 Hypromellose dust may be irritant to the eyes and eye protection is 
recommended. 
 Excessive dust generation should be avoided to minimize the risks 
of explosion. 
 Hypromellose is combustible. 
 
(Hand book of Pharmaceutical Excipients by Raymond C. Row) 
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DIPHENYL CARBONATE 
 
 
Synonym 
 
Phenyl Carbonate 
 
Structure 
 
 
Emprical Formula 
 
C13 H10 O3 
 
Molecular Weight 
 
214.216 g/mol. 
 
Melting Point 
 
830C 
 
Boiling Point 
 
306 0 C 
 
Solubility 
 
Soluble in Ethanol, diethyl ether, Carbon tetrachloride ,acetic acid insoluble in water 
                
Description 
 
White powder 
 
Applications 
Polycarbonates can be prepared by transesterifying diphenyl carbonate with 
Bisphenol A, and phenol is a co-product. Phosgene is avoided as a result. These 
polycarbonates may be recycled by reversing the process transesterifying the 
polycarbonate with phenol to yield diphenyl carbonate and bisphenol A. 
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MICROCRYSTALLINE CELLULOSE 
 
 
Structural Formula 
 
 
  
Non-proprietary Name 
 BP: Microcrystalline Cellulose 
 JP: Microcrystalline Cellulose 
 PhEur: Cellulose, Microcrystalline 
 USP-NF: Microcrystalline Cellulose 
Synonyms 
 
 Avicel PH; Cellets; Celex; cellulose gel; hellulosum microcristallinum; 
 Celphere; Ceolus KG; crystalline cellulose; E460; Emcocel; 
 Ethispheres; Fibrocel; MCC Sanaq; Pharmacel; Tabulose; Vivapur. 
Empirical Formula 
 
(C6H10O5)n 
 
Molecular weight 
   
   
36000g/mol 
 
Functional Category 
 
 Adsorbent and suspending agent 
 Tablet and capsule diluents 
 Tablet disintegrant   
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.Description 
 
. Microcrystalline cellulose is a purified, partially depolymerized cellulose that             
occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. 
Solubility 
Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in 
water, dilute acids, and most organic solvents 
pH 
pH 5.0-7.5 
 
Melting point 
260 – 2700C. 
Density 
0.337 g/cm3 
Incompatibilities 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
Method of manufacture 
Microcrystalline cellulose is manufactured by controlled hydrolysis with dilute mineral 
acid solutions of a-cellulose, obtained as a pulp from fibrous plant materials. Following 
hydrolysis, the hydrocellulose is purified by filtration and the aqueous slurry is spray dried 
to form dry, porous particles of a broad size distribution.  
Stability & Storage condition  
Microcrystalline cellulose is a stable though hygroscopic material. The bulk material 
should be stored in a well-closed container in a cool, dry place.  
Applications 
1. Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluents in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression Processes. 
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2. In addition to its use as a binder/diluent, microcrystalline cellulose also has  
some lubricant and disintegrant properties that make it useful in tableting. 
3. Microcrystalline cellulose is also used in cosmetics and food products; 
Handling precaution 
Microcrystalline cellulose may be irritant to the eyes. Gloves, eye protection, 
and a dust mask are recommended. 
(Hand book of Pharmaceutical Excipients by Raymond C. Rowe et.al. 2009) 
 
 
 
 
 
 
 
 
 
MAGNESIUM STEARATE 
 
 
Structure 
 
 
 
Structural Formula 
 
[CH3 (CH2)16COO] 2Mgs 
 
Nonproprietary Names 
 
 BP: Magnesium Stearate 
 
 JP: Magnesium Stearate 
 PhEur: Magnesium Stearate 
 USP-NF: Magnesium Stearate 
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Synonyms  
 
 Dibasic magnesium stearate 
 Magnesium distearate  
 Magnesiistearas 
  Magnesium octadecanoate; 
 Octadecanoic acid 
 Magnesium salt 
 Synpro90. 
Empirical formula 
 
C36H70MgO4 
 
Molecular weight 
 
591.24 g/mol 
 
Description 
 Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable. 
Powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the skin. 
Functional categories 
 
Tablet and capsule lubricant. 
 
Solubility 
 
Practically insoluble in ethanol, ethanol (95%), ether and water; slightly soluble in 
warm benzene and warm ethanol (95%). 
Melting point 
 
         117–150˚C 
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Density 
                     1.092 g/cm3 
 Loss on drying 
                    46.0% 
Stability and storage conditions 
Magnesium stearate is stable and should be stored in a well-closed container in a 
cool, dry place 
Incompatibilities 
 
Incompatible with strong acids, alkalis, and iron salts. Avoid  mixing with strong 
oxidizing materials. 
Applications 
It is primarily used as a lubricant in capsule and tablet manufacture. 
 
 
(Hand book of Pharmaceutical Excipients. Pharmaceutical Press, 
 
London.   5thedtition) 
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POLYVINYL ALCOHOL 
 
 
 
Synonyms 
 
 Airvol 
 
 Elvanol 
 
 Gohsenol 
 
 
Structural formula 
 
 
 Emprical formula 
 
(C2H4O)n  
 
Functional category 
 
 Coating agentLubricant 
 
 Stabilizing agent 
 
 Viscosity-increasing agent 
 
Description 
 
Polyvinyl alcohol occurs as an odorless, white to cream-colored granular powder. 
 
Solubility 
 
Soluble in water, slightly soluble in ethanol, insoluble in organic solvents. 
 
Applications 
 
 Polyvinyl alcohol is used primarily in topical pharmaceutical and 
ophthalmic formulations 
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 It is used as a stabilizing agent for emulsions 
 
Safety  
 
 
 PVA is generally considered a non-toxic material. 
 
 It is non-irritant to the skin and eyes at concentrations up to 10%; 
 
 concentrations up to 7% are used in cosmetics. 
 
 
Handling precaution (Ansari KA et.al., 2011) 
 
 
 protection and gloves recommended 
 
 PVA dust may be an irritant on inhalation 
 
 Handle in a well-ventilated environment 
 
 CHAPTER Ix 
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CHAPTER IX 
EXPERIMENTAL PROTOCOL 
 
1. CALIBRATION OF DAPOXETINE HCL 
a) Preparation of Dissolution Medium 
0.01 N Hydrochloric acid 
0.85 ml of Hydrochloric acid diluted in 1000 ml distilled water. 
Phosphate buffer pH 6.8 
50ml of 0.2M potassium dihydrogen phosphate is placed in 200 ml volumetric 
flask. 22.4 ml of 0.2M sodium hydroxide is added and makeup to the volume with 
distilled water. 
0.2 M Potassium dihydrogen phosphate 
27.218 gm of potassium dihydrogen phosphate is dissolved and diluted to 1000 
ml with distilled water. 
0.2M Sodium hydroxide 
8 gm of sodium hydroxide is dissolved and makeup to 1000 ml with distilled 
water. 
b) Determination of absorption maximum (λmax) (Supriya A et al., 2018) 
A known weight (100 mg) of drug (Dapoxetine Hcl) is dissolved in 100ml 
of methanol to make a primary stock solution (1000µg/ml). The stock solution is 
further diluted using a 0.01N hydrochloric acid solution to 10µg/ ml concentration. 
The resultant solution is scanned in the range of (200- 400nm) by UV 
Spectrophotometer (UV-1700 Shimadzu corporation, Japan) to get absorption 
maximum (λ max). And, also a absorption maximum is estimated similarly using 
phosphate buffer pH (6.8). 
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c) Preparation of calibration curve 
From the above prepared stock solution, (5 to 50µg/ml) concentration solutions 
are prepared using the 0.01N hydrochloric acid solution. The absorbance of these 
solutions is measured at λ max by UV- spectrophotometer (UV-1700 Shimadzu 
corporation, Japan). A standard curve is plotted using concentration on X-axis and the 
absorbance obtained on Y-axis. And also a standard curve is prepared similarly 
using phosphate buffer pH (6.8). 
2. PREFORMULATION (COMPATABILITY) STUDIES 
Compatibility Studies for Drug and Excipients 
  The compatibility studies were performed for the development of dosage form, 
preformulation studies is carried out to confirm that there was no interaction between 
the drug and excipients. Infra spectrophotometer studies used to check the 
compatibility studies between excipients. 
Fourier Transform-Infra Red (FT-IR) Studies (ADLIN JINO NESALIN J et al., 2009) 
                 Infrared Spectrum analysis of drug (Dapoxetine Hcl), polymers (chitosan, 
ethyl cellulose, hydroxyl propyl methyl cellulose, Betacyclodextrin, Diphenyl 
Carbonate)  a n d  the physical mixtures of drug with the polymers are 
obtained from FT-IR Spectrophotometer (Shimadzu, Japan) by KBr disk method. It 
is an important tool plays a major role in determining the compatibility between the 
drug and polymer. A known weight of samples are mixed with KBr powder and 
compressed to 10-mm discs by hydraulic press at pressure of 150 bar for 30 s. 
The scanning range and resolution are 400 – 4000cm-1 and 4cm1. The spectra 
obtained are compared and interpreted for the shifting of functional peaks or the 
appearance and disappearance of new functional peaks (Afifa Bathool et al., 2012). 
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3. FORMULATION OF DAPOXETINE HCL NANOPARTICLES 
Solvent Evaporation Method (Ansari KA et al., 2011): 
Nanoparticles prepared by polymers like chitosan, ethyl cellulose, hydroxyl 
propyl methyl cellulose; Betacyclodextrin, Diphenyl Carbonate and polyvinyl alcohol 
were prepared by solvent evaporation method. Disperse phase consisting of 
Dapoxetine (100 mg) and requisite quantity of polymers dissolved in 20 ml solvent 
(dichloromethane) was slowly added to a definite amount of PVA in 100ml of 
aqueous continuous phase. The reaction mixture was stirred at 1000 rpm for two- 
three hours on a magnetic stirrer. The nanoparticles formed were collected by filtration 
through whatman filter paper and dried in oven at 50 0 C for 2 hours. The dried 
nanoparticles were stored in vaccumdesicater to ensure the removal of residual 
solvent (Ahmed  et al., 2016). 
 
 
Figure: 1 
 
Hyper-Cross Linked ( Betacyclodextrin) Nanoparticles 
            β-cyclodextrin Nanoparticles was prepared by using diphenylcarbonate for 
cross linking process Briefly, an amount of anhydrous cyclodextrin(1:1,1:2,1:3,1:4) 
was put to react in melted diphenylcarbonate at 900 C for atleast 5 hours. Then, 
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the solid was ground in mortar and Soxhlet extracted with ethanol to remove 
either impurities or unreacted diphenylcarbonate. The reaction was carried out using a 
cross-linked excess, at four different molar ratios, e.g. 1:1,1:2,1:3,1:4 (β-CD:cross 
linker). After purification, NP was stored 25
0
C until further use. This reaction was  also 
carried out in the presence of ultrasound, and two different types of NP, namely, 
crystalline (1:1 ,1:2, 1:3,1:4 NPs), and Paracrystalline were formed based on the 
process conditions of the synthesis (Sureshkumar P et al., 2015). 
 Preparation of Dapoxetine Hcl Loaded Nanoparticles 
          Dapoxetine Hcl was dispersed in aqueous suspensions of the various 
types of nanoparticles in a ratio of 1:1, 1:2, 1:3, 1:4 (drug to NP by weight) and was 
stirred for 24 hours. After 24h, the suspension were centrifuged at 2000rpm for 10 
min to separate the uncomplexed drug as a residue below colloidal supernatants 
were freeze dried to obtain drug loaded NP formulations, named as F1:1 F1:2 F1:3 
F1:4 and Fpara depending upon the ratio of β-CD: cross-linker. The drug- loaded NS 
formulations were stored in a covered vaccum desicator at room temperature. 
4. CHARACTERIZATION OF DAPOXETINE HCL NANOPARTICLES 
  All the formulations are evaluated for its production yield, particle 
size, polydispersity index, zeta potential, drug content, entrapment efficiency, 
solubilization efficiency and In vitro drug release studies and Kinetics of drug release 
studies (Akas M et al., 2006 ). 
a) Production yield 
  The production yield of the Nanoparticles is calculated for each batch by 
dividing the total weight of product (M) by the total expected weight of drug and 
polymer. Weight of nanoparticles (M).  
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b) Theoretical drug loading 
Theoretical drug loading in nanoparticles is estimated by using the following 
formula, 
 
c) Determination of drug content 
   Sample containing 100 mg equivalent Dapoxetine Hcl Nanoparticles are 
dissolved and the volume is made upto 100ml with pH 6.8 phosphate buffer. From 
the above solution 10 ml is pipette out and made upto 100 ml with phosphate 
buffer. The absorbance of resulting solution is determined at λmax (292nm) 
using UV Spectrophotometer (UV-1700 Shimadzu corporation, Japan) and the 
drug content is estimated.  
d) Entrapment Efficiency 
   For the drug entrapment efficiency tests, the nanoparticles of F1- F16 were 
performed. Before starting the chemical (spectrophotometric) analyses for the drug 
entrapment efficiency, the repeatability of measurements between different batches 
was ensured by repeated analyses. The 10mg of the nanoparticle was analyzed by 
dissolving sample in 10ml of distilled water. After the drug was dissolved, 10 ml of clear 
layer of dissolved drug is taken (Abdul Hasan Sathali et al.,2015). 
 Thereafter, the amount of drug in the water phase was detected by a UV-
spectrophotometric method at 292nm (U.V Spectrophotometer, systronics). The 
test was repeated with another sample. The amount of the drug in the suspension 
was analyzed by centrifugation at 500rpm for 5 minutes and by measuring the 
concentration of the drug in the clear supernatant layer by the UV-spectrophotometric 
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method. The test was again repeated with another sample. The concentration of the 
drug is determined with the help of calibration curve. The amount of drug inside the 
particles was calculated by subtracting the amount of drug in the aqueous phase of 
the suspension from the total amount of the drug in the nanoparticles suspension. The 
entrapment efficiency (%) of drug was calculated by the following equation. 
 
% Entrapment Efficiency = Total amount of drug – Concentration of drug × 100 
Total amount of drug 
e) Determination of Particle size and Zeta potential 
  The mean particle size (z-average), polydispersity index (PI) and zeta potential of 
dapoxetine nanoparticles formulations are determined by dynamic light scattering 
technique using a zeta size analyzer (Nano ZS 90, Malvern Instruments Ltd.,UK). The 
freeze dried powders are redispersed with water to obtain a proper scattering 
intensity before measurement (Natarajan Tamilselvan et al.,2015).s 
f) In vitro dissolution studies 
I) Non- inclusion complex method (Solvent evaporation method) 
  USP dissolution apparatus Type I (Basket method) at rotation speed of 100 rpm 
is used for invitro testing of drug dissolution of solvent evaporation method 
formulation. For each batch, sample of 10 mg equivalent Dapoxetine Hcl 
nanoparticles containing in enteric capsules are taken and subjected to dissolution 
studies with 900 ml 0.01N hydrochloric acid (2 hours) and phosphate buffer pH 
6.8 (10 hours) as dissolution medium. Bath temperature is maintained at 37±0.5°C 
throughout study.  
   A sample (1.4 ml) of the solution is withdrawn from the dissolution apparatus. 
Samples were taken at appropriate time intervals for 1 hour, 2 hour,3 hour,  up to  
1 2  hourls sampling for up to 6 hours and finally for twelth hour. Fresh dissolution 
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medium was replenished each time when sample is withdrawn to compensate the 
volume. 
    Absorbance values of sample solutions are measured against respective 
buffer solutions at λmax (292nm) in UV Spectrophotometer (UV-1700 Shimadzu 
corporation, Japan). The cumulative percentage drug release is calculated.  
ii) Inclusion complex method (Hyper cross-linker nanoparticles)  
   The invitro release was carried out using multi compartment rotating cells with a 
dialysis membrane (Sartorious, cut off 12,000Da). The donor phase consisted of 
formulations containing fixed amount of Dapoxetine Hcl nanoparticles in 0.01N 
hydrochloric acid &Phosphate buffer at pH6.8 (1.4ml), The receiving phase 
consisted of phosphate buffer, pH 6.8 added with 0.5%w/v sodium lauryl sulphate 
(1ml) to maintain proper sink conditions .The receiving phase was completely 
withdrawn and replaced with fresh medium after fixed time intervals. Suitably 
diluted and analyzed using UV spectrophotometer at 292 nm. The experiment 
was carried out in triplicate. 
g) Invitro Kinetic analysis 
    In order to investigate the drug release mechanism from Controlled 
release nanoparticles formulations, the percentage cumulative drug release data is 
analyzed with following mathematical model (Amighi K et al., 2005). 
 Zero-order 
 First order 
 Higuchi 
 Hixson-Crowell cube root law 
 Korsmeyer-peppas model. 
  The zero order rate Equation describes the systems where the drug release rate 
is independent of its concentration. 
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Qt = Q0 + K0t 
Where, Qt is the amount of drug dissolved in time t, Q0 is the initial amount of 
drug in the solution (most times, Q0= 0) and K0 is the zero order release constant 
expressed in units of concentration/time .To study the release kinetics, data obtained 
from in vitro drug release studies are plotted as cumulative amount of drug released 
versus time. 
  The first order Equation describes the release from a system where the release 
rate is concentration dependent. 
Log C = log C0–kt / 2.303 
 
   Where C is the concentration of the drug at time (t), C0 is the initial 
concentration of the drug and k is the first-order release rate constant. The data 
obtained are plotted as log cumulative percentage of drug remaining vs. time. Higuchi 
described the release of drugs from porous, insoluble matrix as a square root of time 
dependent process based on Fickian diffusion as shown in following Equation. 
F t=Q=KH×t1/2 
 Where Q is the amount of drug released in time t. 
This model is based on the hypotheses that 
initial drug concentration in the matrix is much higher than drug solubility 
drug diffusion takes place only in one dimension (edge effect must 
be negligible) 
drug particles are much smaller than system thickness 
matrix swelling and dissolution are negligible 
drug diffusivity is constant and 
perfect sink conditions are always attained in the release environment. 
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  The data obtained are plotted as cumulative percentage drug release versus 
square root of time. Hixson and Crowell (1931) recognized that the Particles’ regular 
area is proportional to the cube root of its volume. They derived the equation 
W01/3-Wt1/3= κ t 
Where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt is 
the remaining amount of drug in the pharmaceutical dosage form at time t and κ 
(kappa) is a constant incorporating the surface volume relation. The equation 
describes the release from systems where there is a change in surface area and 
diameter of particles. To study the release kinetics, data obtained from in vitro drug 
release studies are plotted as cube root of drug % remaining in matrix vs. time. 
  Korsmeyer – Peppas model describes the fraction of drug release relates 
exponentially with respect to time (Sureshkumar P et al., 2015). 
Mt / M∞ = K t n 
Where Mt / M∞ is a fraction of drug released at time t, k is the release rate 
constant and n is the release exponent. In this model, the value of n characterizes 
the release mechanism of drug. To study the release kinetics, data obtained from 
Invitro drug release studies are plotted as log cumulative percentage drug release 
versus log time (Bhatt Neha et al., 2013). 
Release exponent (n) Drug transport 
 
mechanism 
Rate as a function 
of time 
0.5 Fickian diffusion t-0.5 
0.45< n-0.89 Non-fickian transport tn-1 
0.89 Case II transport Zero order release 
Higher than 0.89 Super case II 
transport 
tn-1 
Table: 1 
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5. SELECTION AND EVALUATION OF BEST FORMULATION 
Selection of best formulation 
The best formulation selection is based on the results obtained from 
Production yield 
Drug content 
particle size, poly dispersity Index and Zeta potential 
entrapment efficiency 
solubilization efficiency 
In vitro drug release studies 
kinetics of drug release. 
6. Evaluation of Best Formulation 
a) Infrared (IR) spectroscopic studies (Ansari KA et al., 2011) 
Infrared spectrum (IR) analysis is carried out for the selected best 
formulations (F6) to find out the interactions between the drug and excipients used 
as per the procedure mentioned on drug polymer interaction studies. 
b) Determination of Particle Size 
            The particle size distribution was determined by using dynamic light 
scattering technique (DLS) technique used for the particle size distribution in is a 
Malvern particle size analyzer (Nano ZS 90, Malvern Instruments Ltd., UK). In this 
technique the particle sizes of batch of the nanoparticles were observed and from 
the standard deviation and mean particle size of the nanoparticles, the polydispersity 
index (PDI) was calculated. The poly dispersity index is the indication for the 
nature of dispersity. The freeze dried powders are redispersed with water to obtain 
a proper scattering intensity before measurement. 
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c) Morphological studies of nanoparticles by using Scanning Electron 
Microscopy (SEM) 
  Morphological evaluation of the selected Nanoparticles formulation is carried 
out in scanning electron microscope (SEM) (Hitachi X650, Tokyo, Japan).All samples 
are examined on a brass stub using carbon double-sided tape. Powder samples are 
glued and mounted on metal sample plates. The samples are gold coated (thickness 
≈15–20 nm) with a sputter coater (Fison Instruments, UK) using an electrical 
potential of 2.0kV at 25 mA for 10 min. An excitation voltage of 20 kV was used in 
the experiments (Natarajan Tamilselvan et al.,2015). 
d) X-ray Powder Diffraction (XRPD) analysis 
  The crystalline state of the samples, including the drug and freeze-dried 
powders are studied in X-ray diffractometer (XRD-462, Digaku, Japan). XRPD is 
carried out in symmetrical reflection mode using Copper line as the source of radiation 
and the wavelength is set at 1.5405A˚. Standard runs using a 40 kV and 30mA in this 
process. Samples are performed with a scanning rate of 0.10000/min and the 
scanning range of the 2 from the initial angle 4˚to the final angle 90.˚  
e) Stability Studies 
  The nanoparticle formulation F1-F16 was subjected to stability studies 
according to ICH guidelines by storing at 25
0
C/60% RH for 30 days and 40
0
C /75% 
RH for 30 days. These samples were analyzed and checked for changes in 
physical appearance,  d r u g  content and Entrapment efficiency, invitro drug 
release studies at regular intervals. The observations of short term storage 
conditions and accelerated conditions indicate no significant changes in the 
parameter even when it was subjected to stress testing for a period of 2 months. 
When the formulation was studied for short – term storage conditions, the drug 
content in the formulation within the 95% confidence interval and hence the slight 
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decrease in the drug content and entrapment efficiency was statistically not 
significant. 
7. PREPARATION AND EVALUATION DAPOXTINE HCL NANOPARTICLES 
LOADED CAPSULES 
 Dapoxetine Hcl nanoparticles capsules were formulated by Hand filling 
method. Micro crystalline cellulose is used as a binder and diluents; magnesium 
stearate is used as a Lubricant. All the ingredients are passed through #60mesh 
separately. Then the ingredients were weighed and mixed in geometrical order after 
sufficient mixing of drug as well as other components and formulated into capsules. 
Dapoxetine Hcl nanoparticle capsules were prepared by Hand filling method without 
using any solubility enhancement method for comparison of invitro drug release 
studies with Dapoxetine Hcl nanoparticles capsules and Dapoxetine Hcl capsules. 
(a) Pre compressional evaluation of powder blend 
i). Angle of repose  
 The flow characteristics are evaluated by determining angle of repose. 
Improper Flow of powder is due to frictional forces between the particles. These 
frictional forces are quantified by angle of repose. Angle of repose is defined as 
the maximum angle possible between the surface of a pile of the powder and the 
horizontal plane. Angle of repose is calculated using the equation. 
tan θ = h/r 
θ = tan-1h/r 
Where,  
 h = height of pile 
r = radius of the base of the pile 
θ = angle of repose 
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Table: 2 
ii) Bulk Density 
 Apparent bulk density is determined by pouring pre sieved drug excipients 
blend into a graduated cylinder and measuring the volume and weight “as it is”. It is 
expressed in g/mL and is given by, 
Db = M / VO 
Where, Db is the bulk density, M is the mass of powder and VO is the Bulk volume of 
the powder. 
iii). Tapped density (Yuminoki K et al 2014): 
 It is determined by placing a graduated cylinder, containing a known mass of 
drug excipients blend, on mechanical tapping apparatus. The tapped volume is 
measured by tapping the powder to constant volume. It is expressed in g/mL. 
Dt = M / Vt 
Where, Dt is the tapped density, M is the mass of powder and Vt is the tapped 
volume of the powder. 
iv)  Compressibility index (or) Carr’s Index (I) 
  Compressibility index is an important measure that can be obtained from the 
bulk and tapped densities.  A material having values less than 20 to 30% is defined 
as the free flowing  material, based on the apparent bulk density and tapped density. 
Angle of repose Type of flow 
<20˚ Excellent 
20˚-30˚ Good 
30˚-35˚ Moderate 
35˚-40˚ Poor 
>40˚ Very poor 
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The percentage compressibility of the bulk drug is determined by using the 
following formula. 
I = Dt – Db / Dt × 100 
Where, I is the Compressibility index, Dt is the tapped density of the powder and Db is 
he bulk density of the powder (Natarajan Tamilselvan et al.,2015). 
Table:3 
v). Hausner’s ratio 
 It indicates the flow properties of the powder. The ratio of Tapped density to 
bulk density of the powder or granules is called Hausner’s ratio. H = Dt / Db 
Where, H is the Hausner’s ratio, Dt is the tapped density of the powder and Db is the 
bulk density of the powder (Wang ZH et al., 2015). 
Compressibility index (%) Type of flow 
10 Excellent 
11-15 Good 
15-20 Fair 
21-25 Passable 
26-31 Poor 
32-37 very poor 
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Table : 4 
 
vi)  Drug content 
 Weight of the powder material equivalent to 10 mg of Dapoxetine Hcl 
nanoparticles capsule is taken and transferred into 100 ml volumetric flask. Then 30 
ml of Phosphate buffer pH 6.8 is added slowly, mixed properly and the volume is 
made up to 100 ml with Phosphate buffer pH 6.8. The above solution is filtered 
and 10 ml of filtrate is taken into 100 ml volumetric flask and made up to final volume 
with Phosphate buffer and the drug content is estimated by measuring the 
absorbance at λmax 292 nm using a UV- spectrophotometer. The drug content is 
determined by using the formula, (Ansari KA et al., 2011) 
       Sample absorbance 
Drug content =        --------------------------------- × 100 
Standard absorbance 
ii) Post Compression Evaluation of Capsules 
a) General Appearance 
  Size of Capsule  :  4(100mg)   
Hausner’s 
ratio 
Type of flow 
1-1.11 Excellent 
1.12-1.18 Good 
1.19s-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.54 very poor 
>1.60 very very poor 
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  Shape of Capsule  : Tube 
  Color of Capsule  : Dark brown 
e) Weight Variation Test 
  Twenty capsules are selected at random, individually weighed. Open the 
capsules without losing any part of the shell and remove the content as completely 
as possible. Weigh the shell. The difference between weight and weight of the 
content. The uniformity of weight is determined according to I.P. specification. As per 
IP not more than two of individual weights should deviate from average weight by 
more than 10% and none deviate more than twice that percentage. The following 
percentage deviation in weight. 
 
 
 
 
 
 
 
Table: 5 
vi)  Drug content uniformity 
  Ten capsules are weighed and taken contents from capsules without losing the 
drug. A quantity of powder weighing equivalent to 100 mg of drug is taken in a 100ml 
volumetric flask and Phosphate buffer pH 6.8 is added. The solution is filtered using 
membrane filter (0.45μm) and 10 ml of filtrate is taken into 100 ml volumetric flask 
and made up to final volume with Phosphate buffer pH 6.8. Then its absorbance is 
measured at 292nm using UV Visible spectrometer. The amount of drug present in 
one capsule is calculated using standard graph. The capsules comply with the test if  
 
Average Net weight 
of 
 
Capsules 
 
Percentage deviation 
 
Number of tablets 
 
Less than 300mg 
±10% 
 
+20% 
Minimum 18 
 
Maximum 2  
300mg or more 
±7.5% 
 
+15% 
Minimum 18 
 
Maximum 2 
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not more than one of the individual values thus obtained is outside the limits 85 to 115 
% of the average value and none is outside the limits of 75 to 125%.  
 
       Sample absorbance 
Drug content =        ----------------------------------   × 100 
Standard absorbance 
 
vii) In vitro drug release studies  
  Dissolution characteristics of the formulated dapoxetine hcl nanoparticles 
loaded capsules were carried out using USP Type I (Basket) dissolution test 
apparatus for 12hrs (Wang ZH et al., 2015). 
Method 
  900 ml of 0.01N Hydrochloric acid for 2 hours and 10 hours in Phosphate buffer 
pH 6.8 was filled in dissolution vessel and temperature of the medium is set at 37°C ± 
0.5°C. One capsule of best formulation is placed in each dissolution vessel and the 
rotational speed of basket was set at 75rpm. 1.4ml of sample is withdrawn at pre 
determined time interval of every one hour for up to 12 hours and same volume of fresh 
medium is replaced immediately. The withdrawn sample is diluted to 10ml in 
volumetric flask and filtered through 0.45μ membrane filter. The resultant samples are 
analyzed for drug content at 292nm using UV-Visible spectrophotometer. 
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Table: 6 
8. Comparison of Invitro drug release studies of Dapoxetine Hcl nanoparticles 
capsules with Dapoxetine Hcl capsules (Sureshkumar P et al., 2015): 
  Comparison of invitro drug release studies of Dapoxetine Hcl nanoparticles 
capsule with Dapoxetine Hcl capsules performed using dissolution tester (Basket type, 
LABINDIA 2000, India). Capsules were added to the 900 ml of 0.1N Hydrochloric Acid 
at 37°C ± 0.5°C, which is stirred with a rotating basket at 75 rpm. 1.4ml samples are 
withdrawn from the dissolution apparatus at the time in travel of 1,2,3 and upto 12 
hours. Equal volume of fresh medium is replaced in to the dissolution medium after 
each sampling to maintain its constant volume throughout the test. Assay carried 
out using UV spectrophotometer (Shimdzu 1700UV/Visible Spectrophotometer, 
Japan) at 292 nm (ADLIN JINO NESALIN J et al., 2009). 
 
 
Parameter Specifications 
Dissolution Medium 0.01N Hydrochloric acid 
Phosphate Buffer pH 6.8 
 
 
 
Phosphate Buffer pH 6.8 
Temperature 37.0 ± 0.5 °C 
Initial Volume 900ml 
Rotation Speed 75rpm 
Drawn Volume 1.4 ml 
Running Time 2 hrs in 0.01N Hydrochloric acid 
10 hrs in Phosphate Buffer pH 6.8 
 
Phosphate Buffer pH 6.8 
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9. Preclinical evaluation: 
The present investigation is undertaken to study the effect of anti depressant 
activity of Dapoxetine Hcl nanoparticles in experimental rats. 
Experimental animals: 
   Albino Wister rats weighing 180-220 gm were used for the study. The rats were 
in the animal house of the Dept. of pharmacology K.M. College of Pharmacy, Madurai. 
Under suitable conditions of housing, temperature, ventilation and nutrition were used 
for anti-depressant activity.  The animal were fed with standard pelleted diet and 
distilled water and libitum was maintained at 21-230C under a constant 12 hours light 
and dark cycle. The animal care and experimental protocols were in accordance with 
CPCSEA/IAEC. 
Standard drug: 
Imipramine (15 mg/kg) is used for antidepressant activity in a standard drug. 
Experimental design: 
Experimental rats are randomly divided in to 4 groups and each group contains six 
animals. 
 Group I     -  Received 10ml/kg of normal saline-Intra peritoneally. 
 Group II    -   Received 15mg/kg Imipramine-Intra peritoneally 
 Group III   -  Received 2.7mg/kg pure drug-Intra peritoneally 
 Group IV   -  Received 2.7mg/kg formulated drug-Intra peritoneally. 
 
 
CHAPTER IX                                                                   EXPERIMENTAL PROTOCOL 
 
Dept. of Pharmaceutics, College of Pharmacy, MMC, Madurai.                  Page 115 
 
Statistical analysis: 
 Results are expressed as mean ± SEM.  
 Data was analyzed by one way ANOVA was used for multiple comparison 
followed Newman Keul’s multiple range test. 
 P<0.05 was considered a statistical significance. 
Forced swimming test: 
 The most frequently used behavioral model for screening anti-depressant like 
activity in rats. Rats were individually forced to swim in open-glass chamber (25 * 
15*25 cm) containing fresh water to a height of 15 cm and maintained at 23-
250C. At this height of water, animals were not able to support themselves by 
toughing the bottom or the side walls of the chamber with their hand paws or tail. 
 Each animal showed vigorous movement during initial 2 min period of the test. 
The duration of immobility was manually recorded during the next 4 min of the 
total 6 min testing period.  
 Rats were considered to be immobile when they ceased struggling and remained 
floating motionless in water. Making only these movements necessary to keep 
their head above water. 
 Values were mean ± S.E.M for (n=6). Expressed as the time (in sec) of 6 animals 
in each group and a P<0.01 values are significantly different from normal control. 
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CHAPTER XI 
RESULTS AND DISCUSSION 
 
I. Standard curves for Dapoxetine Hcl: 
a) Determination of (maximum absorption) λmax: 
The maximum absorbance (λmax) of the Dapoxetine Hcl was estimated by 
scanning the drug solution (10μ/ml) between 200 nm-400 nm regions in 
the UV spectrophotometer. The obtained spectrum that the absorption maximum 
(λmax) at 292 nm in 0.01N Hydrochloric Acid and 292 nm in Phosphate Buffer pH 
6.8.The result was shown in Figure: 1A & 1B. 
0.1N Hydrochloric Acid: 
The λmax of Dapoxetine Hcl was determined by adding 10 ml of 10µ/ml 
0.01N Hydrochloric acid and scanning the solution of drug using UV 
spectrophotometer and was measured at 292 nm .The absorbance of the solutions 
(5-50 µ/ml) was measured in UV spectrophotometer at λmax of 292nm. The 
correlation coefficient was found to be γ=0.9994. The Dapoxetine Hcl obeys the 
Beers law within the concentration of 5 to 50 µg/ml. The results were given in Table: 
1A & FIG: 2A. 
Phosphate Buffer pH 6.8: 
The λmax of Dapoxetine Hcl was determined by adding 0.2M 10 ml of 
10µ/ml Phosphate Buffer pH 6.8 solution and scanning the solution of drug 
using UV spectrophotometer and was measured at 292 nm .The absorbance of the 
solutions (5-50 µ/ml) was measured in UV spectrophotometer at λmax of 292nm. 
The correlation coefficient was found to be γ=0.9996. The Dapoxetine Hcl obeys the 
Beers law within the concentration of 5 to 50 µg/ml. (Wang ZH et al.,2015). The results 
were given in Table: 1B & FIG: 2B 
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II. PREFORMULATIN (COMPATABILITY) STUDIES: 
Fourier Transform- Infra Red (FT-IR) Studies: 
FT-IR spectrum of the drug and polymers were shown in the figure: 3A-3L IR 
spectroscopy was used to investigate the interactions between and drug. The FT-IR 
spectral analysis of Dapoxetine Hcl alone showed that the principal peaks were 
observed at wave numbers confirming the drug (Singling Tang et al., 2011). 
S.No Functional 
Groups 
Range Wave 
Number 
Intensity 
1 N-H  Stretching 3300-3500cm-1 3469 cm-1 Medium
 
2 O-H Stretching 2500-3300 cm-1 2544 cm-1 Strong 
3 C-H Stretching 2700-3300 cm-1 2627 cm-1 Medium
 
4 C=O Stretching 1780-1650 cm-1 1629 cm-1 Strong 
5 C-N Stretching 1230-1020 cm-1 1062 cm-1 Medium 
 
Table: 1 
 
In the FT-IR spectra of physical mixture of Dapoxetine Hcl and ethyl 
cellulose, Dapoxetine Hcl and Chitosan, Dapoxetine Hcl and H P M C  
K 1 0 0 M , Dapoxetine Hcl and Betacyclodextrin a n d  Diphenyl carbonate the 
major peaks of Dapoxetine Hcl were observed at wave numbers 3469 cm
-1
, 2544 
cm-
1, 2627 cm
-1
, 1629 cm
-1
, 1062 cm
-1
, It was confirmed that there are no major 
shifting as well as any loss of functional peaks between the spectra of drug and the 
physical mixture. The drug and individual polymer (physical mixture) confirmed that 
are no interaction between the drug and polymer (Masilamanb K et al., 2015). 
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III. PREPARATION OF DAPOXETINE HCL NANOPARTICLES: 
1. Solvent Evaporation Method: 
        Controlled release nanoparticles of Dapoxetine Hcl were prepared by 
using  Solvent evaporation method Using different ratio of polymers Table 2A & 2B 
shows the composition of various prepared controlled release nanoparticles .The 
Drug (Dapoxetine Hcl) and polymer (Ethyl cellulose) was in the ratio of 1:1, 1:2, 1:3 
and 1:4 for F1,F2, F3 and F4 respectively, Dapoxetine Hcl and polymer (Chitosan) in 
the ratio of 1:1, 1:2, 1:3 and 1:4 for F5, F6, F7 and F8 respectively, Dapoxetine Hcl 
and polymer (HPMC K100 M) in the ratio of 1:1, 1:2, 1:3 and 1:4 for F9, F10, 
F11, and F12 respectively. Disperse phase consisting of Dapoxetine Hcl (100 mg) 
dissolved in methanol and requisite quantity of polymers dissolved in 20 ml solvent 
(dichloromethane) was slowly added to a definite amount of PVA in 100ml of 
aqueous continuous phase. The reaction mixture was stirred at 1000 rpm for two to 
three hours on a magnetic stirrer. The nanoparticles formed were collected by 
filtration through whatman filter paper and dried in oven at 50 0 C for 2 hours. The 
dried nanoparticles were stored in vaccum desicator to ensure the removal of 
residual solvent (Umar PS et al., 2015). 
2. Hyper Cross-Linked β-Cyclodextrin Method: 
  Dapoxetine Hcl and polymer Betacyclodextrin and Diphenyl carbonate in the 
ratio of 1:1, 1:2, 1:3 and 1:4 for F13, F14, F15 and F16 respectively Shown in 
Table.2B. A series of four types of β-cyclodextrin Nanoparticles was prepared 
by using diphenylcarbonate for cross linking as previously prepared. Briefly, an 
amount of anhydrous cyclodextrin was put to react in melted diphenylcarbonate at 
90
0
C for atleast 5 hours. Then, the solid was ground in mortar and Soxhlet extracted 
with methanol to remove either impurities or unreacted diphenylcarbonate. The 
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reaction was carried out using a cross linked excess, at four different molar ratios, 
e.g. 1:1, 1:2, 1:3, 1:4 (β- CD:cross linker). After purification, NP was stored 25
0
C 
until further use. This reaction was also carried out in the presence of ultrasound, 
and two different types of NP, namely, crystalline (1:1, 1:2,  1:3, 1:4 NP), and 
paracrystalline (1:1, 1:2, 1:3, 1:4 NP Para), were formed based on the process 
conditions of the synthesis (Supriya A et al., 2018). 
2.1 Preparation of Dapoxetine Hcl Loaded Nanoparticles: 
Dapoxetine Hcl was dispersed in aqueous suspensions of the various 
types of nanoparticles in a ratio of 1:1, 1:2, 1:3 & 1:4 (drug to NP by weight) and 
was stirred for 24 hours. After 24h, the suspension were centrifuged at 2000rpm 
for 10 min to separate the uncomplexed drug as a residue below colloidal 
supernatants were freeze dried to obtain drug loaded NP formulations, named as F1:1 
F1:2 F1:3  F 1:4 and Fpara depending upon the ratio of β-CD: cross-linker. The 
drug- loaded NP formulations were stored in a covered vaccum desicator at room 
temperature (Singling Tang et al., 2011). 
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IV. CHARACTERIZATION OF CONTROLLED RELEASE NANOPARTICLES: 
A) Production Yield: 
The Production yield of prepared controlled release nanoparticles (F1-F16) was 
shown in Table: 4 Increasing polymer ratio in the formulation led to increase the 
product yield).The low percent yield in some formulations may also due to 
nanoparticles lost during successive decantation during drying process. The 
percentage yield of produced nanoparticles F1 to F16 is shown in figure: 4  
B)    Determination of drug content: 
Sample containing 100 mg equivalent Dapoxetine Hcl Nanoparticles are 
dissolved and the volume is made upto 100ml with pH6.8 phosphate buffer. From 
the above solution 10 ml is pipette out and made upto 100 ml with phosphate 
buffer. The Absorbance of resulting solution is determining at λmax (292 nm) using 
UV spectrophotometer (UV-1700 Shimadzu corporation, Japan) and the drug 
content is estimated shown in Table: 4 & FIG: 6. (Ansari KA et.al., 2011) 
C)   Theoretical drug loading: 
  Theoretical drug loading for controlled release nanoparticles formulation F1- F16 
shown in Table: 4 & FIG: 5. 
D)    Solubilization efficiency: 
Solubilization efficiency of pure drug (Dapoxetine Hcl) and selected best 
formulation F2, F6. F10, F14 were shown in Table-5 and Figure.8. Nanoparticle 
formulation F6 showed highest solubility in distilled water (9.66mg/10ml) as 
compared with pure drug (1.56 mg/10ml). Thus the solubility of nanoparticle 
formulation was increased when compared to pure drug. The solubility of formulation 
and pure drug in phosphate buffer pH (6.8) were 8.08 mg/10ml and 9 . 9 1 0 g/10ml 
respectively. Thus the solubility of Dapoxetine Hcl in nanoparticle formulation was 
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increased when compared to pure drug. Hence, the noticeable increased 
saturation solubility of Dapoxetine Hcl in the formulation of nanoparticle was 
mainly attributed to the decreased particle size and increased surface area. The 
results can be explained by the Ostwald–Freundlich equation which demonstrates 
that the saturation solubility of the drug increases with reduction of particle size.  
E)    Entrapment efficiency: 
    Drug entrapment efficiency for prepared controlled release nanoparticles 
was observed in the range from 54.53 % to 90.94 %. The Dapoxetine Hcl loaded 
Ethyl cellulose controlled release nanoparticles was found to be 63.43% to 74.85% 
for formulations F1 to F4 respectively. Dapoxetine Hcl loaded Chitosan controlled 
release nanoparticles was found to be 58.44 % to 90.94 % for formulations F5 to F8 
respectively. The Dapoxetine Hcl loaded HPMC K100 M controlled release 
nanoparticles was found to be 58.64 % to 76.57 % for formulations F9 to F12 
respectively. The Dapoxetine Hcl loaded Betacyclodextrin controlled release 
nanoparticles was found to be 54.53% to 69.92 % for formulations F13 to F16 
respectively. Among the different drug polymer ratios investigated Formulation F6 
(Chitosan 1:4 ratio), showed the maximum capacity for drug entrapment efficiency 
as shown in figure: 7. ( Wang ZH et al.,2015). Drug entrapment efficiency was 
increased with increasing polymer concentration in Nanoparticle shown in Table 4 & 
Figure: 7. 
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F)    Particle Size Analysis: 
  The particle size, polydispersity index and zeta potential for nanoparticle 
formulation are shown in Table 7. The particle size analysis revealed that the 
particle size measured by laser light scattering method is around 200-400 nm 
with low poly dispersity index values  (0.812), as known , the polydispersity index is 
a parameter used to define the particle size distribution of nanoparticles. It is a 
dimension less number and it values ranges from 0.5-0.7 for mono dispersed 
particles, values greater than 0.7 are characteristic of samples with a broad size 
distribution. Therefore, it can be stated that the particle size distribution is 
unimodel, having a narrow range and a homogenous size distribution. Particle size of 
nanoparticles shown in figure: 11. When the polymer to drug ratio was increased, 
the proportion of larger particles was high, because the viscosity of the polymer 
and drug dispersion was increased with increase of polymer to drug ratio.   
G)   Zeta Potential: 
The zeta potentials of Dapoxetine Hcl nanoparticle F6 formulations shown in 
Table: 7 & Figure: 11, were sufficiently high (+38.1 mV) probably due to presence of 
chitin groups structure which ensure physical stability between nanoparticle through 
electrostatic repulsion, and thereby avoiding aggregations. Increase in the charge on 
the particles is directly proportional to the polymer ratio used in the formulation. This 
is mainly because of more cation on the surface of the particles; higher is the stability 
of the nanoparticles (Masilamanb K et al., 2015). 
H)   In vitro Release studies: 
The dissolution study was carried out in 0.1N Hydrochloric acid for 2 hours 
and phosphate buffer of pH 6.8 for the 10 hours. The results of in-vitro drug 
release studies from the controlled release Nanoparticles of Dapoxetine Hcl are 
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shown in the Table-6A-6D. The cumulative percentage drug release after 12 hours 
was found to be 85.44% 82.69%, 79.77%, and 73.13% for the formulations of F1 
to F4, 94.25% , 96.93%,  92.87% and 90.22% for the formulations of F5 to F8, 
90.93%, 8 5.49%, 8 0.52% and 77.47% for the formulations of F9 to F12, 91.09 %, 
8 6 . 1 9 % , 81.05% and 7 2 . 2 9 % for the formulation of F13 to F16 . It was found 
that the drug release was prolonged up to 12 hrs. Dapoxetine Hcl loaded chitosan 
nanoparticles F6 formulation exhibited good controlled release characteristics. The 
release rate was related to drug: polymer ratio. It was observed that the drug release 
decreased with an increase in the amount of polymer for each formulation. The initial 
burst effect of some formulations may be due to presence of drug particle on the 
surface of the nanoparticles, this initial drug release may also attribute as a desired 
effect to ensure Minimum effective concentration of drug to produce 
pharmacological action (Umar PS et al., 2015). 
Initial burst release of nanoparticle formulation was probably due to the 
Dapoxetine Hcl which was present in the formulations as the inclusion complex; also it 
was adsorbed or encapsulated as non- inclusion complex on the nanoparticle 
surface the complexation of Dapoxetine Hcl in nanoparticle formulations. Thus, it was 
expected that the increased concentration of polymer, which retarded the release of 
dapoxetine hcl from nanoparticle formulations might be useful for controlling its 
release. The F6 formulation showed the controlled release due to increase 
concentration of polymer but F5 formulation showed the intermediate release .This 
may be happened because of nanopores on the surface of nanoparticles which depend 
on the concentration of polymer. Another biorelevant consideration is that transit 
time of a drug through the absorptive area of the gastrointestinal tract is between 9 
to 12 hours this includes 2-3 hours of gastric residence time. The release of 
Dapoxetine Hcl from prepared Ethyl cellulose nanoparticles showed cumulative 
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percentage drug release in the range of 73.13% to 85.44% and Chitosan 
nanoparticles showed drug release in the range of 90.22% to 9 6 . 9 3 % and HPMC 
K100 M nanoparticles showed in the range of 7 7 . 4 7 % to 90.93%.and 
Betacyclodextrin nanoparticles showed in the range of 72.29% to 91.19% (Singling 
Tang et al., 2011). The cumulative percentage drug release for formulations F1 to F16 
as shown in figure: 12B-12E. 
I) Kinetic analysis: 
The release data was modeled for Zero order, First order, Higuchi model, 
Hixson- Crowell model, Korsmeyer-Peppas model. The correlation coefficient of F1 to 
F16 formulations for Zero order, Higuchi, Hixson-Crowell and first order equations 
was shown in Table 8. Formulation F6 (Chitosan NP 1:2 ratios) was found high 
correlation to zero order kinetics 0.990 respectively Figure: 13A &13 D as well as 
Higuchi plot 0.879   Figure: 15A &15D rather than Hixson-Crowell models. 
Higuchi model (Bhay S. Sapre et al., 2012): 
     The release kinetics of all the formulations is best fitted the Higuchi model. 
Higuchi model with R2 values ranges from 0.816 to 0.926 for F6.  From these 
higuchi’s model values, the release kinetics showed purely diffusion controlled. 
The release kinetics is shown in figure: 15A-15D.  
Korsmeyer-peppas model (Masilamanb K et al., 2015) 
   The drug release was proportional to square root of time, indicating that the drug 
release from polymeric (Chitosan) microcapsules was diffusion controlled. The data 
obtained was also put in Korsemeyer-peppas equation in order to find out release 
exponent (n value ranges is 0.410 to 0.691), which describes the drug 
release mechanism by Non Fickian diffusion. The release kinetics is shown in Figure: 
16A-16D.
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J) Stability studies (Bhay S. Sapre et al., 2012): 
Stability studies of the prepared nanoparticles were carried out, by storing  
formulation F6 at 25°C ± 2°C/ 60% ± 5% RH in humidity control oven for sixty 
days. Drug content, entrapment efficiency studies & invitro release studies were 
determined after 60 days. The results of drug content after 60 days of stability testing 
at different storage conditions are shown in (Table 9). Formulation (F6) showed slight 
decrease in drug content (97.95% )respectively and entrapment efficiency (91.00%)  
at  25 0C + 20 C /60% RH after 60 days of storage whereas at 40
0
±2°C/75% RH the 
formulation F6  showed significant decrease in the drug content (98.00%) and 
entrapment efficiency (89.91%) after 60 days of storage. The observations of the 
storage conditions are shown in Table 9, results indicated no significant changes in 
the parameter even when it was subjected to testing for 2 months when F6 was 
studied for short term storage conditions, the drug content in the formulation within the 
95% confidence interval and hence slight decrease in the drug content was 
statistically not significant. From the stability studies it was confirmed that 
nanoparticle formulations of Dapoxetine Hcl remained more stable at storage 
conditions (Abdul Hasan Sathali. A., and Gopinath.M., et al., 2013). 
 K)  Invivo studies of nanoparticle formulation Experimental Animals: 
IV.SELECTION OF BEST FORMULATION: 
          The best formulations were selected by Production yield, Entrapment 
Efficiency, Particle size, Zeta potential , In vitro drug release and kinetic drug release. 
From the above results of characterization F6 was selected as the best formulation 
shown Table-4 & 7 
Because, 
 Production yield 
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 Entrapment efficiency 
 Solubilization efficiency 
 Particle size, Zeta potential & Polydispersity Index 
 Invitro dissolution studies 
 Release kinetics: closest linearity to zero order kinetics(0.990), 
 Non-Fickian diffusion mechanism.  
S.No 
Formulation 
Code 
Production 
Yield 
Entrapment 
Efficiency 
Particle 
Size 
(nm) 
Zeta 
Potential 
Solubilization 
Efficiency 
1 F6 82.88 90.94 628 +38.1 9.910 
Table-2 
V. EVALUATION OF BEST FORMULATION: 
The selected best formulation F6 was subjected to,  
 FT-IR 
 Particle size, Zeta potential & Polydispersity Index 
 Scanning Electron Microscopy 
 X-ray powder diffraction study 
 Invivo studies of nanoparticle formulation (F6). 
CHAPTER XI                                                                   RESULTS AND DISCUSSION 
 
Dept. of Pharmaceutics, College of Pharmacy, MMC, Madurai.                  Page 128 
 
1) FTIR Spectroscopic study: 
  The results obtained from FTIR study of best formulation was shown in 
Figure: 18. The peaks obtained in the pure Dapoxetine Hcl were also found in final 
formulation, which indicates that there is no interaction between the drug and 
excipients. 
2) SEM Analysis of Best Formulation (Ansari KA et al., 2011) 
The morphology of the nanoparticles by solvent evapo ra t ion  method were 
investigated by Scanning electron microscopy (SEM) It was observed by SEM 
analysis that the nanoparticles were uniformly spherical in shape. The particle 
and porous nature of the nanoparticles with rough surface and presence of holes 
/hollow cavity due to the collapse of the wall of the nanoparticles during in situ drying 
process. Thus the rate of solvent removal from the embryonic nanoparticles exerts an 
influence on the morphology of the end product. Porous structure was observed on 
the surface due to the rapid diffusion of the solvent, there is a possibility of rupture of 
the capsule wall. SEM photographs were shown in Figure-20A-20E. 
3) X-Ray Powder Diffraction Study: 
The XRPD patterns of pure drug Dapoxetine Hcl with Chitosan NP formulation 
(F6) was presented in (Figure 21). The XRPD patterns of pure drug showed us sharp 
peaks (at 2θ 18.96°, 22.74 ° and 25.36°) which are the characteristic of a 
crystalline compound. Drug crystallinity peaks were also detectable in 
formulation. This result confirmed that the characteristic peaks were still 
preserved indicating the crystalline state was not changed. As we know, the 
amorphous form can generally enhance the dissolution rate and bioavailability of 
drugs due to its high-energy. According to that principle and with the XRPD 
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analysis considered, the enhancement of dissolution rate of Dapoxetine Hcl may be 
due to the reduction of particle size or the influence of polymers rather than the 
appearance of amorphous form. Moreover, compared with the amorphous form, the 
maintenance of crystalline state was beneficial to a long-term stability. 
4) Invivo studies of nanoparticle formulations Experimental Animals:  
Dapoxetine Hcl loaded nanoparticles could be able to maintain the serotonin level 
in depression over the period of observation (12 h) by selecting the suitable polymers. 
The results can be attributed to the efficacy of formulated Dapoxetine Hcl 
nanoparticles in treating depression as well as its role in maintaining the therapeutic 
levels until extended period of time. These observations could be also explained as 
the nanoparticle drug delivery system containing drug Dapoxetine Hcl, enhance its 
solubility, absorption as well as remain longer period in systemic circulation invivo 
studies. 
5) Result of invivo studies of anti depressant activity of Dapoxetine 
Hcl nanoparticles in experimental rats: 
 Forced swim test (Ansari KA et al., 2011) : 
Table 11 - values shown that animals treated with pure drug and formulated drug 
(2.7 mg/kg) showed decrease in their immobility times, which was significant (68.0 ± 
1.20) and 72.0 ± 1.28) when compared with control (152.0v ±4.35). Similarly animals 
treated with Imipramine (15mg/kg) as expected showed a significant decrease in the 
immobility time (54.0 ± 1.05), (p<0.01).  
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VI. PREPARATION OF DAPOXETINE HCL LOADED NANOPARTICLE 
CAPSULES: 
The Dapoxetine Hcl nanoparticle capsules of best formulation (F6) were 
prepared by using hand filling method. The individually weighed powder blends of 
Dapoxetine Hcl nanoparticle along with other excipients mentioned in Table 12 were 
formulated into capsules. Each Dapoxetine Hcl nanoparticle capsules contains 
30mg equivalent of Dapoxetine Hcl, microcrystalline cellulose is used as a diluent, 
magnesium stearate is used as a lubricant. The prepared Dapoxetine Hcl nanoparticle 
capsules were dark brown in color and tube in shape. 
a) Compatibility Studies: 
FT-IR Spectroscopy (Ansari KA et.al., 2011)  
  FT-IR spectrum of the drug and polymers were shown in the figure:21 IR 
spectroscopy was used to investigate the interactions between and drug. The FT-IR 
spectral analysis of Dapoxetine Hcl alone showed that the principal peaks were 
observed at wave numbers confirming the drug. 
 
S.No Functional 
Groups 
Range Wave 
Number 
Intensity 
1 N-H  Stretching 3300-3500cm-1 3469 cm-1 Medium
 
2 O-H Stretching 2500-3300 cm-1 2544 cm-1 Strong 
3 C-H Stretching 2700-3300 cm-1 2627 cm-1 Medium
 
4 C=O Stretching 1780-1650 cm-1 1629 cm-1 Strong 
5 C-N Stretching 1230-1020 cm-1 1062 cm-1 Medium 
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In the FT-IR spectra of physical mixture of Dapoxetine Hcl nanoparticle (best 
formulation), Dapoxetine Hcl and Chitosan, with other excipients like microcrystalline 
cellulose and magnesium stearate the major peaks of Dapoxetine Hcl were 
observed at wave numbers 3469 cm
-1
, 2544 cm-
1, 2627 cm
-1
, 1629 cm
-1
, 1062 cm
-1
. 
It was confirmed that there are no major shifting as well as any loss of functional 
peaks between the spectra of drug and the physical mixture. The drug and individual 
polymer (physical mixture) confirmed that are no interaction between the drug and 
polymer (Clark’s analysis of drugs and poisons, 3rd edition). 
i) Angle of repose (θ): 
  The Angle of repose for formulated powder blend in the range of 32⁰62’ which 
indicates good flow properties of powder blend. The results were given in the Table 
10 & Figure: 23. 
ii)   Bulk density (gm/ml): 
  The bulk density of powder blends was in the range of 0.4629 gm/ml, which 
indicates, that the powder blends were not bulky. (Singling Tang et al., 2011).                         
The results were shown in the Table 10 & Figure: 24. 
iii) Tapped density (gm/ml): 
  The tapped density of powder blends was in the range of 0 .5618 gm/ml, the 
results were shown in the table, which indicates smaller particles to occupy the voids 
between larger particles. The results were shown in the Table 10 & Figure: 24 
iv)  Compressibity index (%): 
  Compressibility index were found to be in between 17.59 % which indicates that the 
powder blend have good flow property (Abdul Hasan Sathali et al.,2015). The 
results were shown in Table 10 & Figure: 23. 
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v)  Hausner’s ratio (Abdul Hasan Sathali et al.,2015): 
The Hausner’s ratio of powder blend was found to be in the range of 1.21 % which 
indicates good flow properties of powder blend. The results were shown in the Table 
10 & Figure:24. 
vi)     Drug content (%) (Bhay S. Sapre et al., 2012) : 
  The percentage drug content of formulation (F6) was found to be in between 
93.20% ensured the uniformity of drug content within the limits of IP 2014 The 
results were shown in table 13 & Figure: 25.  
Post Compression Evaluation of Dapoxetine Hcl Nanoparticles: 
 General Appearance 
 Size of Empty Hard gelatin capsules  : 4 (100mg)  
 Color of Capsules     : Dark brown 
 Shape of capsules     : Tube 
 Weight Variation (Ansari KA et al., 2011): 
In the formulations, the weight variation of Dapoxetine Hcl loaded capsule 
was ranges for Dapoxetine Hcl NP & F6 (88.47 – 108.47mg). Formulated capsules 
were passed the weight variation test as the % weight variation was within the 
pharmacopoeial limits of ± 10% of the average weight, which proved good 
uniformity. The results were shown in Table 13. 
 Estimation of drug content (Peng Quan et al., 2011): 
The percentage of drug content for best formulation (F6) was found to be in the 
ranges from 93.20% which is within acceptable limits, showed that the drug was 
uniformly distributed in the formulation. Hence the percentage of drug content of the 
formulation complies with official specifications as per IP (Limits: not less than 85% 
and not more than 115%). The results were shown in Figigure:25 & Table 13. 
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 Comparison of Invitro Release Studies of Dapoxetine Hcl 
Nanoparticle Capsules with Dapoxetine Hcl Capsules: 
The Invitro dissolution studies of the formulations of Dapoxetine Hcl 
nanoparticle loaded capsules and Dapoxetine Hcl capsule  were carried out in Hcl (0.01 
N Hcl) for 2 hour and Phosphate Buffer pH 6.8 for 10 hours .The study was performed 
for 12 hrs, and cumulative drug release was calculated at different time intervals. The 
invitro drug release profiles for the formulation Dapoxetine  (Shende PK et al.,2015 ). 
Hcl Capsule & F6 was tabulated in Table14. The plot of cumulative drug release (vs) 
time (hr) was plotted F6 and depicted as shown in Fig.19 (Singling Tang et al., 
2011).
 
TABLE 2C: FORMULATION TABLE FOR CONTROLLED RELEASE NANOPARTICLES OF DAPOXETINE HCL BY 
SOLVNT EVAPORATION METHOD 
 
 
 
 
 
  
 
S. 
No 
INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 
1 
Dapoxetine Hcl 
(mg) 
300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 
2 
Ethyl cellulose 
(mg) 
 
300 600 900 1200 
        
    
3 Chitosan (mg) 
    
300 600 900 1200 
    
    
4 HPMC K100 (mg) 
        
300 600 900 1200     
5 B-CD (mg)             
300 600 900 1200 
6 
Polyvinyl 
alcohol(%w/v) 
0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
7 
Dichlro Methane 
(ml) 
20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 
8 Distilled water(ml) 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
TABLE : 8 KINETICS OF INVITRO RELEASE FROM CONTROLLED RELEASE NANOPARTICLES OF DAPOXETINE HCL 
 
 
 
Formulation 
Code 
Zero order 
Kinetics 
First order 
Kinetics 
Higuchi Model 
Korsemeyer-
peppas model 
Hixon 
Crowell 
R2 
value 
K0(mg/h-1) 
R2 
value 
K1(/h-1) 
R2 
value 
KH(mg/h-1) 
R2 
value 
n value 
R2 
value 
KH(h-1/3) 
F1 0.925 6.527 0.895 0.062 0.918 26.33 0.9663 0.576 0.967 0.172 
F2 0.981 7.165 0.965 0.057 0.870 25.73 0.9774 0.433 0.939 0.161 
F3 0.985 7.458 0.976 0.050 0.907 27.12 0.983 0.538 0.988 0.170 
F4 0.983 7.110 0.892 0.060 0.868 24.83 0.9643 0.416 0.976 0.148 
F5 0.995 8.812 0.728 0.0095 0.899 31.26 0.9625 0.523 0.980 0.207 
F6 0.990 7.903 0.900 0.091 0.879 28.78 0.9876 0.597 0.967 0.173 
F7 0.995 8.322 0.932 0.089 0.904 30.64 0.9608 0.486 0.961 0.155 
F8 0.994 8.050 0.938 0.079 0.911 29.77 0.9608 0.460 0.902 0.136 
F9 0.986 7.978 0.927 0.078 0.923 29.83 0.9844 0.480 0.980 0.207 
F10 0.995 7.181 0.927 0.062 0.915 26.60 0.9651 0.490 0.967 0.173 
F11 0.995 6.806 0.26 0.054 0.894 24.92 0.9585 0.572 0.961 0.155 
F12 0.964 6.277 0.858 0.046 0.816 22.30 0.9702 0.574 0.902 0.136 
F13 0.974 8.023 0.966 0.078 0.926 30.02 0.9717 0.502 0.990 0.206 
F14 0.996 8.322 0.903 0.080 0.891 29.61 0.9762 0.552 0.956 0.210 
F15 0.982 7.793 0.971 0.064 0.895 28.01 0.9897 0.513 0.983 0.179 
F16 0.971 6.317 
0.889 
 
0.043 0.831 2168 0.9832 0.520 0.921 0.130 
 TABLE 1 A: CALIBRATION OF DAPOXETINE IN 0.01N HYDROCHLORIC ACID 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
S.No. 
Concentration in 
µg/ml 
Absorbance ±  SD 
1 5 0.0821 ± 0.0006 
2 10 0.1469 ± 0.0060 
3 15 0.2164 ± 0.0070 
4 20 0.2792 ± 0.0070 
5 25 0.3534 ± 0.0080 
6 30 0.4247 ± 0.0090 
7 35 0.5025 ± 0.0040 
8 40 0.5701 ± 0.0090 
9 45 0.6399 ± 0.0080 
10 50 0.6953 ± 0.0020 
Regression Value: 0.9994 ± 0.000081649 
 TABLE 1 B: CALIBRATION OF DAPOXETINE IN PHOPHATE BUFFER pH 6.8 
 
 
 
 
 
                                     
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
S.No.: 
 
Concentration in 
µg/ml 
 
Absorbance ±  
SD 
1 5 0.0726 ± 0.0015 
2 10 0.1390 ± 0.0005 
3 15 0.2085 ± 0.0004 
4 20 0.2720 ± 0.0005 
5 25 0.3399 ± 0.0019 
6 30 0.4076 ± 0.0019 
7 35 0.4732 ± 0.0012 
8 40 0.5373 ± 0.0006 
9 45 0.6152 ± 0.0049 
10 50 0.6763 ± 0.0023 
 
Regression Value:0.9996  ± 0.00008144 
 
 TABLE: 2A FORMULATION TABLE FOR CONTROLLED RELEASE 
NANOPARTICLES OF DAPOXETINE HCL 
 
  
 
S.NO: 
 
FORMULATION 
CODE 
 
DRUG : 
POLYMER 
RATIO 
 
DRUG 
(DAPOXETINE 
HCL) 
 
CHITOSAN 
 
ETHYL 
CELLULOSE 
1 F1 1 : 1 300 300 300 
2 F2 1 : 2 300 600 600 
3 F3 1 : 3 300 900 900 
4 F4 1 : 4 300 1200 1200 
5 F5 1 : 1 300 300 300 
6 F6 1 : 2 300 600 600 
7 F7 1 : 3 300 900 900 
8 F8 1 : 4 300 1200 1200 
9 F9 1 : 1 300 300 300 
10 F10 1 : 2 300 600 600 
11 F11 1 : 3 300 900 900 
12 F12 1 : 4 300 1200 1200 
13 F13 1 : 1 300 300 300 
14 F14 1 : 2 300 600 600 
15 F15 1 : 3 300 900 900 
16 F16 1 : 4 300 1200 1200 
 TABLE: 2B FORMULATION TABLE FOR CONTROLLED RELEASE 
NANOPARTICLES OF DAPOXETINE HCL 
 
  
 
S.NO 
 
FORMULATI
ON CODE 
 
DRUG : 
POLYMER 
RATIO 
 
DRUG 
(DAPOXETINE) 
 
HPMC 
KM100 
 
B-CD 
 
DPC 
1 F1 1 : 1 300 300 300 300 
2 F2 1 : 2 300 600 600 600 
3 F3 1 : 3 300 900 900 900 
4 F4 1 : 4 300 1200 1200 1200 
5 F5 1 : 1 300 300 300 300 
6 F6 1 : 2 300 600 600 600 
7 F7 1 : 3 300 900 900 900 
8 F8 1 : 4 300 1200 1200 1200 
9 F9 1 : 1 300 300 300 300 
10 F10 1 : 2 300 600 600 600 
11 F11 1 : 3 300 900 900 900 
12 F12 1 : 4 300 1200 1200 1200 
13 F13 1 : 1 300 300 300 300 
14 F14 1 : 2 300 600 600 600 
15 F15 1 : 3 300 900 900 900 
16 F16 1 : 4 300 1200 1200 1200 
 TABLE: 3 FORMULATION & RPM FOR THE CONTROLLED RELEASE 
NANOPARTICLES 
 
Formulation 
Code 
Drug: 
Polymer 
Ratio 
Drug 
 
(mg) 
Polymer 
 
(mg) 
 
RPM 
F1 1 : 1 300 300 1000 
F2 1 : 2 300 600 1000 
F3 1 : 3 300 900 1000 
F4 1 : 4 300 1200 1000 
F5 1 : 1 300 300 1000 
F6 1 : 2 300 600 1000 
F7 1 : 3 300 900 1000 
F8 1 : 4 300 1200 1000 
F9 1 : 1 300 300 1000 
F10 1 : 2 300 600 1000 
F11 1 : 3 300 900 1000 
F12 1 :  4 300 1200 1000 
F13 1 : 1 300 300 1000 
F14 1 : 2 300 600 1000 
F15 1 : 3 300 900 1000 
F16 1 : 4 300 1200 1000 
 
  
TABLE: 4  PRODUCTION YIELD, THEORETICAL YIELD, ACTUAL LOADING, 
DRUG CONTENT &ENTRAPMENT EFFICIENCY FOR CONTROLLED 
RELEASE NANOPARTICLES 
S.  
No.: 
Formulation   
Code 
Production 
yield               
(%) 
Theoretical 
Loading         
(%) 
Experimental 
Drug 
Content (%) 
Entrapment 
Efficiency      
(%) 
1 F1 81.8 61.09 90.22 ± 0.71 67.71 
2 F2 78.22 42.61 95.01 ± 0.74 74.85 
3 F3 83.58 29.91 89.57 ± 0.92 63.43 
4 F4 81.57 24.43 86.88 ± 0.91 68.12 
5 F5 78.00 64.10 82.56 ± 1.01 69.25 
6 F6 82.88 40.21 98.20 ± 0.57 90.94 
7 F7 80.25 31.45 90.17 ± 0.56 77.94 
8 F8 79.80 25.06 91.34 ± 0.40 58.44 
9 F9 80.50 62.11 91.03 ± 0.40 67.99 
10 F10 76.11 43.79 94.03 ± 0.25 76.57 
11 F11 83.17 30.06 91.46 ± 0.86 62.28 
12 F12 80.40 24.87 86.33 ± 1.47 58.64 
13 F13 77.83 64.24 91.88 ± 0.57 69.92 
14 F14 79.00 42.19 93.21 ± 0.67 65.26 
15 F15 81.08 30.83 89.28 ± 0.31 54.53 
16 F16 80.73 24.77 86.11 ±  0.78 68.76 
 
TABLE : 5  COMPARISON OF SOLUBILITY OF SELECTED FORMULATION 
 
WITH PURE DRUG (DAPOXTINE HCL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SL 
 
NO. 
 
 
 
 
SOLVENT 
 
USED 
SOLUBILITY IN EACH SOLVENT(mg/10ml) 
 
 
PURE 
 
DRUG 
 
 
F2 
 
 
F6 
 
 
F10 
 
 
F14 
 
 
1 
 
 
Distilled 
Water 
 
 
1.56±0.010 
 
 
8.79±0.014 
 
 
9.66±0.018 
 
 
9.04±0.013 
 
 
8.430±0.015 
 
 
2 
0.01N 
 
Hydrochloric 
 
Acid 
 
2.146±0.021 
 
2.586±0.018 
 
 
3.172±0.025 
 
 
2.277±0.010 
 
2.577±0.017 
3 
Phosphate 
 
Buffer pH6.8 
 
8.073±0.015 
 
9.235±0.011 
 
9.910±0.048 
 
9.132±0.069 
 
9.101±0.076 
 TABLE: 6A  IN-VITRO RELEASE PROFILE OF ETHYL CELLULOSE CONTROLLED 
RELEASE NANOPARTICLES  OF DAPOXTINE HCL 
 
 
 
 
 
Time in 
 
hours 
Cumulative % Release (Ethyl Cellulose) 
F1 (1:1) F2 (1:2) F3 (1:3) F4 (1:4) 
Mean +SD Mean +SD Mean +SD Mean +SD 
1 
1.29 0.33 2.70 0.33 1.75 0.06 1.15 0.17 
2 
7.93 0.43 11.70 1.95 8.85 0.35 5.22 0.75 
3 
22.93 0.73 20.71 0.22 16.14 0.82 4.52 1.91 
4 
30.43 0.45 25.59 0.25 24.48 0.97 21.02 0.34 
5 
35.24 0.87 31.30 1.41 33.16 0.70 25.81 0.54 
6 
41.26 0.89 35.99 1.47 43.46 1.55 37.49 0.77 
7 
47.70 0.82 42.61 0.57 52.50 1.18 43.43 0.71 
8 
55.52 1.05 49.77 0.88 61.00 1.15 51.27 0.76 
9 
62.67 0.81 55.35 0.65 66.02 0.74 57.16 1.31 
10 
68.90 1.12 61.54 1.33 70.23 1.46 63.16 0.60 
11 
75.10 0.86 76.44 1.75 75.06 0.72 68.36 0.67 
12 
85.44 1.21 82.69 1.02 79.77 0.93 73.13 0.57 
 TABLE: 6B  IN-VITRO RELEASE PROFILE OF CHITOSAN CONTROLLED 
RELEASE NANOPARTICLES OF DAPOXTINE HCL 
 
 
 
 
 
Time in 
 
hours 
Cumulative % Release (Chitosan) 
F5  (1:1) F6  (1:2) F7  (1:3) F8  (1:4) 
Mean +SD Mean +SD Mean +SD Mean +SD 
1 
1.92 0.21 2.63 0.24 2.13 0.21 2.13 0.24 
2 
9.98 0.32 19.04 0.67 8.48 0.66 8.63 0.66 
3 
19.96 0.53 19.86 0.65 20.05 0.45 20.05 0.44 
4 
28.47 0.73 28.08 0.31 28.92 0.25 29.37 0.69 
5 
37.19 0.43 34.14 0.86 38.55 1.19 38.16 1.12 
6 
45.07 1.07 40.80 1.08 46.31 0.788 46.22 0.78 
7 
55.54 0.87 47.23 0.77 55.93 1.46 55.43 0.27 
8 
66.21 1.61 54.69 1.10 63.21 0.94 63.46 0.43 
9 
73.05 1.26 64.11 0.98 71.09 0.49 70.77 1.43 
10 
83.45 1.19 73.88 0.45 80.11 1.04 77.44 2.13 
11 
89.27 0.23 83.92 1.72 88.52 1.29 84.34 2.57 
12 
94.25 0.55 96.93 0.69 92.87 1.28 90.22 0.31 
 TABLE: 6C IN-VITRO RELEASE PROFILE OF HPMC K100 
CONTROLLED RELEASE NANOPARTICLES OF DAPOXTINE HCL 
 
  
Time in 
 
hours 
Cumulative % Release (HPMC K100) 
F9 (1:1) F10 (1:2) F11  (1:3) F12  (1:4) 
Mean +SD Mean +SD Mean +SD Mean +SD 
1 
2.10 0.22 1.98 0.06 1.61 0.25 1.98 0.25 
2 
9.90 0.16 10.11 0.14 8.91 0.65 7.12 1.04 
3 
20.23 1.31 21.34 1.92 17.56 0.66 11.61 1.41 
4 
31.54 0.79 30.42 0.44 23.15 0.87 15.87 0.34 
5 
44.47 1.41 35.22 0.87 31.17 0.52 20.68 0.79 
6 
51.21 0.37 41.36 0.89 37.29 0.09 26.02 1.20 
7 
58.69 0.63 47.69 0.81 42.26 1.07 31.63 0.68 
8 
65.02 0.71 55.52 1.05 48.91 0.12 38.76 1.20 
9 
71.94 0.41 62.67 0.81 55.91 0.55 45.72 1.08 
10 
76.14 1.36 68.90 1.04 64.35 0.61 56.72 1.61 
11 
83.15 1.69 76.43 0.96 72.87 1.32 66.01 1.50 
12 
90.93 0.85 85.49 0.73 80.52 0.78 77.47 1.66 
 TABLE:  6D  IN-VITRO RELEASE PROFILE OF BETACYCLODEXTTRIN 
CONTROLLED RELEASE NANOPARTICLES OF DAPOXTINE HCL 
 
 
  
Time in 
 
hours 
Cumulative % Release (Betacyclodextrin) 
F13  (1:1) F14 (1:) F5  (1:3) F16  (1:4) 
Mean +SD Mean +SD Mean +SD Mean +SD 
1 
1.84 0.01 1.84 0.55 1.59 0.39 1.29 0.02 
2 
10.01 0.07 9.45 0.88 7.94 1.05 8.90 0.76 
3 
19.49 0.48 18.99 1.26 13.82 1.81 13.12 0.41 
4 
34.52 1.75 24.59 2.36 21.05 1.23 16.97 0.62 
5 
44.52 1.32 31.18 0.76 35.55 1.06 21.58 0.55 
6 
54.10 1.44 44.48 1.59 44.65 1.09 26.45 0.53 
7 
59.22 1.03 53.27 2.06 52.43 0.25 31.54 0.09 
8 
66.82 1.91 61.98 2.10 60.62 1.07 37.45 0.87 
9 
73.09 1.02 69.03 0.07 68.41 1.21 45.17 0.54 
10 
77.77 1.09 75.77 1.12 72.36 1.18 56.86 1.83 
11 
83.59 0.06 84.63 0.79 77.41 0.79 67.33 1.55 
12 
89.09 1.35 91.19 1.34 81.05 1.34 72.29 1.91 
 TABLE: 7  PARTICLE SIZE, PDI, ZETA POTENTIAL & DRUG RELEASE 
FOR BEST FORMULATION (F6) 
 
 
MEAN DIAMETER(nm) 
 
628 
 
PDI 
 
0.812 
 
 
ZETA POTENTIAL(mV) 
 
38.1 
 
% OF DRUG RELEASE 
 
96.93 
 
TABLE: 9 STABILITY STUDY OF BEST FORMULATION (F6) STORED AT 
25°C±20C/65%RH AND 40°C/ 70%RH 
 
 
 
EVALUATION 
PARAMETER 
 
 
 
STORING 
TEMPERATURE 
 
 
 
Initial 
 
 
 
30 Days 
 
 
 
60 Days 
 
 
 
 
% Drug content 
 
250C± 20C/65%RH 
 
 
98.20 ±0.16% 
 
 
98.10 ±0.27% 
 
 
  97.95±0.17% 
 
 40°C ± 20C /70%RH 
 
 
98.20 ±0.16% 
 
 
98.08 ±0.28% 
 
 
98.00± 0.17% 
 
 
 
% Entrapment 
efficiency 
 
250C± 20C/65%RH 
 
 
90.94 ±0.28% 
 
 
90.12 ±0.28% 
 
 
90.00±0.15% 
 
40°C ±20C /70%RH 
 
 
90.94±0.28% 
 
 
90.07 ±0.28% 
 
 
89.91±0.15% 
 
Cumulative 
% drug 
Release 
 
250C±20C/65%RH 
 
 
96.93±0.47% 
 
 
96.56±0.31% 
 
 
96.12±0.218% 
 
40°C ±20C /70%RH 
 
 
 
96.93±0.47% 
 
 
96.56±0.31% 
 
 
96.02±0.218% 
 
  
 
TABLE:10  PRECOMPRESSION STUDIES FOR ISRADIPINE 
NANOPARTICLE CAPSULES (F6) 
 
 
 
Formulation code 
 
F6 
 
Angle of Repose (ϴ) ±SD* 
 
320 62’ 
 
      Bulk Density (G/Ml) ±SD* 
 
0.4629 ± 0.06 
 
    Tapped Density (G/Ml) ±SD* 
 
0.5618 ± 0.10 
 
Hausner Ratio ±SD 
 
1.21 ± 0.51 
 
Compressibility index (%) ±SD* 
 
17.59 ± 0.83 
 
 
 
 
  
 TABLE: 11 INVIVO STUDIES OF ANTI DEPRESSANT ACTIVITY OF DAPOXETINE 
HCL NANOPARTICLES IN EXPERIMENTAL RATS: 
 
Groups 
 
Treatment 
 
Drug mg/kg 
 
Immobility period Mean 
± S.E.M. 
 
G-I 
 
Control 
 
10 ml/kg 
 
152. ± 4.35 
 
G-II 
 
Std. control 
Imipramine 
 
15 mg/kg 
 
 
54.0 ± 1.05 
 
G-III 
 
Pure Drug 
 
2.7 mg/kg 
 
68.0 ± 1.20 
 
G-IV 
 
Formulated 
Drug 
 
2.7 mg/ kg 
 
72.0 ± 1.2 
  
TABLE: 12 COMPOSITION OF DAPOXETINE HCL – CHITOSAN 
NANOPARTICLES 
 
 
SL 
NO. 
 
 
INGREDIENTS 
 
FOR 1 
CAPSULES 
(mg) 
 
FOR 50 
CAPSULES 
(g) 
 
 
1 
 
 
 
 
 
 
Dapoxetine Hcl – Chitosan 
nanoparticles (equivalent to 
30 mg of Dapoxetine Hcl) 
 
 
 
75.5mg 
 
 
 
 
 
 
3.775gm 
 
 
 
2 
 
 
Microcrystalline cellulose 
 
 
23.5mg 
 
 
1.175gm 
 
 
3 Magnesium stearate 
 
1mg 
 
0.050gm 
 
 
 
TABLE: 13   POST COMPRESSION FOR DAPOXETINE HCL NANOPARTICLE & 
BEST FORMULATION OF F6 CAPSULES 
 
 
 
FORMULATION 
CODE 
 
LENGTH  
OF 
CAPSULE 
(mm) 
 
WEIGHT 
VARIATION ±10% 
(±15mg) 
 
DRUG 
CONTENT % 
±SD* 
 
DAPOXETINE  
HCL  
CAPSULES 
 
 
17 
 
 
144.15 
 
 
88.15 ± 0.010 
 
 
F6  
 
 
17 
 
 
146.23 
 
 
93.20 ± 0.012 
 
  
 TABLE: 14 IN-VITRO RELEASE PROFILE OF DAPOXETINE HCL AND F6 
CAPSULES OF CONTROLLED RELEASE NANOPARTICLES OF 
DAPOXETINE HCL 
 
 
Cumulative %  Drug Release (CHITOSAN) 
 
Time in 
Hours 
Dapoxetine Hcl 
Capsules 
F6(1:4) 
Chitosan NP Capsules 
Mean +SD Mean +SD 
1 1.98 0.25 2.63 0.24 
2 8.12 1.04 11.04 0.67 
3 15.61 1.41 19.86 0.65 
4 21.87 0.34 28.08 0.31 
5 30.68 0.79 34.14 0.86 
6 39.02 1.20 40.80 1.08 
7 46.63 0.68 47.23 0.77 
8 52.76 1.20 54.69 1.10 
9 60.72 1.08 64.11 0.98 
10 67.72 1.61 73.88 0.45 
11 74.01 1.50 83.92 1.72 
12 82.47 1.66 96.93 0.69 
 
 
 FIG: 1A- DETERMINATION OF λmax OF DAPOXETINE HCL IN 0.01N HCL 
 
 
FIG: 1B- DETERMINATION OF λmax OF DAPOXETINE HCL IN PHOSPHATE 
BUFFER pH6.8 
 
  
 FIG: 2A-CALIBRATION OF DAPOXETINE HCL IN 0.01N HCL 
 
 
FIG: 2B-CALIBRATION OF DAPOXETINE HCL IN PHOSPHATE BUFFER pH 
6.8 
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FIGURE: 3A-FT-IR SPECTRUM OF DAPOXETINE HCL 
 
 
FIGURE: 3B-FT-IR SPECTRUM OF ETHYL CELLULOS 
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 FIGURE: 3C-FT-IR SPECTRUM OF CHITOSAN 
 
 
 
FIGURE: 3D-FT-IR SPECTRUM OF HPMC K100 
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FIGURE: 3F-FT-IR SPECTRUM OF DIPHENYL CARBONATE 
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 FIGURE: 3G-FT-IR SPECTRUM OF POLYVINYL ALCOHOL 
 
 
FIGURE: 3H- FT-IR SPECTRUM OF DAPOXETINE HCL + ETHYL 
CELLULOSE 
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 FIGURE: 3 I -FT-IR SPECTRUMS OF DAPOXETINE HCL + CHITOSAN 
 
 
FIGURE: 3 J -FT-IR SPECTRUM OF DAPOXETINE HCL + HPMC K100 
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FIGURE :9   PARTICLS SIZE FOR CHITOSAN NPs (F6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE: 10 ZETA POTENTIAL FOR CHITOSAN NPs (F6)  
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 FIGURE: 20A  SEM IMAGES OF DAPOXETIN HCL CHITOSAN 
NANOPARTICLES (F6): 
 
 
 
FIGURE: 20B SEM IMAGES OF DAPOXETIN HCL CHITOSAN 
NANOPARTICLES (F6): 
 
  
 FIGURE: 20C SEM IMAGES OF DAPOXETIN HCL CHITOSAN 
NANOPARTICLES (F6): 
 
 
 
FIGURE: 20D SEM IMAGES OF DAPOXETIN HCL CHITOSAN 
NANOPARTICLES (F6): 
 
  
 FIGURE: 20E SEM IMAGES OF DAPOXETIN HCL CHITOSAN 
NANOPARTICLES (F6): 
 
  
FIGURE: 21 POWDER DIFFRACTION OF CHITOSAN NPs (F6)  
 
  
  
FIGURE: 22 FT-IR SPECTURM OF BEST FORMULATION F6 (1:2) DAPOXETINE 
HCL CHITOSAN NANOPARTICLES LOADED CAPSULES 
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CHAPTER-XI 
SUMMARY AND CONCLUSION 
 The goal of any drug delivery system is to provide a therapeutic amount of 
drug to the proper site in the body and also to achieve and maintain 
the desired drug concentration. 
 The λ max of Dapoxetine Hcl as found to be 292 nm in 0.01N Hydrochloric 
acid and 292nm in Phosphate buffer pH6.8 in 10μg/ml solution. 
 Dapoxetine Hcl is a highly potent SSRI was used as a model drug to 
develop a controlled release formulation. Dapoxetine Hcl designed to 
prolong the release increase the drug bioavailability, diminish the side effects 
of irritating drugs and also reducing the frequency of administration, thereby 
improving the patient compliance and therapeutic efficacy. 
 The Dapoxetine Hcl obeys the Beers law within the concentration of 5 to 50 
μg/ml. 
 Dapoxetine Hcl is having low solubility and short duration elimination half life 
(1-1.6 hour), the drug displays extensive first pass metabolism. 
 The purpose of this study was to prepare Dapoxetine Hcl nanoparticles for 
control release of Dapoxetine Hcl to improve the oral bioavailability, enhance 
the solubility and dissolution rate by decreasing particle size of drug. 
 Infrared spectroscopic studies confirmed that there was no interaction 
between drug and polymers. 
 The controlled release Dapoxetine Hcl nanoparticles were prepared by 
Solvent evaporation by using Ethyl cellulose, Chitosan & HPMC K100 M and 
hyper-cross linked method using Betacyclodextrin and Diphenyl carbonate 
polymers of 1:1, 1:2, 1:3, 1:4 ratios. 
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 The production yield of the formulated controlled release nanoparticles (F1 to 
F16) in the range of 76.11% to 83.58 %. 
 The drug content of the formulated controlled release nanoparticles (F1 to 
F16) in the range of 82.56 % to 98.20 %. 
 The Theoretical loading of the formulated controlled release nanoparticles 
(F1- F16) in the range of 24.43 % to 64.24%. 
 The entrapment efficiency increased with increasing the concentration of 
polymers and the formulations containing chitosan nanoparticles F6 (1:2) 
showed better entrapment (90.94%) among all formulation. 
 The solubility of selected formulation (F6) in 0.2M Phosphate buffer pH6.8 
increased when compared to pure drug. 
 Particle size distribution was determined by Malvern zeta size, the size 
range for produced nanoparticles in the range of 200nm to 400 nm. 
 The polydispersity index of selected nanoparticle formulation (F6) was 0.812 
which indicated a narrow range and a homogeneous size distribution of 
particles. 
 Zeta potential value of Dapoxetine Hcl nanoparticles showed a positive 
surface charge (+38.1 mV) this is because of more anion on the surface of the 
particles higher the charge higher is the stability of the nanoparticle. 
 The invitro dissolution study was carried out in 0.01N Hydrochloric acid for 2 
hours and phosphate buffer pH 6.8 for 10 hours. The formulations shows 
controlled release of drug upto 12 hrs and all formulations showed more 
than75% of      drug release. 
 The release kinetics showed that the formulations were complies with Zero 
order kinetics followed by diffusion controlled mechanism and Korsemeyar 
peppas n values were more than 0.4 indicating Nonfickian diffusion. 
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 The best formulation F6 was selected based on production yield, entrapment 
efficiency, solubilization efficiency, particle size, polydispersity index & zeta 
potential and in-vitro drug release and release kinetics. 
 
 The best formulation F6 was evaluated by infrared spectroscopy, particle size, 
polydispersity index & zeta potential, Scanning Electron microscopy, X-ray 
powder diffraction method (X-PRD) and DSC. 
 
 Best formulation of nanoparticles shown the extent of drug release was 
found to be F6 (96.93 %) in 12hrs. 
 
 SEM studies confirmed the morphology of the nanoparticle formulation. 
 
 The crystalline state of the nanoparticle formulation was not altered 
according to the XRPD analysis. 
 
 The stability studies confirmed that the developed Dapoxetine Hcl 
nanoparticles are physically and chemically stable and retain their 
pharmaceutical properties at various temperature and humidity conditions 
over a period of 2 month. One formulation were selected for invivo studies on 
mice. The administration of Dapoxetine Hcl loaded nanoparticle significantly 
inhibit the serotonin reuptake in the synaptic cleft similar trend but the extent 
of decrease is greater compared to standard drug. The sudden decrease of 
blood pressure after administration of Dapoxetine Hcl (standard) was due to 
burst release of drug from nanoparticle which was observed during invitro 
drug release studies. The anti-depressive activity of Dapoxetine Hcl loaded 
nanoparticles is lesser than control. Hence, Chitosan NP could be able to 
maintain the serotonin level over the period of observation(12h).The results 
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can be attributed to the efficacy  of formulated Dapoxetine HCL nanoparticles 
in treating hypertension as well as its role in maintaintaing the therapeutic 
levels until extended period of time. 
 The Dapoxetine Hcl nanoparticle & selected best formulation (F6) was 
formulated into capsules using suitable diluents (MCC) by hand filling 
method. 
 The formulated capsules were analyzed for pre compression and 
post compression parameter drug content, invitro drug release studies. 
 The pre compression parameters of all the formulations were within the 
required limit was indicated good flow property, suitable for formulation of the 
capsules. 
 The post compression parameters such as general appearance, weight 
variation, uniformity of content and invitro studies of all formulations were 
within the acceptable limits. 
 FTIR studies of selected best formulation shows that no interaction 
between the drug and excipients. 
 Dapoxetine Hcl chitosan nanoparticle capsules showed increased drug 
release profile when compared with Dapoxetine Hcl capsules. 
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CONCLUSION 
 
Hence, it was concluded that nanoparticle a good approach to release the 
drug in a controlled manner to the targeted site and enhance the solubility and 
dissolution property of Dapoxetine Hcl by solvent evaporation method for the 
successful incorporation of Dapoxetine Hcl with high entrapment efficiency. The 
solubility studies suggested that the nanoparticle formulations enhanced the 
bioavailability of Dapoxetine Hcl by improving its solubility and dissolution rate 
when compared to pure drug. Furthermore, it could be presumed that if the 
nanometer range of particles  were obtained, the bioavailability might be  increased. 
Thus the nanoparticles as controlled release formulations can be useful for delivery 
of short elimination half life, low bioavailability through orally. Thus nanoparticle 
drug delivery system provides site specific drug delivery and prolongs dosage 
interval and thus improving patient compliance. The invivo release studies 
results indicated the efficacy of formulated Dapoxetine Hcl nanoparticles in 
treating depression as well as its role in maintaining the therapeutic levels until 
extended period of time. 
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